<?xml version="1.0" encoding="UTF-8"?>
<xml><header><hits>20206</hits><query>"qt prolongation"</query></header><results><bibdataset><bibrecord><item-info><date-sort>2014-01-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2015 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.3233/JRS-140612</doi><lui>L373285808</lui><pui>373285808</pui><car-id>351838754</car-id><embase>2014400406</embase><medl>24902506</medl></itemidlist><history><date-created>2014-06-29</date-created><date-loaded>2014-07-01</date-loaded><date-aip-loaded>2014-06-23</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Cardiovascular agents/adverse effects</author-keyword><author-keyword>communication</author-keyword><author-keyword>drug approval</author-keyword><author-keyword>drug labeling/legislation &amp; jurisprudence</author-keyword><author-keyword>torsades de pointes/chemically induced</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Quality of drug label information on QT interval prolongation</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: Information regarding QT-prolongation in the drug label may vary between products. This could lead to suboptimal risk minimization strategies. Objective: To systematically assess the variation in the extent and content of information on QT prolongation in the summary of product characteristics (SPC) of recently approved medicinal products. Methods: Drug labels of products centrally approved in Europe between 2006 and 2012 were screened. Of drugs including the term 'QT' in the SPC, the message on QT-prolongation ('no prolongation'/'unclear drug-QT association'/'possibly QT-prolongation'/'QT-prolongation') and the advice on cautionary measures pertaining to QT-prolongation in the label were examined, as well as their association. Results: Of the 175 screened products, 44 contained information on QT in the SPC ('no QT-prolongation': 23%, 'unclear drug-QT association': 43%, 'possibly QT-prolongation': 16%, 'QT-prolongation': 18%). 62% contained advices to act with caution in patients with additional risk factors for QT-prolongation. Products that more likely to have QT-prolonging properties according to the SPC provided more information on QT-prolongation in the SPC ('no prolongation': 10% and for the category 'QT-prolongation': 100%). Conclusions: The extent and content of information on QT-prolongation varies considerably between SPCs, and in almost half of the drugs a clear message on QT-prolongation was lacking in the SPC. © 2014 - IOS Press and the authors.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="nld">Netherlands</sourcecountry><sourcetitle>International Journal of Risk and Safety in Medicine</sourcetitle><sourcetitle-abbrev>Int. J. Risk Saf. Med.</sourcetitle-abbrev><issn><issntype>electronic</issntype><issnnr>18786847</issnnr></issn><issn><issntype>print</issntype><issnnr>09246479</issnnr></issn><codencode>IJMDE</codencode><volisspag><volume>26</volume><issue>2</issue><firstpage>89</firstpage><volissidx>18786847||2014||26||2</volissidx><volissidx>09246479||2014||26||2</volissidx><lastpage>98</lastpage></volisspag><publicationyear>2014</publicationyear><publicationdate><pubdatetext>2014</pubdatetext></publicationdate><website><email>www.iospress.nl/site/html/09246479.html</email></website><publisher><affiliation><address-part>Nieuwe Hemweg 6B</address-part><city>Amsterdam</city><country code="nld">Netherlands</country></affiliation><publishername>IOS Press</publishername></publisher></source><enhancement><classifications><clsemclass>18</clsemclass><clsemclass>37</clsemclass><clsemclass>39</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>orphan drug</drgterm><mainterm>orphan drug</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug information</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug labeling</mainterm><weight>a</weight></descriptor><descriptor><mainterm>health care personnel</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University</organization></affiliation><author><autidx>Warnier M.J.</autidx><given-name>Miriam J.</given-name><initials>M.J.</initials><seq>1</seq><surname>Warnier</surname></author><author><autidx>De Boer A.</autidx><given-name>Anthonius</given-name><initials>A.</initials><seq>5</seq><surname>De Boer</surname></author><author><autidx>De Bruin M.L.</autidx><email>m.l.debruin@uu.nl</email><given-name>Marie L.</given-name><initials>M.L.</initials><seq>7</seq><surname>De Bruin</surname></author></author-group><author-group><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht</organization></affiliation><author><autidx>Warnier M.J.</autidx><given-name>Miriam J.</given-name><initials>M.J.</initials><seq>1</seq><surname>Warnier</surname></author><author><autidx>Rutten F.H.</autidx><given-name>Frans H.</given-name><initials>F.H.</initials><seq>3</seq><surname>Rutten</surname></author><author><autidx>Hoes A.W.</autidx><given-name>Arno W.</given-name><initials>A.W.</initials><seq>4</seq><surname>Hoes</surname></author></author-group><author-group><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><author><autidx>Holtkamp F.A.</autidx><given-name>Frank A.</given-name><initials>F.A.</initials><seq>2</seq><surname>Holtkamp</surname></author><author><autidx>Mol P.G.M.</autidx><given-name>Peter G.M.</given-name><initials>P.G.M.</initials><seq>6</seq><surname>Mol</surname></author><author><autidx>De Bruin M.L.</autidx><email>m.l.debruin@uu.nl</email><given-name>Marie L.</given-name><initials>M.L.</initials><seq>7</seq><surname>De Bruin</surname></author></author-group><author-group><affiliation><city-group>Groningen</city-group><country code="nld">Netherlands</country><organization>Department of Clinical Pharmacology, University Medical Center Groningen</organization></affiliation><author><autidx>Holtkamp F.A.</autidx><given-name>Frank A.</given-name><initials>F.A.</initials><seq>2</seq><surname>Holtkamp</surname></author><author><autidx>Mol P.G.M.</autidx><given-name>Peter G.M.</given-name><initials>P.G.M.</initials><seq>6</seq><surname>Mol</surname></author></author-group><author-group><affiliation><address-part>PO-box 80082, 3508 TB</address-part><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences</organization></affiliation><author><autidx>De Bruin M.L.</autidx><email>m.l.debruin@uu.nl</email><given-name>Marie L.</given-name><initials>M.L.</initials><seq>7</seq><surname>De Bruin</surname></author></author-group><authorlist><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University</organization></affiliation><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht</organization></affiliation><autidx>Warnier M.J.</autidx><given-name>Miriam J.</given-name><initials>M.J.</initials><seq>1</seq><surname>Warnier</surname><aggregatedAuthorId>warnier m.j.__warnier__miriam j.</aggregatedAuthorId><uniqueAuthorId>warnier__miriam j.__m.j.____xkSeF6twHnI=</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><affiliation><city-group>Groningen</city-group><country code="nld">Netherlands</country><organization>Department of Clinical Pharmacology, University Medical Center Groningen</organization></affiliation><autidx>Holtkamp F.A.</autidx><given-name>Frank A.</given-name><initials>F.A.</initials><seq>2</seq><surname>Holtkamp</surname><aggregatedAuthorId>holtkamp f.a.__holtkamp__frank a.</aggregatedAuthorId><uniqueAuthorId>holtkamp__frank a.__f.a.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht</organization></affiliation><autidx>Rutten F.H.</autidx><given-name>Frans H.</given-name><initials>F.H.</initials><seq>3</seq><surname>Rutten</surname><aggregatedAuthorId>rutten f.h.__rutten__frans h.</aggregatedAuthorId><uniqueAuthorId>rutten__frans h.__f.h.____lU7t+QFjXiA3</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht</organization></affiliation><autidx>Hoes A.W.</autidx><given-name>Arno W.</given-name><initials>A.W.</initials><seq>4</seq><surname>Hoes</surname><aggregatedAuthorId>hoes a.w.__hoes__arno w.</aggregatedAuthorId><uniqueAuthorId>hoes__arno w.__a.w.____lU7t+QFjXiA3</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University</organization></affiliation><autidx>De Boer A.</autidx><given-name>Anthonius</given-name><initials>A.</initials><seq>5</seq><surname>De Boer</surname><aggregatedAuthorId>de boer a.__de boer__anthonius</aggregatedAuthorId><uniqueAuthorId>de boer__anthonius__a.____xkSeF6twHnI=</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><affiliation><city-group>Groningen</city-group><country code="nld">Netherlands</country><organization>Department of Clinical Pharmacology, University Medical Center Groningen</organization></affiliation><autidx>Mol P.G.M.</autidx><given-name>Peter G.M.</given-name><initials>P.G.M.</initials><seq>6</seq><surname>Mol</surname><aggregatedAuthorId>mol p.g.m.__mol__peter g.m.</aggregatedAuthorId><uniqueAuthorId>mol__peter g.m.__p.g.m.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University</organization></affiliation><affiliation><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><affiliation><address-part>PO-box 80082, 3508 TB</address-part><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences</organization></affiliation><autidx>De Bruin M.L.</autidx><email>m.l.debruin@uu.nl</email><given-name>Marie L.</given-name><initials>M.L.</initials><seq>7</seq><surname>De Bruin</surname><aggregatedAuthorId>de bruin m.l.__de bruin__marie l.</aggregatedAuthorId><uniqueAuthorId>de bruin__marie l.__m.l.____xkSeF6twHnI=</uniqueAuthorId></author></authorlist><correspondence><affiliation><address-part>PO-box 80082, 3508 TB</address-part><city-group>Utrecht</city-group><country code="nld">Netherlands</country><organization>Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences</organization></affiliation><email>m.l.debruin@uu.nl</email><person><initials>M.L.</initials><persidx>De Bruin M.L.</persidx><surname>De Bruin</surname></person></correspondence><grantlist><grant><grant-acronym>UU</grant-acronym><grant-agency>Utrecht University</grant-agency></grant></grantlist></head><tail><bibliography><refcount>15</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>chemical compound</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>drug</ancestor><ancestor>general and inorganic chemicals</ancestor><ancestor>orphan drug</ancestor></ancestors><drgterm>orphan drug</drgterm><mainterm>orphan drug</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug information</ancestor><ancestor>information</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>drug information</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>drug labeling</ancestor><ancestor>pharmaceutics</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>drug labeling</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care personnel</ancestor><ancestor>named groups by occupation</ancestor><ancestor>named groups of persons</ancestor></ancestors><mainterm>health care personnel</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>orphan drug</dt></dgidx><dsidx><dst>qt prolongation</dst></dsidx><stidx><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2018-06-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2018 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1111/fcp.12371</doi><lui>L622650235</lui><pui>622650235</pui><absn>PS2 - 001</absn><car-id>911246565</car-id><osin>76701699</osin></itemidlist><history><date-created>2018-06-23</date-created><date-loaded>2018-06-26</date-loaded></history><dbcollection code="EMBCNF">EMBCNF</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Hydroxyzine and QT prolongation: Three studies in real life</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Introduction: Hydroxyzine is an old H1-antihistamine which has been recently accused to cause QT prolongation. Very little data is available about this side effect in the literature and it is only fundamental data [1]. We decided to explore the hydroxyzine risk of QT prolongation in real-life conditions. Material and methods: Primarily, we conducted a prospective study to evaluate the impact of hydroxyzine on hospitalized patients QT, and we analyzed data of patients concerned by this side effect. Then we performed a descriptive study of QT prolongation reports with hydroxyzine in the French PharmacoVigilance database. Lastly, we did a comparative study of QT prolongation with H1-antihistamines in VIGIBASE®. Results: We included 37 patients in the cohort of the prospective study. Among them 7 patients presented a QT prolongation. They all had other risk factors of QT prolongation such as renal insufficiency or use of other drug known to prolong QT. We found 42 cases of QT prolongation imputed to hydroxyzine in the French Pharmacovigilance data base. In all cases, there were other risk factors of QT prolongation. Fourteen H1-antihistamines out of the 24 investigated were associated with a significant ROR value. For 7 of them, QT prolongation was indicated in the side effects section of the SMPC (Summary of Product Characteristics) and 4 were listed in CREDIBLEMEDS® list. Discussion/Conclusion: The prospective study demonstrated that hydroxyzine common use in patient with risk factors of QT prolongation greatly increases the risk of QT prolongation. This was confirmed by data found in the French PharmacoVigilance database. In our comparative study in VIGIBASE®, QT prolongation was associated with most H1-antihistamines while this risk was only described in the literature for some of them. These studies have strong arguments supporting the noxious effect of hydroxyzine and more widely of all H1-antihistamines on QT and shows that QT prolongation might be a class effect of H1-antihistamines. Hydroxyzine prescription should be used with caution in patients with QT prolongation risk factors. We intend to communicate further information to prescribers to ensure the best possible care of patients treated with hydroxyzine.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="nld">Netherlands</sourcecountry><sourcetitle>Fundamental and Clinical Pharmacology</sourcetitle><sourcetitle-abbrev>Fundam. Clin. Pharmacol.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>14728206</issnnr></issn><conferenceinfo><confevent><conflocation><clcountry code="FRA">France</clcountry><city>Toulouse</city></conflocation><confname>Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers, CIC Meeting 2018</confname><enddate>2018-06-14</enddate><startdate>2018-06-12</startdate></confevent></conferenceinfo><volisspag><volume>32</volume><firstpage>76</firstpage><volissidx>14728206||2018||32||</volissidx><supplement>Supplement 1</supplement></volisspag><publicationyear>2018</publicationyear><publicationdate><pubdate day="01" month="06" year="2018">2018-06-01</pubdate></publicationdate><publisher><publishername>Blackwell Publishing Ltd</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>2192-20-3</cas-registry-number><cas-registry-number>64095-02-9</cas-registry-number><cas-registry-number>68-88-2</cas-registry-number><chemical-name>hydroxyzine</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>endogenous compound</drgterm><mainterm>endogenous compound</mainterm><weight>b</weight></descriptor><descriptor><drgterm>hydroxyzine</drgterm><mainterm>hydroxyzine</mainterm><weight>a</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><mainterm>clinical article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>cohort analysis</mainterm><weight>b</weight></descriptor><descriptor><mainterm>comparative study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>conference abstract</mainterm><weight>b</weight></descriptor><descriptor><mainterm>controlled study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug surveillance program</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug therapy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospital patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>kidney failure</disterm><mainterm>kidney failure</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prescription</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prospective study</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk assessment</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor><disterm>side effect</disterm><mainterm>side effect</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><author><autidx>Hamel-Senecal L.</autidx><initials>L.</initials><seq>1</seq><surname>Hamel-Senecal</surname></author><author><autidx>Cesbron A.</autidx><initials>A.</initials><seq>3</seq><surname>Cesbron</surname></author><author><autidx>Lelong-Boulouard V.</autidx><initials>V.</initials><seq>4</seq><surname>Lelong-Boulouard</surname></author><author><autidx>Alexandre J.</autidx><initials>J.</initials><seq>5</seq><surname>Alexandre</surname></author><author><autidx>Fedrizzi S.</autidx><initials>S.</initials><seq>6</seq><surname>Fedrizzi</surname></author></author-group><author-group><affiliation><city>Caen</city><country code="fra">France</country><organization>Departement De Medecine Generale, UNICAEN</organization></affiliation><author><autidx>Humbert X.</autidx><initials>X.</initials><seq>2</seq><surname>Humbert</surname></author></author-group><authorlist><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><autidx>Hamel-Senecal L.</autidx><initials>L.</initials><seq>1</seq><surname>Hamel-Senecal</surname><aggregatedAuthorId>hamel-senecal l.__hamel-senecal__</aggregatedAuthorId><uniqueAuthorId>hamel-senecal____l.____KAUApjYK4g==</uniqueAuthorId></author><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Departement De Medecine Generale, UNICAEN</organization></affiliation><autidx>Humbert X.</autidx><initials>X.</initials><seq>2</seq><surname>Humbert</surname><aggregatedAuthorId>humbert x.__humbert__</aggregatedAuthorId><uniqueAuthorId>humbert____x.____aYWjD0gID28=</uniqueAuthorId></author><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><autidx>Cesbron A.</autidx><initials>A.</initials><seq>3</seq><surname>Cesbron</surname><aggregatedAuthorId>cesbron a.__cesbron__</aggregatedAuthorId><uniqueAuthorId>cesbron____a.____KAUApjYK4g==</uniqueAuthorId></author><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><autidx>Lelong-Boulouard V.</autidx><initials>V.</initials><seq>4</seq><surname>Lelong-Boulouard</surname><aggregatedAuthorId>lelong-boulouard v.__lelong-boulouard__</aggregatedAuthorId><uniqueAuthorId>lelong-boulouard____v.____KAUApjYK4g==</uniqueAuthorId></author><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><autidx>Alexandre J.</autidx><initials>J.</initials><seq>5</seq><surname>Alexandre</surname><aggregatedAuthorId>alexandre j.__alexandre__</aggregatedAuthorId><uniqueAuthorId>alexandre____j.____KAUApjYK4g==</uniqueAuthorId></author><author><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><autidx>Fedrizzi S.</autidx><initials>S.</initials><seq>6</seq><surname>Fedrizzi</surname><aggregatedAuthorId>fedrizzi s.__fedrizzi__</aggregatedAuthorId><uniqueAuthorId>fedrizzi____s.____KAUApjYK4g==</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Caen</city><country code="fra">France</country><organization>Service De Pharmacologie, CHU</organization></affiliation><person><initials>L.</initials><persidx>Hamel-Senecal L.</persidx><surname>Hamel-Senecal</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>chemicals and drugs</ancestor><ancestor>endogenous compound</ancestor><ancestor>natural products and their synthetic derivatives</ancestor></ancestors><drgterm>endogenous compound</drgterm><mainterm>endogenous compound</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>anxiolytic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>hydroxyzine</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>hydroxyzine</drgterm><mainterm>hydroxyzine</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical article</ancestor><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>clinical article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>cohort analysis</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>methodology</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>cohort analysis</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>comparative study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>comparative study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>conference abstract</ancestor><ancestor>conference paper</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>conference abstract</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>controlled study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>controlled study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>drug surveillance program</ancestor><ancestor>in vivo study</ancestor><ancestor>postmarketing surveillance</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>drug surveillance program</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>hospital patient</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>hospital patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>kidney disease</ancestor><ancestor>kidney failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>urinary tract disease</ancestor><ancestor>urogenital tract disease</ancestor></ancestors><disterm>kidney failure</disterm><mainterm>kidney failure</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug use</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>prescription</ancestor></ancestors><mainterm>prescription</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>prospective study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>prospective study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk assessment</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk assessment</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>iatrogenic disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>side effect</ancestor></ancestors><disterm>side effect</disterm><mainterm>side effect</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>adult</ag></agidx><dgidx><dt>endogenous compound</dt><dt>hydroxyzine</dt></dgidx><dsidx><dst>kidney failure</dst><dst>qt prolongation</dst><dst>side effect</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>clinical article</stt><stt>cohort analysis</stt><stt>comparative study</stt><stt>controlled study</stt><stt>drug surveillance program</stt><stt>human</stt><stt>prospective study</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-05-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2011 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1080/10543400903581978</doi><lui>L358733704</lui><pui>358733704</pui><embase>2010252566</embase><medl>20358435</medl><pii>921496027</pii></itemidlist><history><date-created>2010-05-21</date-created><date-loaded>2010-05-25</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Bazett</author-keyword><author-keyword>ECG</author-keyword><author-keyword>Fridericia</author-keyword><author-keyword>Heart-rate correction</author-keyword><author-keyword>Mixed models</author-keyword><author-keyword>QT interval</author-keyword><author-keyword>Thorough QT study</author-keyword><author-keyword>Torsades des pointes</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Statistical characterization of QT prolongation</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>The appropriate assessment of QT prolongation remains controversial. We suggest that before the relative merits of various methods can be evaluated, we must state what we assume an assessment of QT prolongation should be about. As a general framework for the assessment of QT prolongation we propose that an assessment of "absolute" or "uncorrected" QT prolongation is properly carried out through a between-treatment (active versus placebo) comparison of the marginal distributions of QT data; an assessment of "heart rate corrected" QT prolongation is carried out through a between-treatment comparison of the conditional distributions of QT data (conditional on RR interval or heart rate). Under this general framework, conditional QT prolongation is, in general, a function of RR interval, and we discuss three possible summary characteristics for that function. We show how current procedures for the assessment of QT prolongation relate to the general approach (that is, to betweentreatment contrasts of the marginal and conditional expectation of the QT interval), and to each other. It transpires that only the so-called "one-step procedure" can provide a complete characterization of conditional QT prolongation. We show that the "two-step procedure" with data-driven correction provides an unbiased estimate of expected conditional QT prolongation, which may, from a clinical point of view, be a more satisfactory characteristic than the conventional characteristic, QT prolongation at the reference RR interval. We strongly suggest that two-step procedures with fixed correction be abandoned in the analysis of thorough QT/QTc studies: Fixed correction is either redundant (when a drug has no effect on average RR interval), or systematically biased (when a drug does affect average RR interval). Copyright © Taylor &amp; Francis Group, LLC.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>Journal of Biopharmaceutical Statistics</sourcetitle><sourcetitle-abbrev>J. Biopharm. Stat.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10543406</issnnr></issn><issn><issntype>electronic</issntype><issnnr>15205711</issnnr></issn><codencode>JBSTE</codencode><volisspag><volume>20</volume><issue>3</issue><firstpage>543</firstpage><volissidx>10543406||2010||20||3</volissidx><volissidx>15205711||2010||20||3</volissidx><lastpage>562</lastpage></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>May 2010</pubdatetext></publicationdate><publisher><affiliation><address-part>325 Chestnut St, Suite 800</address-part><city>Philadelphia</city><country code="usa">United States</country></affiliation><publishername>Taylor and Francis Inc.</publishername></publisher><issuetitle>Continued Discussion in Design and Analysis of Thorough QTc Studies</issuetitle></source><enhancement><classifications><clsemclass>17</clsemclass><clsemclass>18</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>analytic method</mainterm><weight>b</weight></descriptor><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>clinical assessment</mainterm><weight>b</weight></descriptor><descriptor><mainterm>controlled study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>heart rate</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>placebo effect</mainterm><weight>b</weight></descriptor><descriptor><mainterm>priority journal</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>RR interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>statistical analysis</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>Bloemfontein 9300</city-group><country code="zaf">South Africa</country><organization>Department of Mathematical Statistics and Actuarial Science</organization><organization>University of the Free State</organization></affiliation><author><autidx>Schall R.</autidx><email>schallr@ufs.ac.za</email><given-name>Robert</given-name><initials>R.</initials><seq>1</seq><surname>Schall</surname></author></author-group><author-group><affiliation><city-group>Bloemfontein</city-group><country code="zaf">South Africa</country><organization>Quintiles Biostatistics</organization></affiliation><author><autidx>Schall R.</autidx><email>schallr@ufs.ac.za</email><given-name>Robert</given-name><initials>R.</initials><seq>1</seq><surname>Schall</surname></author></author-group><author-group><affiliation><city-group>Biberach an der Riss</city-group><country code="deu">Germany</country><organization>Clinical Biostatistics</organization><organization>Boehringer Ingelheim Pharma</organization></affiliation><author><autidx>Ring A.</autidx><given-name>Arne</given-name><initials>A.</initials><seq>2</seq><surname>Ring</surname></author></author-group><author-group><affiliation><city-group>Ulm</city-group><country code="deu">Germany</country><organization>Institute for Biometry</organization><organization>University of Ulm</organization></affiliation><author><autidx>Ring A.</autidx><given-name>Arne</given-name><initials>A.</initials><seq>2</seq><surname>Ring</surname></author></author-group><authorlist><author><affiliation><city-group>Bloemfontein 9300</city-group><country code="zaf">South Africa</country><organization>Department of Mathematical Statistics and Actuarial Science</organization><organization>University of the Free State</organization></affiliation><affiliation><city-group>Bloemfontein</city-group><country code="zaf">South Africa</country><organization>Quintiles Biostatistics</organization></affiliation><autidx>Schall R.</autidx><email>schallr@ufs.ac.za</email><given-name>Robert</given-name><initials>R.</initials><seq>1</seq><surname>Schall</surname><aggregatedAuthorId>schall r.__schall__robert</aggregatedAuthorId><uniqueAuthorId>schall__robert__r.____SSxJBQCftQq8</uniqueAuthorId></author><author><affiliation><city-group>Biberach an der Riss</city-group><country code="deu">Germany</country><organization>Clinical Biostatistics</organization><organization>Boehringer Ingelheim Pharma</organization></affiliation><affiliation><city-group>Ulm</city-group><country code="deu">Germany</country><organization>Institute for Biometry</organization><organization>University of Ulm</organization></affiliation><autidx>Ring A.</autidx><given-name>Arne</given-name><initials>A.</initials><seq>2</seq><surname>Ring</surname><aggregatedAuthorId>ring a.__ring__arne</aggregatedAuthorId><uniqueAuthorId>ring__arne__a.____RbmJAJVCCpE=</uniqueAuthorId></author></authorlist><correspondence><affiliation><city-group>Bloemfontein 9300</city-group><country code="zaf">South Africa</country><organization>Department of Mathematical Statistics and Actuarial Science</organization><organization>University of the Free State</organization></affiliation><email>schallr@ufs.ac.za</email><person><initials>R.</initials><persidx>Schall R.</persidx><surname>Schall</surname></person></correspondence></head><tail><bibliography><refcount>16</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>analysis</ancestor><ancestor>analytic method</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>analytic method</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical assessment</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>evaluation and follow up</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>clinical assessment</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>controlled study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>controlled study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug activity</ancestor><ancestor>pharmacodynamics</ancestor><ancestor>pharmacology</ancestor><ancestor>placebo effect</ancestor></ancestors><mainterm>placebo effect</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>priority journal</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>priority journal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>rr interval</ancestor></ancestors><mainterm>RR interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor></ancestors><mainterm>statistical analysis</mainterm><weight>a</weight></explosion></explosions><idxs><dsidx><dst>qt prolongation</dst></dsidx><stidx><stt>controlled study</stt><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2013-09-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2014 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1007/s40264-013-0087-x</doi><lui>L71277765</lui><pui>71277765</pui><absn>ISP3695-51</absn></itemidlist><history><date-created>2014-01-06</date-created><date-loaded>2014-01-08</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Information on QT-interval prolongation properties of medicinal products in the european and american drug label</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: QT-interval prolongation is one of the most common adverse drug reactions leading to regulatory action. Although the occurrence of QT prolongation is generally rare, it can be potentially fatal by causing ventricular arrhythmia. We have noticed that information regarding QT prolonging properties of drugs varies between different sources. Objective: To compare the QT prolonging properties described in the European and American drug label. Methods: The European and American drug labels of products that were centrally approved in Europe between 1.1.2006 and 1.5.2012 were screened. Of those mentioning 'QT', we determined the nature of the message on QT prolongation (no prolongation/unclear drug-QT association/ potentially QT prolongation/QT prolongation). The kappa statistic was calculated to estimate the agreement between the message in the European SPC and the American drug label. Results: Of the 172 selected products approved in Europe, 30 products were not approved by the FDA (44 %). A quarter of the products reported on QT prolongation in both the European and the American drug label (n = 36/142). In one-fifth of the products (n = 28/142), only the American drug label reported on QT prolongation, of which 24 (86 %) contained a negative message (drug does not prolong the QT interval). Two products reported only in the European drug label on QT prolongation (1 %). The agreement on the message about QT prolongation between the European and USA drug label was moderate (kappa 0.42). There was a tendency for the FDA drug label to be more explicit on drug-associated QT prolongation than the European SPC (Unclear message on QT prolongation: FDA 6 %, EMA 12 %). One drug had no QT prolonging properties according to the European label of the EMA, while this drug did prolong the QT interval according to the American label. Conclusion: This study showed that there was moderate concordance between the nature of the QT prolonging effect described in the European and American drug label. The American drug label tended to be more explicit, and more often contained a negative message on QT prolongation than the European drug label.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Drug Safety</sourcetitle><sourcetitle-abbrev>Drug Saf.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>01145916</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Pisa</city-group><clcountry code="ITA">Italy</clcountry></conflocation><confname>13th International Society of Pharmacovigilance, ISoP Annual Meeting: "The Renaissance of Pharmacovigilance"</confname><enddate>2013-10-04</enddate><startdate>2013-10-01</startdate></confevent></conferenceinfo><volisspag><volume>36</volume><issue>9</issue><firstpage>887</firstpage><volissidx>01145916||2013||36||9</volissidx></volisspag><publicationyear>2013</publicationyear><publicationdate><pubdatetext>September 2013</pubdatetext></publicationdate><publisher><publishername>Adis International Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>drug surveillance program</mainterm><weight>a</weight></descriptor><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>Europe</mainterm><weight>b</weight></descriptor><descriptor><mainterm>Food and Drug Administration</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>kappa statistics</mainterm><weight>b</weight></descriptor><descriptor><disterm>adverse drug reaction</disterm><mainterm>adverse drug reaction</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><author><autidx>Warnier M.</autidx><initials>M.</initials><seq>1</seq><surname>Warnier</surname></author><author><autidx>De Boer A.</autidx><initials>A.</initials><seq>5</seq><surname>De Boer</surname></author><author><autidx>De Bruin M.</autidx><initials>M.</initials><seq>7</seq><surname>De Bruin</surname></author></author-group><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><author><autidx>Holtkamp F.</autidx><initials>F.</initials><seq>2</seq><surname>Holtkamp</surname></author><author><autidx>Mol P.</autidx><initials>P.</initials><seq>6</seq><surname>Mol</surname></author></author-group><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><author><autidx>Rutten F.</autidx><initials>F.</initials><seq>3</seq><surname>Rutten</surname></author><author><autidx>Hoes A.</autidx><initials>A.</initials><seq>4</seq><surname>Hoes</surname></author></author-group><authorlist><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>Warnier M.</autidx><initials>M.</initials><seq>1</seq><surname>Warnier</surname><aggregatedAuthorId>warnier m.__warnier__</aggregatedAuthorId><uniqueAuthorId>warnier____m.____LKkEAEZ/B4I=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><autidx>Holtkamp F.</autidx><initials>F.</initials><seq>2</seq><surname>Holtkamp</surname><aggregatedAuthorId>holtkamp f.__holtkamp__</aggregatedAuthorId><uniqueAuthorId>holtkamp____f.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><autidx>Rutten F.</autidx><initials>F.</initials><seq>3</seq><surname>Rutten</surname><aggregatedAuthorId>rutten f.__rutten__</aggregatedAuthorId><uniqueAuthorId>rutten____f.____zigBAODTDRI=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><autidx>Hoes A.</autidx><initials>A.</initials><seq>4</seq><surname>Hoes</surname><aggregatedAuthorId>hoes a.__hoes__</aggregatedAuthorId><uniqueAuthorId>hoes____a.____zigBAODTDRI=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>De Boer A.</autidx><initials>A.</initials><seq>5</seq><surname>De Boer</surname><aggregatedAuthorId>de boer a.__de boer__</aggregatedAuthorId><uniqueAuthorId>de boer____a.____LKkEAEZ/B4I=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><autidx>Mol P.</autidx><initials>P.</initials><seq>6</seq><surname>Mol</surname><aggregatedAuthorId>mol p.__mol__</aggregatedAuthorId><uniqueAuthorId>mol____p.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>De Bruin M.</autidx><initials>M.</initials><seq>7</seq><surname>De Bruin</surname><aggregatedAuthorId>de bruin m.__de bruin__</aggregatedAuthorId><uniqueAuthorId>de bruin____m.____LKkEAEZ/B4I=</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><person><initials>M.</initials><persidx>Warnier M.</persidx><surname>Warnier</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>drug surveillance program</ancestor><ancestor>in vivo study</ancestor><ancestor>postmarketing surveillance</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>drug surveillance program</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>eastern hemisphere</ancestor><ancestor>europe</ancestor><ancestor>geographic names</ancestor></ancestors><mainterm>Europe</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>food and drug administration</ancestor><ancestor>health care concepts</ancestor><ancestor>health care organization</ancestor></ancestors><mainterm>Food and Drug Administration</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>kappa statistics</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor></ancestors><mainterm>kappa statistics</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adverse drug reaction</ancestor><ancestor>adverse event</ancestor><ancestor>diseases</ancestor><ancestor>iatrogenic disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>adverse drug reaction</disterm><mainterm>adverse drug reaction</mainterm><weight>b</weight></explosion></explosions><idxs><dsidx><dst>adverse drug reaction</dst><dst>heart ventricle arrhythmia</dst><dst>qt prolongation</dst></dsidx><stidx><stt>drug surveillance program</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2003-12-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2009 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.2143/AC.58.6.2005324</doi><lui>L37541685</lui><pui>37541685</pui><embase>2003513917</embase><medl>14713185</medl></itemidlist><history><date-created>2003-12-30</date-created><date-loaded>2003-12-30</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>LADD</author-keyword><author-keyword>Prolongation</author-keyword><author-keyword>QT</author-keyword><author-keyword>Syndrome</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Lacrimo-auriculo-dento-digital syndrome with QT prolongation</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>We present a case of a young boy in whom lacrimo-auriculo-dental-digital (LADD) syndrome with QT prolongation was detected. According to Bazett's formula, corrected QT was 504 ms. There were no published data about LADD syndrome with QT prolongation. This is the first case concerning LADD syndrome associated with QT prolongation. It is known that deafness and QT prolongation occur in potassium channel dysfunction. QT prolongation and deafness may be associated with potassium channel dysfunction in patients with LADD syndrome. As a result QT prolongation may be a new component of the LADD syndrome.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="bel">Belgium</sourcecountry><sourcetitle>Acta Cardiologica</sourcetitle><sourcetitle-abbrev>Acta Cardiol.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00015385</issnnr></issn><codencode>ACCAA</codencode><volisspag><volume>58</volume><issue>6</issue><firstpage>567</firstpage><volissidx>00015385||2003||58||6</volissidx><lastpage>570</lastpage></volisspag><publicationyear>2003</publicationyear><publicationdate><pubdatetext>December 2003</pubdatetext></publicationdate><publisher><affiliation><address-part>Weldadigheidsstraat 49</address-part><city>Leuven</city><country code="bel">Belgium</country></affiliation><publishername>Acta Cardiologica</publishername></publisher></source><enhancement><classifications><clsemclass>7</clsemclass><clsemclass>18</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>potassium channel</drgterm><mainterm>potassium channel</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>case report</mainterm><weight>b</weight></descriptor><descriptor><mainterm>child</mainterm><weight>b</weight></descriptor><descriptor><mainterm>clinical examination</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>b</weight></descriptor><descriptor><disterm>external ear malformation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>external ear malformation</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>hypodontia</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>hypodontia</mainterm><weight>b</weight></descriptor><descriptor><link><linkterm>diagnosis</linkterm></link><mainterm candidate="true">LADD syndrome</mainterm><weight>b</weight></descriptor><descriptor><disterm>long QT syndrome</disterm><link><linkterm>diagnosis</linkterm></link><link><linkterm>etiology</linkterm></link><mainterm>long QT syndrome</mainterm><weight>a</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><disterm>malformation syndrome</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>malformation syndrome</mainterm><weight>a</weight></descriptor><descriptor><disterm>nail dysplasia</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>nail dysplasia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>pathophysiology</mainterm><weight>b</weight></descriptor><descriptor><disterm>ptosis (eyelid)</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>ptosis (eyelid)</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>Afyon</city-group><country code="tur">Turkey</country><organization>Department of Cardiology</organization><organization>School of Medicine</organization><organization>Afyon Kocatepe University</organization></affiliation><author><autidx>Onrat E.</autidx><email>eronrat@aku.edu.tr</email><given-name>Ersel</given-name><initials>E.</initials><seq>1</seq><surname>Onrat</surname></author><author><autidx>Kaya D.</autidx><given-name>Dayimi</given-name><initials>D.</initials><seq>2</seq><surname>Kaya</surname></author></author-group><author-group><affiliation><city-group>Afyon</city-group><country code="tur">Turkey</country><organization>Dept. of Molec. Biol. and Genetics</organization><organization>Faculty of Science</organization><organization>Afyon Kocatepe University</organization></affiliation><author><autidx>Onrat S.T.</autidx><given-name>Serap Tutgun</given-name><initials>S.T.</initials><seq>3</seq><surname>Onrat</surname></author></author-group><author-group><affiliation><city-group>03200 Afyon</city-group><country code="tur">Turkey</country><organization>Afyon Kocatepe University</organization><organization>A. N. Sezer Uygulama Arast., Hast.</organization><organization>Kardiyoloji Anabilim Dali</organization></affiliation><author><autidx>Onrat E.</autidx><email>eronrat@aku.edu.tr</email><given-name>Ersel</given-name><initials>E.</initials><seq>1</seq><surname>Onrat</surname></author></author-group><authorlist><author><affiliation><city-group>Afyon</city-group><country code="tur">Turkey</country><organization>Department of Cardiology</organization><organization>School of Medicine</organization><organization>Afyon Kocatepe University</organization></affiliation><affiliation><city-group>03200 Afyon</city-group><country code="tur">Turkey</country><organization>Afyon Kocatepe University</organization><organization>A. N. Sezer Uygulama Arast., Hast.</organization><organization>Kardiyoloji Anabilim Dali</organization></affiliation><autidx>Onrat E.</autidx><email>eronrat@aku.edu.tr</email><given-name>Ersel</given-name><initials>E.</initials><seq>1</seq><surname>Onrat</surname><aggregatedAuthorId>onrat e.__onrat__ersel</aggregatedAuthorId><uniqueAuthorId>onrat__ersel__e.____ziypBAB/gwoM</uniqueAuthorId></author><author><affiliation><city-group>Afyon</city-group><country code="tur">Turkey</country><organization>Department of Cardiology</organization><organization>School of Medicine</organization><organization>Afyon Kocatepe University</organization></affiliation><autidx>Kaya D.</autidx><given-name>Dayimi</given-name><initials>D.</initials><seq>2</seq><surname>Kaya</surname><aggregatedAuthorId>kaya d.__kaya__dayimi</aggregatedAuthorId><uniqueAuthorId>kaya__dayimi__d.____ziypBAB/gwoM</uniqueAuthorId></author><author><affiliation><city-group>Afyon</city-group><country code="tur">Turkey</country><organization>Dept. of Molec. Biol. and Genetics</organization><organization>Faculty of Science</organization><organization>Afyon Kocatepe University</organization></affiliation><autidx>Onrat S.T.</autidx><given-name>Serap Tutgun</given-name><initials>S.T.</initials><seq>3</seq><surname>Onrat</surname><aggregatedAuthorId>onrat s.t.__onrat__serap tutgun</aggregatedAuthorId><uniqueAuthorId>onrat__serap tutgun__s.t.____ziypBAB/gwoM</uniqueAuthorId></author></authorlist><correspondence><affiliation><city-group>03200 Afyon</city-group><country code="tur">Turkey</country><organization>Afyon Kocatepe University</organization><organization>A. N. Sezer Uygulama Arast., Hast.</organization><organization>Kardiyoloji Anabilim Dali</organization></affiliation><email>eronrat@aku.edu.tr</email><person><degrees>Dr.</degrees><initials>E.</initials><persidx>Onrat E.</persidx><surname>Onrat</surname></person></correspondence></head><tail><bibliography><refcount>10</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>carrier proteins and binding proteins</ancestor><ancestor>cation channel</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>ion channel</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>peptides and proteins</ancestor><ancestor>potassium channel</ancestor></ancestors><drgterm>potassium channel</drgterm><mainterm>potassium channel</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>case report</ancestor><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>case report</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>child</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor><ancestor>juvenile</ancestor></ancestors><mainterm>child</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical examination</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>examination</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>medical care</ancestor><ancestor>medical examination</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>clinical examination</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>congenital disorder</ancestor><ancestor>congenital malformation</ancestor><ancestor>diseases</ancestor><ancestor>ear disease</ancestor><ancestor>ear malformation</ancestor><ancestor>ear nose throat disease</ancestor><ancestor>external ear disease</ancestor><ancestor>external ear malformation</ancestor><ancestor>infant disease</ancestor><ancestor>newborn disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by developmental age</ancestor></ancestors><disterm>external ear malformation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>external ear malformation</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>congenital disorder</ancestor><ancestor>diseases</ancestor><ancestor>hypodontia</ancestor><ancestor>hypoplasia</ancestor><ancestor>infant disease</ancestor><ancestor>mouth disease</ancestor><ancestor>newborn disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by developmental age</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>tooth disease</ancestor></ancestors><disterm>hypodontia</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>hypodontia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>ladd syndrome</ancestor></ancestors><link><linkterm>diagnosis</linkterm></link><mainterm candidate="true">LADD syndrome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac channelopathy</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>channelopathy</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>long qt syndrome</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>long QT syndrome</disterm><link><linkterm>diagnosis</linkterm></link><link><linkterm>etiology</linkterm></link><mainterm>long QT syndrome</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>congenital disorder</ancestor><ancestor>congenital malformation</ancestor><ancestor>diseases</ancestor><ancestor>infant disease</ancestor><ancestor>malformation syndrome</ancestor><ancestor>multiple malformation syndrome</ancestor><ancestor>newborn disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by developmental age</ancestor></ancestors><disterm>malformation syndrome</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>malformation syndrome</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>nail disease</ancestor><ancestor>nail dysplasia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>skin appendage disease</ancestor><ancestor>skin disease</ancestor></ancestors><disterm>nail dysplasia</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>nail dysplasia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>pathophysiology</ancestor></ancestors><mainterm>pathophysiology</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>eye disease</ancestor><ancestor>eyelid disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>prolapse</ancestor><ancestor>ptosis (eyelid)</ancestor></ancestors><disterm>ptosis (eyelid)</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>ptosis (eyelid)</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>child</ag></agidx><dgidx><dt>potassium channel</dt></dgidx><dsidx><dst>external ear malformation</dst><dst>hypodontia</dst><dst>long qt syndrome</dst><dst>malformation syndrome</dst><dst>nail dysplasia</dst><dst>ptosis (eyelid)</dst></dsidx><gnidx><gn>male</gn></gnidx><stidx><stt>case report</stt><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2015-05-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2015 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L71895980</lui><pui>71895980</pui><absn>PRM125</absn></itemidlist><history><date-created>2015-05-27</date-created><date-loaded>2015-06-05</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Psychotropic pharmacotherapy associated with QT prolongation among veterans with posttraumatic stress disorder</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Objectives: In 2012, the FDA issued Drug Safety Communications on several drugs associated with QT prolongation and fatal ventricular arrhythmias. Among these was citalopram, a selective serotonin reuptake inhibitor (SSRI) commonly used to treat posttraumatic stress disorder (PTSD). As minimal research has assessed drug-related QT prolongation in patients with severe mental illnesses, this study explores psychotropic drugs associated with QT prolongation among Veterans diagnosed with PTSD. Methods: Patients with PTSD in the Veterans Health Administration in 2006-2009 were reviewed, identifying 176 Veterans diagnosed with QT prolongation. Cases were matched 1:4 on age, gender, visit date and setting, and physical comorbidity. Classification trees assessed QT prolongation risk among prescribed medications for the combined sample (N= 880). Finally, five-year survival by prolonged QT status was analyzed. Results: Receipt of any drug with known risk of QT prolongation varied by group (23% QT vs. 15% control, p&lt; 0.01). Psychotropic medications conferring significant risks included the antipsychotic ziprasidone (3% vs. 1%, p= 0.02) and the anxiolytic buspirone (6% vs. 2%, p= 0.01) but not the SSRIs citalopram and fluoxetine. Classification trees found sotalol and the tricyclic antidepressant amitriptyline carried greater risk among cardiac patients, and methadone, especially if prescribed with quetiapine, among non-cardiac patients. Per preliminary adjusted survival model, patients with QT prolongation were at increased risk for mortality (HR= 1.60; 95% CI: 1.04- 2.44). Conclusions: Decision models are particularly advantageous when exploring nonlinear relationships or non-additive interactions. These findings may potentially impact clinical decision-making concerning treatment for PTSD. For patients at higher risk of QT prolongation, antidepressants other than amitriptyline should be considered. Medications for comorbid conditions should also be closely monitored for heightened risk of QT prolongation. This study further highlights the importance of routine use of electrocardiograms for QT monitoring among patients with PTSD taking these agents.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Value in Health</sourcetitle><sourcetitle-abbrev>Value Health</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10983015</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Philadelphia, PA</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>ISPOR 20th Annual International Meeting Research</confname><enddate>2015-05-20</enddate><startdate>2015-05-16</startdate></confevent></conferenceinfo><volisspag><volume>18</volume><issue>3</issue><firstpage>A32</firstpage><volissidx>10983015||2015||18||3</volissidx></volisspag><publicationyear>2015</publicationyear><publicationdate><pubdatetext>May 2015</pubdatetext></publicationdate><publisher><publishername>Elsevier Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>psychotropic agent</drgterm><mainterm>psychotropic agent</mainterm><weight>a</weight></descriptor><descriptor><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></descriptor><descriptor><drgterm>amitriptyline</drgterm><mainterm>amitriptyline</mainterm><weight>b</weight></descriptor><descriptor><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>b</weight></descriptor><descriptor><drgterm>ziprasidone</drgterm><mainterm>ziprasidone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>quetiapine</drgterm><mainterm>quetiapine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>neuroleptic agent</drgterm><mainterm>neuroleptic agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>methadone</drgterm><mainterm>methadone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>tricyclic antidepressant agent</drgterm><mainterm>tricyclic antidepressant agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>b</weight></descriptor><descriptor><drgterm>fluoxetine</drgterm><mainterm>fluoxetine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>buspirone</drgterm><mainterm>buspirone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>anxiolytic agent</drgterm><mainterm>anxiolytic agent</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>drug therapy</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>veteran</mainterm><weight>a</weight></descriptor><descriptor><mainterm>human</mainterm><weight>a</weight></descriptor><descriptor><disterm>posttraumatic stress disorder</disterm><mainterm>posttraumatic stress disorder</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>survival</mainterm><weight>b</weight></descriptor><descriptor><mainterm>cardiac patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>model</mainterm><weight>b</weight></descriptor><descriptor><mainterm>classification</mainterm><weight>b</weight></descriptor><descriptor><mainterm>mortality</mainterm><weight>b</weight></descriptor><descriptor><mainterm>monitoring</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug safety</mainterm><weight>b</weight></descriptor><descriptor><mainterm>comorbidity</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gender</mainterm><weight>b</weight></descriptor><descriptor><mainterm>interpersonal communication</mainterm><weight>b</weight></descriptor><descriptor><mainterm>health care management</mainterm><weight>b</weight></descriptor><descriptor><mainterm>veterans health</mainterm><weight>b</weight></descriptor><descriptor><mainterm>clinical decision making</mainterm><weight>b</weight></descriptor><descriptor><disterm>mental disease</disterm><mainterm>mental disease</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>b</weight></descriptor><descriptor><mainterm>Food and Drug Administration</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Temple</city><country code="USA">United States</country><organization>Center for Applied Health Research</organization><organization>Central Texas Veterans Health Care System Jointly with Baylor Scott and White Health</organization><state>TX</state></affiliation><author><autidx>Stock E.M.</autidx><initials>E.M.</initials><seq>1</seq><surname>Stock</surname></author><author><autidx>Zeber J.E.</autidx><initials>J.E.</initials><seq>2</seq><surname>Zeber</surname></author><author><autidx>Copeland L.A.</autidx><initials>L.A.</initials><seq>5</seq><surname>Copeland</surname></author></author-group><author-group><affiliation><city>Temple</city><country code="USA">United States</country><organization>Baylor Scott and White Health</organization><state>TX</state></affiliation><author><autidx>McNeal C.J.</autidx><initials>C.J.</initials><seq>3</seq><surname>McNeal</surname></author><author><autidx>Banchs J.E.</autidx><initials>J.E.</initials><seq>4</seq><surname>Banchs</surname></author></author-group><authorlist><author><affiliation><city>Temple</city><country code="USA">United States</country><organization>Center for Applied Health Research</organization><organization>Central Texas Veterans Health Care System Jointly with Baylor Scott and White Health</organization><state>TX</state></affiliation><autidx>Stock E.M.</autidx><initials>E.M.</initials><seq>1</seq><surname>Stock</surname><aggregatedAuthorId>stock e.m.__stock__</aggregatedAuthorId><uniqueAuthorId>stock____e.m.____f3sBVgcf8g==</uniqueAuthorId></author><author><affiliation><city>Temple</city><country code="USA">United States</country><organization>Center for Applied Health Research</organization><organization>Central Texas Veterans Health Care System Jointly with Baylor Scott and White Health</organization><state>TX</state></affiliation><autidx>Zeber J.E.</autidx><initials>J.E.</initials><seq>2</seq><surname>Zeber</surname><aggregatedAuthorId>zeber j.e.__zeber__</aggregatedAuthorId><uniqueAuthorId>zeber____j.e.____f3sBVgcf8g==</uniqueAuthorId></author><author><affiliation><city>Temple</city><country code="USA">United States</country><organization>Baylor Scott and White Health</organization><state>TX</state></affiliation><autidx>McNeal C.J.</autidx><initials>C.J.</initials><seq>3</seq><surname>McNeal</surname><aggregatedAuthorId>mcneal c.j.__mcneal__</aggregatedAuthorId><uniqueAuthorId>mcneal____c.j.____yQAApeMLAQ==</uniqueAuthorId></author><author><affiliation><city>Temple</city><country code="USA">United States</country><organization>Baylor Scott and White Health</organization><state>TX</state></affiliation><autidx>Banchs J.E.</autidx><initials>J.E.</initials><seq>4</seq><surname>Banchs</surname><aggregatedAuthorId>banchs j.e.__banchs__</aggregatedAuthorId><uniqueAuthorId>banchs____j.e.____yQAApeMLAQ==</uniqueAuthorId></author><author><affiliation><city>Temple</city><country code="USA">United States</country><organization>Center for Applied Health Research</organization><organization>Central Texas Veterans Health Care System Jointly with Baylor Scott and White Health</organization><state>TX</state></affiliation><autidx>Copeland L.A.</autidx><initials>L.A.</initials><seq>5</seq><surname>Copeland</surname><aggregatedAuthorId>copeland l.a.__copeland__</aggregatedAuthorId><uniqueAuthorId>copeland____l.a.____f3sBVgcf8g==</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Temple</city><country code="USA">United States</country><organization>Center for Applied Health Research</organization><organization>Central Texas Veterans Health Care System Jointly with Baylor Scott and White Health</organization><state>TX</state></affiliation><person><initials>E.M.</initials><persidx>Stock E.M.</persidx><surname>Stock</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychotropic agent</ancestor></ancestors><drgterm>psychotropic agent</drgterm><mainterm>psychotropic agent</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>citalopram</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents affecting water, molecule or ion transport</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha 1 adrenergic receptor blocking agent</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>amitriptyline</ancestor><ancestor>analgesic agent</ancestor><ancestor>analgesic, antiinflammatory, antirheumatic and antigout agents</ancestor><ancestor>antidepressant agent</ancestor><ancestor>antimigraine agent</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>central depressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>cholinergic receptor affecting agent</ancestor><ancestor>cholinergic receptor blocking agent</ancestor><ancestor>hypnotic sedative agent</ancestor><ancestor>ion transport affecting agent</ancestor><ancestor>noradrenalin uptake inhibitor</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin noradrenalin reuptake inhibitor</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor><ancestor>sodium channel affecting agent</ancestor><ancestor>sodium channel blocking agent</ancestor><ancestor>tricyclic antidepressant agent</ancestor><ancestor>vasoactive agent</ancestor><ancestor>voltage gated sodium channel blocking agent</ancestor></ancestors><drgterm>amitriptyline</drgterm><mainterm>amitriptyline</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>atypical antipsychotic agent</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dopamine receptor affecting agent</ancestor><ancestor>dopamine receptor blocking agent</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>indole derivative</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>tranquilizer</ancestor><ancestor>ziprasidone</ancestor></ancestors><drgterm>ziprasidone</drgterm><mainterm>ziprasidone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>atypical antipsychotic agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dopamine receptor affecting agent</ancestor><ancestor>dopamine receptor blocking agent</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>psychotropic agent</ancestor><ancestor>quetiapine</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>quetiapine</drgterm><mainterm>quetiapine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor></ancestors><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>neuroleptic agent</drgterm><mainterm>neuroleptic agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>analgesic agent</ancestor><ancestor>analgesic, antiinflammatory, antirheumatic and antigout agents</ancestor><ancestor>central depressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>drugs used in the treatment of addiction</ancestor><ancestor>methadone</ancestor><ancestor>narcotic agent</ancestor><ancestor>narcotic analgesic agent</ancestor><ancestor>opiate agonist</ancestor><ancestor>opiate receptor affecting agent</ancestor></ancestors><drgterm>methadone</drgterm><mainterm>methadone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tricyclic antidepressant agent</ancestor></ancestors><drgterm>tricyclic antidepressant agent</drgterm><mainterm>tricyclic antidepressant agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>beta adrenergic receptor blocking agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>sotalol</ancestor></ancestors><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>amine</ancestor><ancestor>antidepressant agent</ancestor><ancestor>aromatic amine</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>fluoxetine</ancestor><ancestor>functional group</ancestor><ancestor>groups with a carbon-nitrogen bond only</ancestor><ancestor>organic compound</ancestor><ancestor>organonitrogen derivative</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>fluoxetine</drgterm><mainterm>fluoxetine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor stimulating agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha 1 adrenergic receptor stimulating agent</ancestor><ancestor>alpha adrenergic receptor stimulating agent</ancestor><ancestor>amide</ancestor><ancestor>anxiolytic agent</ancestor><ancestor>buspirone</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>carboxyl group</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>functional group</ancestor><ancestor>functional groups containing oxygen</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>lactam</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>nucleic acids, nucleic acid components and their derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>piperidine derivative</ancestor><ancestor>psychotropic agent</ancestor><ancestor>pyrimidine derivative</ancestor><ancestor>pyrimidines and pyrimidine derivatives</ancestor><ancestor>serotonin agonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>buspirone</drgterm><mainterm>buspirone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>anxiolytic agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>anxiolytic agent</drgterm><mainterm>anxiolytic agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>named groups by occupation</ancestor><ancestor>named groups of persons</ancestor><ancestor>nonmedical occupations</ancestor><ancestor>veteran</ancestor></ancestors><mainterm>veteran</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>anxiety disorder</ancestor><ancestor>diseases</ancestor><ancestor>mental disease</ancestor><ancestor>posttraumatic stress disorder</ancestor></ancestors><disterm>posttraumatic stress disorder</disterm><mainterm>posttraumatic stress disorder</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>disease course</ancestor><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>general aspects of disease</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>survival</ancestor></ancestors><mainterm>survival</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac patient</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>cardiac patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>model</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>model</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>classification</ancestor><ancestor>coding and classification</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>classification</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mortality</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>mortality</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diagnostic procedure</ancestor><ancestor>medical procedures</ancestor><ancestor>monitoring</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>quality control procedures</ancestor></ancestors><mainterm>monitoring</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug safety</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>drug safety</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>comorbidity</ancestor><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>comorbidity</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender</ancestor><ancestor>gender and sex</ancestor></ancestors><mainterm>gender</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>behavior</ancestor><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>interpersonal communication</ancestor><ancestor>social behavior</ancestor></ancestors><mainterm>interpersonal communication</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care management</ancestor></ancestors><mainterm>health care management</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>health</ancestor><ancestor>military health</ancestor><ancestor>physical constitution and health</ancestor><ancestor>veterans health</ancestor></ancestors><mainterm>veterans health</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>clinical decision making</ancestor><ancestor>cognition</ancestor><ancestor>decision making</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>medical care</ancestor><ancestor>mental function</ancestor><ancestor>thinking</ancestor></ancestors><mainterm>clinical decision making</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>mental disease</ancestor></ancestors><disterm>mental disease</disterm><mainterm>mental disease</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>food and drug administration</ancestor><ancestor>health care concepts</ancestor><ancestor>health care organization</ancestor></ancestors><mainterm>Food and Drug Administration</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>amitriptyline</dt><dt>antidepressant agent</dt><dt>anxiolytic agent</dt><dt>buspirone</dt><dt>citalopram</dt><dt>fluoxetine</dt><dt>methadone</dt><dt>neuroleptic agent</dt><dt>psychotropic agent</dt><dt>quetiapine</dt><dt>serotonin uptake inhibitor</dt><dt>sotalol</dt><dt>tricyclic antidepressant agent</dt><dt>ziprasidone</dt></dgidx><dsidx><dst>heart ventricle arrhythmia</dst><dst>mental disease</dst><dst>posttraumatic stress disorder</dst><dst>qt prolongation</dst></dsidx><stidx><stt>human</stt><stt>model</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2012-08-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2012 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1002/pds.3324</doi><lui>L70935745</lui><pui>70935745</pui><absn>569</absn></itemidlist><history><date-created>2012-12-06</date-created><date-loaded>2012-12-11</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Detection of QT prolongation signals using an electronic health record database</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: Drug-induced QT prolongation can cause life-threatening arrhythmia. However, postmarketing surveillance based on spontaneous reporting systems has a limited ability to detect QT prolongation signal due to the rare incidence and reports.We hypothesized that a surveillance system based on electronic health records (EHRs) could be used to detect the signal because EHRs collect most of the clinical events in a hospital. Objectives: To develop a QT prolongation signal surveillance system using EHR data. Methods: We developed a QT prolongation surveillance system linked to the EHR database of a Korean tertiary teaching hospital. The database contains 15 years of ECG, clinical, and prescription data. The system performed a predefined case-crossover study. From the database, we selected 6,326 subjects (age 20-59 years) who had incident QT prolongation. For each subject, one case and one control period were matched. The drug prescribed in the 24-hour case period just before the event was compared with the drug in an earlier 24-hour control period, separated by a 72-hour washout period. Conditional logistic regression analysis was used to estimate odds ratios and 95% confidence intervals (CIs), after adjusting for hospitalization and concomitant drugs known to be related to QT prolongation. A lower margin of the 95% CI &gt;2 was considered a positive signal. To evaluate the system performance, 20 drugs were selected: 13 known to cause QT prolongation and seven others. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. The time required for analysis was also checked. Results: The sensitivity, specificity, PPV, and NPV of the system were 92.3, 71.4, 85.7, and 83.3%, respectively. On average, only 54 minutes were required to analyze one drug. Conclusions: The developed system was fully automated and successfully detected QT prolongation signals with good performance and short analysis time using the linked EHR data. The system should be useful for surveillance of QT prolongation caused by marketed drugs.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Pharmacoepidemiology and Drug Safety</sourcetitle><sourcetitle-abbrev>Pharmacoepidemiol. Drug Saf.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10538569</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Barcelona</city-group><clcountry code="ESP">Spain</clcountry></conflocation><confname>28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, ICPE 2012</confname><enddate>2012-08-26</enddate><startdate>2012-08-23</startdate></confevent></conferenceinfo><volisspag><volume>21</volume><firstpage>267</firstpage><volissidx>10538569||2012||21||</volissidx><supplement>SUPPL. 3</supplement></volisspag><publicationyear>2012</publicationyear><publicationdate><pubdatetext>August 2012</pubdatetext></publicationdate><publisher><publishername>John Wiley and Sons Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>electronic medical record</mainterm><weight>a</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>a</weight></descriptor><descriptor><mainterm>pharmacoepidemiology</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk management</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>Tertiary (period)</mainterm><weight>b</weight></descriptor><descriptor><mainterm>predictive value</mainterm><weight>b</weight></descriptor><descriptor><mainterm>logistic regression analysis</mainterm><weight>b</weight></descriptor><descriptor><mainterm>crossover procedure</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart arrhythmia</disterm><mainterm>heart arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prescription</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospitalization</mainterm><weight>b</weight></descriptor><descriptor><mainterm>confidence interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>teaching hospital</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospital</mainterm><weight>b</weight></descriptor><descriptor><mainterm>postmarketing surveillance</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><author><autidx>Yoon D.</autidx><given-name>Dukyong</given-name><initials>D.</initials><seq>1</seq><surname>Yoon</surname></author><author><autidx>Park M.Y.</autidx><given-name>Man Young</given-name><initials>M.Y.</initials><seq>2</seq><surname>Park</surname></author><author><autidx>Ahn E.K.</autidx><given-name>Eun Kyoung</given-name><initials>E.K.</initials><seq>3</seq><surname>Ahn</surname></author><author><autidx>Park R.W.</autidx><given-name>Rae Woong</given-name><initials>R.W.</initials><seq>6</seq><surname>Park</surname></author></author-group><author-group><affiliation><city>Seoul</city><country code="KOR">South Korea</country><organization>Medical Research Collaborating Center</organization><organization>Seoul National University Hospital</organization><organization>Seoul National University College ofMedicine</organization></affiliation><author><autidx>Choi N.-K.</autidx><given-name>Nam-Kyong</given-name><initials>N.-K.</initials><seq>4</seq><surname>Choi</surname></author><author><autidx>Lee J.</autidx><given-name>Joongyub</given-name><initials>J.</initials><seq>5</seq><surname>Lee</surname></author></author-group><authorlist><author><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><autidx>Yoon D.</autidx><given-name>Dukyong</given-name><initials>D.</initials><seq>1</seq><surname>Yoon</surname><aggregatedAuthorId>yoon d.__yoon__dukyong</aggregatedAuthorId><uniqueAuthorId>yoon__dukyong__d.____zsxLBQDpQg0t</uniqueAuthorId></author><author><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><autidx>Park M.Y.</autidx><given-name>Man Young</given-name><initials>M.Y.</initials><seq>2</seq><surname>Park</surname><aggregatedAuthorId>park m.y.__park__man young</aggregatedAuthorId><uniqueAuthorId>park__man young__m.y.____zsxLBQDpQg0t</uniqueAuthorId></author><author><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><autidx>Ahn E.K.</autidx><given-name>Eun Kyoung</given-name><initials>E.K.</initials><seq>3</seq><surname>Ahn</surname><aggregatedAuthorId>ahn e.k.__ahn__eun kyoung</aggregatedAuthorId><uniqueAuthorId>ahn__eun kyoung__e.k.____zsxLBQDpQg0t</uniqueAuthorId></author><author><affiliation><city>Seoul</city><country code="KOR">South Korea</country><organization>Medical Research Collaborating Center</organization><organization>Seoul National University Hospital</organization><organization>Seoul National University College ofMedicine</organization></affiliation><autidx>Choi N.-K.</autidx><given-name>Nam-Kyong</given-name><initials>N.-K.</initials><seq>4</seq><surname>Choi</surname><aggregatedAuthorId>choi n.-k.__choi__nam-kyong</aggregatedAuthorId><uniqueAuthorId>choi__nam-kyong__n.-k.____nY2OD4bvEU8=</uniqueAuthorId></author><author><affiliation><city>Seoul</city><country code="KOR">South Korea</country><organization>Medical Research Collaborating Center</organization><organization>Seoul National University Hospital</organization><organization>Seoul National University College ofMedicine</organization></affiliation><autidx>Lee J.</autidx><given-name>Joongyub</given-name><initials>J.</initials><seq>5</seq><surname>Lee</surname><aggregatedAuthorId>lee j.__lee__joongyub</aggregatedAuthorId><uniqueAuthorId>lee__joongyub__j.____nY2OD4bvEU8=</uniqueAuthorId></author><author><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><autidx>Park R.W.</autidx><given-name>Rae Woong</given-name><initials>R.W.</initials><seq>6</seq><surname>Park</surname><aggregatedAuthorId>park r.w.__park__rae woong</aggregatedAuthorId><uniqueAuthorId>park__rae woong__r.w.____zsxLBQDpQg0t</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Suwon</city><country code="KOR">South Korea</country><organization>Biomedical Informatics</organization><organization>Ajou University School of Medicine</organization></affiliation><person><initials>D.</initials><persidx>Yoon D.</persidx><surname>Yoon</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>data processing</ancestor><ancestor>documentation</ancestor><ancestor>electronic medical record</ancestor><ancestor>health care concepts</ancestor><ancestor>health care management</ancestor><ancestor>information</ancestor><ancestor>medical record</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>electronic medical record</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>diseases</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>pharmacoepidemiology</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>pharmacoepidemiology</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk management</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk management</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cenozoic</ancestor><ancestor>environment</ancestor><ancestor>geographic and geological phenomena</ancestor><ancestor>geological time</ancestor><ancestor>phanerozoic</ancestor><ancestor>society and environment</ancestor><ancestor>tertiary (period)</ancestor></ancestors><mainterm>Tertiary (period)</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>prediction and forecasting</ancestor><ancestor>predictive value</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>predictive value</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>logistic regression analysis</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>regression analysis</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor></ancestors><mainterm>logistic regression analysis</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>crossover procedure</ancestor><ancestor>methodology</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>crossover procedure</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart arrhythmia</disterm><mainterm>heart arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug use</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>prescription</ancestor></ancestors><mainterm>prescription</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care management</ancestor><ancestor>hospital management</ancestor><ancestor>hospitalization</ancestor><ancestor>management</ancestor><ancestor>organization and management</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>hospitalization</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>confidence interval</ancestor><ancestor>mathematical parameters</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical concepts</ancestor><ancestor>statistical parameters</ancestor></ancestors><mainterm>confidence interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor><ancestor>teaching hospital</ancestor></ancestors><mainterm>teaching hospital</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor></ancestors><mainterm>hospital</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>postmarketing surveillance</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>postmarketing surveillance</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>b</weight></explosion></explosions><idxs><dsidx><dst>heart arrhythmia</dst><dst>qt prolongation</dst></dsidx><stidx><stt>crossover procedure</stt><stt>postmarketing surveillance</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2011-05-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2011 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.hrthm.2011.03.022</doi><lui>L70390091</lui><pui>70390091</pui><absn>AB19-3</absn><pii>S154752711100289X</pii></itemidlist><history><date-created>2011-04-21</date-created><date-loaded>2011-04-22</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Drug induced qt prolongation and associated outcomes in children admitted to a pediatric tertiary care hospital</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Introduction: Drug induced QT prolongation has been associated with ventricular arrhythmias, Torsade de Pointes, and death. Limited data exists on the incidence of drug induced QT prolongation, its pro-arrhythmic effects, and associated risk factors in hospitalized children. Methods: We performed a retrospective study looking at all children admitted to our institution from January 2005 to December 2009 who received known QT prolonging medications (www.qtdrugs.org). Patients with known congenital Long QT Syndrome or other known exogenous causes of QT prolongation were excluded. Results: During the study period, there were 102,343 admissions to our institution. Of those, 33,332 pts (32.6%) received at least one known QT prolonging medication with 5,189 (15.6%) having an ECG performed during drug administration. Of pts screened while receiving QT prolonging medications, 7.3% (377) had QT prolongation (QTc&gt;450msecs) and 2.1% (110) had marked QT prolongation (QTc&gt;500msecs). Of those with documented QT prolongation, 41 (10.9%) had a ventricular arrhythmia, 10 (2.7%) had Torsades or VF arrest, and 5 (1.3%) had sudden cardiac death. Demographic factors, including age and gender were not associated with an increased risk of arrhythmias or death. Receiving multiple QT prolonging medications was also not associated with an increased risk of arrhythmias or death. Class 1 QT prolonging medications (those generally accepted to carry a risk of Torsades) were associated with marked QT prolongation (p=0.01) and an increased risk of ventricular arrhythmias with 22/104 (21.1%) of pts experiencing VT or VF (OR 3.6; 95% CI 1.9 to 7.0)(p&lt;0.001). Class of QT prolonging medication (p=0.42) and marked QT prolongation (p=0.54) were not however associated with an increased risk of sudden cardiac death. Conclusions: The administration of QT prolonging medications is common in children admitted for treatment to a tertiary care hospital. Ventricular arrhythmias are not rare in hospitalized children with drug induced QT prolongation, and those receiving Class 1 agents with marked QT prolongation are at greatest risk.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Heart Rhythm</sourcetitle><sourcetitle-abbrev>Heart Rhythm</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>15475271</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>San Francisco, CA</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>32nd Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm</confname><enddate>2011-05-07</enddate><startdate>2011-05-04</startdate></confevent></conferenceinfo><contributor-group><affiliation><organization>St. Jude Medical and Medtronic Inc.</organization></affiliation><contributor><ctrbidx>Gillis A.M.</ctrbidx><given-name>Anne M.</given-name><initials>A.M.</initials><degrees>Dr.</degrees><role code="edit">editor</role><seq>1</seq><surname>Gillis</surname></contributor></contributor-group><volisspag><volume>8</volume><issue>5</issue><firstpage>S43</firstpage><volissidx>15475271||2011||8||5</volissidx><supplement>SUPPL. 1</supplement></volisspag><publicationyear>2011</publicationyear><publicationdate><pubdatetext>May 2011</pubdatetext></publicationdate><publisher><publishername>Elsevier</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>child</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>heart rhythm</mainterm><weight>a</weight></descriptor><descriptor><mainterm>hospital</mainterm><weight>a</weight></descriptor><descriptor><mainterm>tertiary health care</mainterm><weight>a</weight></descriptor><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug therapy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>death</mainterm><weight>b</weight></descriptor><descriptor><mainterm>child hospitalization</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospitalized child</mainterm><weight>b</weight></descriptor><descriptor><mainterm>sudden death</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart arrhythmia</disterm><mainterm>heart arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor><mainterm>retrospective study</mainterm><weight>b</weight></descriptor><descriptor><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug administration</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gender</mainterm><weight>b</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><author><autidx>Macicek S.L.</autidx><given-name>Scott L.</given-name><initials>S.L.</initials><seq>1</seq><surname>Macicek</surname></author><author><autidx>Shah K.</autidx><given-name>Kunal</given-name><initials>K.</initials><seq>2</seq><surname>Shah</surname></author><author><autidx>Moffett B.</autidx><given-name>Brady</given-name><initials>B.</initials><seq>3</seq><surname>Moffett</surname></author><author><autidx>Decker J.A.</autidx><given-name>Jamie A.</given-name><initials>J.A.</initials><seq>4</seq><surname>Decker</surname></author><author><autidx>Friedman R.A.</autidx><given-name>Richard A.</given-name><initials>R.A.</initials><seq>5</seq><surname>Friedman</surname></author><author><autidx>Srinivasan C.</autidx><given-name>Chandra</given-name><initials>C.</initials><seq>6</seq><surname>Srinivasan</surname></author><author><autidx>Kim J.J.</autidx><given-name>Jeffrey J.</given-name><initials>J.J.</initials><seq>7</seq><surname>Kim</surname></author></author-group><author-group><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><author><autidx>Macicek S.L.</autidx><given-name>Scott L.</given-name><initials>S.L.</initials><seq>1</seq><surname>Macicek</surname></author><author><autidx>Shah K.</autidx><given-name>Kunal</given-name><initials>K.</initials><seq>2</seq><surname>Shah</surname></author><author><autidx>Moffett B.</autidx><given-name>Brady</given-name><initials>B.</initials><seq>3</seq><surname>Moffett</surname></author><author><autidx>Decker J.A.</autidx><given-name>Jamie A.</given-name><initials>J.A.</initials><seq>4</seq><surname>Decker</surname></author><author><autidx>Friedman R.A.</autidx><given-name>Richard A.</given-name><initials>R.A.</initials><seq>5</seq><surname>Friedman</surname></author><author><autidx>Srinivasan C.</autidx><given-name>Chandra</given-name><initials>C.</initials><seq>6</seq><surname>Srinivasan</surname></author><author><autidx>Kim J.J.</autidx><given-name>Jeffrey J.</given-name><initials>J.J.</initials><seq>7</seq><surname>Kim</surname></author></author-group><authorlist><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Macicek S.L.</autidx><given-name>Scott L.</given-name><initials>S.L.</initials><seq>1</seq><surname>Macicek</surname><aggregatedAuthorId>macicek s.l.__macicek__scott l.</aggregatedAuthorId><uniqueAuthorId>macicek__scott l.__s.l.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Shah K.</autidx><given-name>Kunal</given-name><initials>K.</initials><seq>2</seq><surname>Shah</surname><aggregatedAuthorId>shah k.__shah__kunal</aggregatedAuthorId><uniqueAuthorId>shah__kunal__k.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Moffett B.</autidx><given-name>Brady</given-name><initials>B.</initials><seq>3</seq><surname>Moffett</surname><aggregatedAuthorId>moffett b.__moffett__brady</aggregatedAuthorId><uniqueAuthorId>moffett__brady__b.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Decker J.A.</autidx><given-name>Jamie A.</given-name><initials>J.A.</initials><seq>4</seq><surname>Decker</surname><aggregatedAuthorId>decker j.a.__decker__jamie a.</aggregatedAuthorId><uniqueAuthorId>decker__jamie a.__j.a.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Friedman R.A.</autidx><given-name>Richard A.</given-name><initials>R.A.</initials><seq>5</seq><surname>Friedman</surname><aggregatedAuthorId>friedman r.a.__friedman__richard a.</aggregatedAuthorId><uniqueAuthorId>friedman__richard a.__r.a.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Srinivasan C.</autidx><given-name>Chandra</given-name><initials>C.</initials><seq>6</seq><surname>Srinivasan</surname><aggregatedAuthorId>srinivasan c.__srinivasan__chandra</aggregatedAuthorId><uniqueAuthorId>srinivasan__chandra__c.____LEnMAQB9WQmt</uniqueAuthorId></author><author><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><affiliation><city>Houston</city><country code="USA">United States</country><organization>Baylor College of Medicine</organization><state>TX</state></affiliation><autidx>Kim J.J.</autidx><given-name>Jeffrey J.</given-name><initials>J.J.</initials><seq>7</seq><surname>Kim</surname><aggregatedAuthorId>kim j.j.__kim__jeffrey j.</aggregatedAuthorId><uniqueAuthorId>kim__jeffrey j.__j.j.____LEnMAQB9WQmt</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Houston</city><country code="USA">United States</country><organization>Texas Children's Hospital</organization><state>TX</state></affiliation><person><degrees>Dr.</degrees><initials>S.L.</initials><persidx>Macicek S.L.</persidx><surname>Macicek</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>child</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor><ancestor>juvenile</ancestor></ancestors><mainterm>child</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>heart rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rhythm</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor></ancestors><mainterm>hospital</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>tertiary health care</ancestor></ancestors><mainterm>tertiary health care</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor></ancestors><mainterm>death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>child health care</ancestor><ancestor>child hospitalization</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care management</ancestor><ancestor>health service</ancestor><ancestor>hospital management</ancestor><ancestor>management</ancestor><ancestor>organization and management</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>child hospitalization</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>child</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor><ancestor>hospital patient</ancestor><ancestor>hospitalized child</ancestor><ancestor>juvenile</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>hospitalized child</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>sudden death</ancestor></ancestors><mainterm>sudden death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart arrhythmia</disterm><mainterm>heart arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>retrospective study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>retrospective study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac channelopathy</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>channelopathy</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>long qt syndrome</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>administration of drugs, food and chemicals</ancestor><ancestor>drug administration</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>drug administration</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender</ancestor><ancestor>gender and sex</ancestor></ancestors><mainterm>gender</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>child</ag></agidx><dsidx><dst>heart arrhythmia</dst><dst>heart ventricle arrhythmia</dst><dst>long qt syndrome</dst><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><stidx><stt>retrospective study</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2016-04-05</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2016 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L72242186</lui><pui>72242186</pui></itemidlist><history><date-created>2016-04-12</date-created><date-loaded>2016-04-13</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Qt prolongation is associated with mortality in end stage liver disease patients</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: QT prolongation is associated with increased risk of ventricular arrhythmias and sudden cardiac death. Previous studies have suggested increased prevalence of QT prolongation in end stage liver disease (ESLD) patients. Methods: We aimed to determine the prevalence of QT prolongation in a large series of ESLD patients and its association to clinical variables and mortality. The QT interval was measured and corrected for heart rate for each patient, with a prolonged QT cutoff defined as QT &gt; 450 msec for males and QT &gt; 470 msec for females. Multiple clinical variables were evaluated including sex, age, serum sodium, international normalized ratio, creatinine, total bilirubin, beta-blocker use, Model for End-Stage Liver Disease (MELD), MELD-Na, and etiology of liver disease. Results: Among 406 ESLD patients analyzed, 207 (51.0%) had QT prolongation. The only clinical variable associated with QT prolongation was male gender (OR 3.04, 95% CI 2.01-4.60, p &lt; 0.001). During the study period, 187 patients (46.1%) died. QT prolongation was a significant predictor of mortality (OR 1.69, 95% CI 1.03-2.77, p=0.039). In addition, mortality was also associated with viral etiology of ESLD, elevated MELD score and its components (P &lt; 0.05 for all). Conclusions: QT prolongation was commonly encountered in an ESLD population and served as strong marker for increased mortality. (Figure Presented).</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Journal of the American College of Cardiology</sourcetitle><sourcetitle-abbrev>J. Am. Coll. Cardiol.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>07351097</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Chicago, IL</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>65th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC.16</confname><enddate>2016-04-04</enddate><startdate>2016-04-02</startdate></confevent></conferenceinfo><volisspag><volume>67</volume><issue>13</issue><firstpage>683</firstpage><volissidx>07351097||2016||67||13</volissidx><supplement>SUPPL. 1</supplement></volisspag><publicationyear>2016</publicationyear><publicationdate><pubdate day="05" month="04" year="2016">2016-04-05</pubdate></publicationdate><publisher><publishername>Elsevier USA</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>beta adrenergic receptor blocking agent</drgterm><mainterm>beta adrenergic receptor blocking agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>creatinine</drgterm><mainterm>creatinine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>bilirubin</drgterm><mainterm>bilirubin</mainterm><weight>b</weight></descriptor><descriptor><drgterm>marker</drgterm><mainterm>marker</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>mortality</mainterm><weight>a</weight></descriptor><descriptor><disterm>end stage liver disease</disterm><mainterm>end stage liver disease</mainterm><weight>a</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>a</weight></descriptor><descriptor><mainterm>human</mainterm><weight>a</weight></descriptor><descriptor><mainterm>American</mainterm><weight>a</weight></descriptor><descriptor><mainterm>college</mainterm><weight>a</weight></descriptor><descriptor><mainterm>cardiology</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prevalence</mainterm><weight>b</weight></descriptor><descriptor><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></descriptor><descriptor><mainterm>sodium blood level</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>heart rate</mainterm><weight>b</weight></descriptor><descriptor><mainterm>international normalized ratio</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>model</mainterm><weight>b</weight></descriptor><descriptor><mainterm>population</mainterm><weight>b</weight></descriptor><descriptor><mainterm>virus etiology</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gender</mainterm><weight>b</weight></descriptor><descriptor><disterm>liver disease</disterm><mainterm>liver disease</mainterm><weight>b</weight></descriptor><descriptor><mainterm>etiology</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><author><autidx>Kim S.M.</autidx><given-name>Sun Moon</given-name><initials>S.M.</initials><seq>1</seq><surname>Kim</surname></author><author><autidx>George B.</autidx><given-name>Bennet</given-name><initials>B.</initials><seq>2</seq><surname>George</surname></author><author><autidx>Franco D.A.</autidx><given-name>Diego Alcivar</given-name><initials>D.A.</initials><seq>3</seq><surname>Franco</surname></author><author><autidx>Charnigo R.</autidx><given-name>Richard</given-name><initials>R.</initials><seq>4</seq><surname>Charnigo</surname></author><author><autidx>Campbell C.</autidx><given-name>Charles</given-name><initials>C.</initials><seq>5</seq><surname>Campbell</surname></author><author><autidx>Elayi S.</autidx><given-name>Samy</given-name><initials>S.</initials><seq>6</seq><surname>Elayi</surname></author><author><autidx>Bailey A.</autidx><given-name>Alison</given-name><initials>A.</initials><seq>7</seq><surname>Bailey</surname></author></author-group><authorlist><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Kim S.M.</autidx><given-name>Sun Moon</given-name><initials>S.M.</initials><seq>1</seq><surname>Kim</surname><aggregatedAuthorId>kim s.m.__kim__sun moon</aggregatedAuthorId><uniqueAuthorId>kim__sun moon__s.m.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>George B.</autidx><given-name>Bennet</given-name><initials>B.</initials><seq>2</seq><surname>George</surname><aggregatedAuthorId>george b.__george__bennet</aggregatedAuthorId><uniqueAuthorId>george__bennet__b.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Franco D.A.</autidx><given-name>Diego Alcivar</given-name><initials>D.A.</initials><seq>3</seq><surname>Franco</surname><aggregatedAuthorId>franco d.a.__franco__diego alcivar</aggregatedAuthorId><uniqueAuthorId>franco__diego alcivar__d.a.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Charnigo R.</autidx><given-name>Richard</given-name><initials>R.</initials><seq>4</seq><surname>Charnigo</surname><aggregatedAuthorId>charnigo r.__charnigo__richard</aggregatedAuthorId><uniqueAuthorId>charnigo__richard__r.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Campbell C.</autidx><given-name>Charles</given-name><initials>C.</initials><seq>5</seq><surname>Campbell</surname><aggregatedAuthorId>campbell c.__campbell__charles</aggregatedAuthorId><uniqueAuthorId>campbell__charles__c.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Elayi S.</autidx><given-name>Samy</given-name><initials>S.</initials><seq>6</seq><surname>Elayi</surname><aggregatedAuthorId>elayi s.__elayi__samy</aggregatedAuthorId><uniqueAuthorId>elayi__samy__s.____Tc6uBABnQAjm</uniqueAuthorId></author><author><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><autidx>Bailey A.</autidx><given-name>Alison</given-name><initials>A.</initials><seq>7</seq><surname>Bailey</surname><aggregatedAuthorId>bailey a.__bailey__alison</aggregatedAuthorId><uniqueAuthorId>bailey__alison__a.____Tc6uBABnQAjm</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Lexington</city><country code="USA">United States</country><organization>University of Kentucky</organization><state>KY</state></affiliation><person><initials>S.M.</initials><persidx>Kim S.M.</persidx><surname>Kim</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>beta adrenergic receptor blocking agent</ancestor><ancestor>chemicals and drugs</ancestor></ancestors><drgterm>beta adrenergic receptor blocking agent</drgterm><mainterm>beta adrenergic receptor blocking agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amino acid</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>creatinine</ancestor><ancestor>functional group</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>imidazole derivative</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>polyfunctional group</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>creatinine</drgterm><mainterm>creatinine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>bilirubin</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>porphyrins and porphyrin derivatives</ancestor></ancestors><drgterm>bilirubin</drgterm><mainterm>bilirubin</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>chemicals and drugs</ancestor><ancestor>diagnostic agent</ancestor><ancestor>dyes, reagents, indicators, markers and buffers</ancestor><ancestor>marker</ancestor></ancestors><drgterm>marker</drgterm><mainterm>marker</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mortality</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>mortality</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>digestive system disease</ancestor><ancestor>digestive system function disorder</ancestor><ancestor>diseases</ancestor><ancestor>end stage liver disease</ancestor><ancestor>hepatobiliary disease</ancestor><ancestor>liver disease</ancestor><ancestor>liver dysfunction</ancestor><ancestor>liver failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>end stage liver disease</disterm><mainterm>end stage liver disease</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>american</ancestor><ancestor>citizen group</ancestor><ancestor>named groups of persons</ancestor><ancestor>north american</ancestor><ancestor>population group</ancestor></ancestors><mainterm>American</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>college</ancestor><ancestor>education</ancestor><ancestor>school</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>college</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biomedical disciplines, science and art</ancestor><ancestor>biomedicine</ancestor><ancestor>cardiology</ancestor><ancestor>internal medicine</ancestor><ancestor>medicine</ancestor></ancestors><mainterm>cardiology</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mathematical parameters</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>parameters</ancestor><ancestor>prevalence</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical concepts</ancestor><ancestor>statistical parameters</ancestor></ancestors><mainterm>prevalence</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>heart arrest</ancestor><ancestor>heart disease</ancestor><ancestor>heart failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>sudden cardiac death</ancestor><ancestor>sudden death</ancestor></ancestors><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>blood level</ancestor><ancestor>chemical parameters</ancestor><ancestor>electrolyte blood level</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>sodium blood level</ancestor></ancestors><mainterm>sodium blood level</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>blood clotting parameters</ancestor><ancestor>hematological parameters</ancestor><ancestor>international normalized ratio</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>international normalized ratio</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>model</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>model</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>classification</ancestor><ancestor>coding and classification</ancestor><ancestor>ecological phenomena and functions</ancestor><ancestor>infraspecific rank</ancestor><ancestor>population</ancestor><ancestor>population and population related phenomena</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor><ancestor>taxonomic rank</ancestor><ancestor>taxonomy</ancestor></ancestors><mainterm>population</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>etiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>virus etiology</ancestor></ancestors><mainterm>virus etiology</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender</ancestor><ancestor>gender and sex</ancestor></ancestors><mainterm>gender</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>digestive system disease</ancestor><ancestor>diseases</ancestor><ancestor>hepatobiliary disease</ancestor><ancestor>liver disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>liver disease</disterm><mainterm>liver disease</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>etiology</ancestor><ancestor>general aspects of disease</ancestor></ancestors><mainterm>etiology</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>beta adrenergic receptor blocking agent</dt><dt>bilirubin</dt><dt>creatinine</dt><dt>marker</dt></dgidx><dsidx><dst>end stage liver disease</dst><dst>heart ventricle arrhythmia</dst><dst>liver disease</dst><dst>qt prolongation</dst><dst>sudden cardiac death</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>human</stt><stt>model</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2009-04-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2010 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.ijmedinf.2008.09.001</doi><lui>L50304617</lui><pui>50304617</pui><embase>2009139577</embase><medl>18938105</medl><pii>S1386505608001627</pii></itemidlist><history><date-created>2009-06-10</date-created><date-loaded>2009-06-11</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Concept identification</author-keyword><author-keyword>Decision support</author-keyword><author-keyword>Electrocardiogram</author-keyword><author-keyword>Natural language processing</author-keyword><author-keyword>Negation detection</author-keyword><author-keyword>QT prolongation</author-keyword><author-keyword>Unified Medical Language System</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Objective: Typically detected via electrocardiograms (ECGs), QT interval prolongation is a known risk factor for sudden cardiac death. Since medications can promote or exacerbate the condition, detection of QT interval prolongation is important for clinical decision support. We investigated the accuracy of natural language processing (NLP) for identifying QT prolongation from cardiologist-generated, free-text ECG impressions compared to corrected QT (QTc) thresholds reported by ECG machines. Methods: After integrating negation detection to a locally developed natural language processor, the KnowledgeMap concept identifier, we evaluated NLP-based detection of QT prolongation compared to the calculated QTc on a set of 44,318 ECGs obtained from hospitalized patients. We also created a string query using regular expressions to identify QT prolongation. We calculated sensitivity and specificity of the methods using manual physician review of the cardiologist-generated reports as the gold standard. To investigate causes of "false positive" calculated QTc, we manually reviewed randomly selected ECGs with a long calculated QTc but no mention of QT prolongation. Separately, we validated the performance of the negation detection algorithm on 5000 manually categorized ECG phrases for any medical concept (not limited to QT prolongation) prior to developing the NLP query for QT prolongation. Results: The NLP query for QT prolongation correctly identified 2364 of 2373 ECGs with QT prolongation with a sensitivity of 0.996 and a positive predictive value of 1.000. There were no false positives. The regular expression query had a sensitivity of 0.999 and positive predictive value of 0.982. In contrast, the positive predictive value of common QTc thresholds derived from ECG machines was 0.07-0.25 with corresponding sensitivities of 0.994-0.046. The negation detection algorithm had a recall of 0.973 and precision of 0.982 for 10,490 concepts found within ECG impressions. Conclusion: NLP and regular expression queries of cardiologists' ECG interpretations can more effectively identify QT prolongation than the automated QTc intervals reported by ECG machines. Future clinical decision support could employ NLP queries to detect QTc prolongation and other reported ECG abnormalities. © 2008 Elsevier Ireland Ltd. All rights reserved.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="irl">Ireland</sourcecountry><sourcetitle>International Journal of Medical Informatics</sourcetitle><sourcetitle-abbrev>Int. J. Med. Informatics</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>13865056</issnnr></issn><codencode>IJMIF</codencode><volisspag><volume>78</volume><issue>SUPPL. 1</issue><firstpage>34</firstpage><volissidx>13865056||2009||78||SUPPL. 1</volissidx><lastpage>42</lastpage></volisspag><publicationyear>2009</publicationyear><publicationdate><pubdatetext>April 2009</pubdatetext></publicationdate><publisher><affiliation><address-part>P.O. Box 85</address-part><city>Limerick</city><country code="irl">Ireland</country></affiliation><publishername>Elsevier Ireland Ltd</publishername></publisher></source><enhancement><classifications><clsemclass>18</clsemclass><clsemclass>27</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>algorithm</mainterm><weight>b</weight></descriptor><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>cardiologist</mainterm><weight>b</weight></descriptor><descriptor><mainterm>computer language</mainterm><weight>b</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>b</weight></descriptor><descriptor><mainterm>decision support system</mainterm><weight>b</weight></descriptor><descriptor><mainterm>diagnostic accuracy</mainterm><weight>b</weight></descriptor><descriptor><disterm>ECG abnormality</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>ECG abnormality</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>a</weight></descriptor><descriptor><mainterm>gold standard</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospital patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>information processing</mainterm><weight>b</weight></descriptor><descriptor><mainterm>major clinical study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>medical information system</mainterm><weight>a</weight></descriptor><descriptor><mainterm>priority journal</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><author><autidx>Denny J.C.</autidx><email>josh.denny@vanderbilt.edu</email><given-name>Joshua C.</given-name><initials>J.C.</initials><seq>1</seq><surname>Denny</surname></author><author><autidx>Miller R.A.</autidx><given-name>Randolph A.</given-name><initials>R.A.</initials><seq>2</seq><surname>Miller</surname></author><author><autidx>Waitman L.R.</autidx><given-name>Lemuel Russell</given-name><initials>L.R.</initials><seq>3</seq><surname>Waitman</surname></author><author><autidx>Arrieta M.A.</autidx><given-name>Mark A.</given-name><initials>M.A.</initials><seq>4</seq><surname>Arrieta</surname></author><author><autidx>Peterson J.F.</autidx><given-name>Joshua F.</given-name><initials>J.F.</initials><seq>5</seq><surname>Peterson</surname></author></author-group><author-group><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Medicine</organization><organization>Vanderbilt University Medical Center</organization></affiliation><author><autidx>Denny J.C.</autidx><email>josh.denny@vanderbilt.edu</email><given-name>Joshua C.</given-name><initials>J.C.</initials><seq>1</seq><surname>Denny</surname></author><author><autidx>Peterson J.F.</autidx><given-name>Joshua F.</given-name><initials>J.F.</initials><seq>5</seq><surname>Peterson</surname></author></author-group><authorlist><author><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Medicine</organization><organization>Vanderbilt University Medical Center</organization></affiliation><autidx>Denny J.C.</autidx><email>josh.denny@vanderbilt.edu</email><given-name>Joshua C.</given-name><initials>J.C.</initials><seq>1</seq><surname>Denny</surname><aggregatedAuthorId>denny j.c.__denny__joshua c.</aggregatedAuthorId><uniqueAuthorId>denny__joshua c.__j.c.____SS0CAAqlDj4=</uniqueAuthorId></author><author><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><autidx>Miller R.A.</autidx><given-name>Randolph A.</given-name><initials>R.A.</initials><seq>2</seq><surname>Miller</surname><aggregatedAuthorId>miller r.a.__miller__randolph a.</aggregatedAuthorId><uniqueAuthorId>miller__randolph a.__r.a.____SS0CAAqlDj4=</uniqueAuthorId></author><author><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><autidx>Waitman L.R.</autidx><given-name>Lemuel Russell</given-name><initials>L.R.</initials><seq>3</seq><surname>Waitman</surname><aggregatedAuthorId>waitman l.r.__waitman__lemuel russell</aggregatedAuthorId><uniqueAuthorId>waitman__lemuel russell__l.r.____SS0CAAqlDj4=</uniqueAuthorId></author><author><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><autidx>Arrieta M.A.</autidx><given-name>Mark A.</given-name><initials>M.A.</initials><seq>4</seq><surname>Arrieta</surname><aggregatedAuthorId>arrieta m.a.__arrieta__mark a.</aggregatedAuthorId><uniqueAuthorId>arrieta__mark a.__m.a.____SS0CAAqlDj4=</uniqueAuthorId></author><author><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Medicine</organization><organization>Vanderbilt University Medical Center</organization></affiliation><autidx>Peterson J.F.</autidx><given-name>Joshua F.</given-name><initials>J.F.</initials><seq>5</seq><surname>Peterson</surname><aggregatedAuthorId>peterson j.f.__peterson__joshua f.</aggregatedAuthorId><uniqueAuthorId>peterson__joshua f.__j.f.____SS0CAAqlDj4=</uniqueAuthorId></author></authorlist><correspondence><affiliation><city-group>Nashville, TN</city-group><country code="usa">United States</country><organization>Department of Biomedical Informatics</organization><organization>Vanderbilt University Medical Center</organization></affiliation><email>josh.denny@vanderbilt.edu</email><person><initials>J.C.</initials><persidx>Denny J.C.</persidx><surname>Denny</surname></person></correspondence></head><tail><bibliography><refcount>40</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>algorithm</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>algorithm</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiologist</ancestor><ancestor>health care concepts</ancestor><ancestor>health care personnel</ancestor><ancestor>medical personnel</ancestor><ancestor>named groups by occupation</ancestor><ancestor>named groups of persons</ancestor><ancestor>physician</ancestor></ancestors><mainterm>cardiologist</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>computer language</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>computer language</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>decision support system</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>information system</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>decision support system</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diagnosis</ancestor><ancestor>diagnostic accuracy</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>general pathological parameters</ancestor><ancestor>medical parameters</ancestor><ancestor>medical procedures</ancestor><ancestor>parameters</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>diagnostic accuracy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>ecg abnormality</ancestor><ancestor>heart disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>ECG abnormality</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>ECG abnormality</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>environmental parameters</ancestor><ancestor>gold standard</ancestor><ancestor>parameters</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>quality control procedures</ancestor><ancestor>standard</ancestor><ancestor>standardization</ancestor></ancestors><mainterm>gold standard</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>hospital patient</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>hospital patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>information processing</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>major clinical study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>major clinical study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>health care concepts</ancestor><ancestor>health care management</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>information system</ancestor><ancestor>medical information system</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>medical information system</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>priority journal</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>priority journal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></explosion></explosions><idxs><dsidx><dst>ecg abnormality</dst><dst>qt prolongation</dst></dsidx><stidx><stt>human</stt><stt>major clinical study</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2014-03-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2014 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.jelectrocard.2013.12.002</doi><lui>L52959235</lui><pui>52959235</pui><embase>2014168489</embase><medl>24438862</medl><pii>S0022073613006262</pii></itemidlist><history><date-created>2014-03-19</date-created><date-loaded>2014-03-20</date-loaded><date-aip-loaded>2014-01-20</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Overdose</author-keyword><author-keyword>QT prolongation</author-keyword><author-keyword>Racial differences</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Racial susceptibility for QT prolongation in acute drug overdoses</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background and Purpose QT prolongation independently predicts adverse cardiovascular events in suspected poisoning. We aimed to evaluate the association between race and drug-induced QT prolongation for patients with acute overdose. Methods This was a cross-sectional observational study at two urban teaching hospitals. Consecutive adult ED patients with acute drug overdose were prospectively enrolled over a two year period. The primary outcome, long-QT, was defined using standard criteria: QTc &gt; 470 ms in females and &gt; 460 ms in males. The association between race and drug-induced QT prolongation was tested, considering several confounding variables. Results In 472 patients analyzed (46% female, mean age 42.3), QT prolongation occurred in 12.7%. Blacks had two-fold increased odds of drug-induced QT prolongation (OR 2.01, CI 1.03-3.91) and Hispanics had 48% decreased odds of drug-induced QT prolongation (OR 0.52, CI 0.29-0.94). Conclusions We found significant racial susceptibility to drug-induced QT prolongation in this large urban study of acute overdoses. © 2014 Elsevier Inc.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>Journal of Electrocardiology</sourcetitle><sourcetitle-abbrev>J. Electrocardiol.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00220736</issnnr></issn><issn><issntype>electronic</issntype><issnnr>15328430</issnnr></issn><codencode>JECAB</codencode><volisspag><volume>47</volume><issue>2</issue><firstpage>244</firstpage><volissidx>00220736||2014||47||2</volissidx><volissidx>15328430||2014||47||2</volissidx><lastpage>250</lastpage></volisspag><publicationyear>2014</publicationyear><publicationdate><pubdatetext>March-April 2014</pubdatetext></publicationdate><publisher><affiliation><address-part>650 Avenue of the Americas</address-part><city>New York</city><country code="usa">United States</country></affiliation><publishername>Churchill Livingstone Inc.</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>59729-33-8</cas-registry-number><chemical-name>citalopram</chemical-name></chemical><chemical><cas-registry-number>50-36-2</cas-registry-number><cas-registry-number>53-21-4</cas-registry-number><cas-registry-number>5937-29-1</cas-registry-number><chemical-name>cocaine</chemical-name></chemical><chemical><cas-registry-number>147-24-0</cas-registry-number><cas-registry-number>58-73-1</cas-registry-number><chemical-name>diphenhydramine</chemical-name></chemical><chemical><cas-registry-number>128196-01-0</cas-registry-number><cas-registry-number>219861-08-2</cas-registry-number><chemical-name>escitalopram</chemical-name></chemical><chemical><cas-registry-number>7439-93-2</cas-registry-number><chemical-name>lithium</chemical-name></chemical><chemical><cas-registry-number>1095-90-5</cas-registry-number><cas-registry-number>125-56-4</cas-registry-number><cas-registry-number>23142-53-2</cas-registry-number><cas-registry-number>297-88-1</cas-registry-number><cas-registry-number>76-99-3</cas-registry-number><chemical-name>methadone</chemical-name></chemical><chemical><cas-registry-number>124-90-3</cas-registry-number><cas-registry-number>76-42-6</cas-registry-number><chemical-name>oxycodone</chemical-name></chemical><chemical><cas-registry-number>103-90-2</cas-registry-number><chemical-name>paracetamol</chemical-name></chemical><chemical><cas-registry-number>111974-72-2</cas-registry-number><chemical-name>quetiapine</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><classifications><clsemclass>6</clsemclass><clsemclass>18</clsemclass><clsemclass>37</clsemclass><clsemclass>52</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>anticonvulsive agent</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>anticonvulsive agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>benzodiazepine derivative</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>benzodiazepine derivative</mainterm><weight>b</weight></descriptor><descriptor><drgterm>citalopram</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>citalopram</mainterm><weight>b</weight></descriptor><descriptor><drgterm>cocaine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>cocaine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>diphenhydramine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>diphenhydramine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>escitalopram</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>escitalopram</mainterm><weight>b</weight></descriptor><descriptor><drgterm>lithium</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>lithium</mainterm><weight>b</weight></descriptor><descriptor><drgterm>methadone</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>methadone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>oxycodone</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>oxycodone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>paracetamol</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>paracetamol</mainterm><weight>b</weight></descriptor><descriptor><drgterm>quetiapine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>quetiapine</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><mainterm>African American</mainterm><weight>b</weight></descriptor><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><disterm>drug overdose</disterm><link><linkterm>etiology</linkterm></link><mainterm>drug overdose</mainterm><weight>a</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><mainterm>Hispanic</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>major clinical study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>outcome assessment</mainterm><weight>b</weight></descriptor><descriptor><mainterm>priority journal</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><link><linkterm>etiology</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>race difference</mainterm><weight>b</weight></descriptor><descriptor><mainterm>urban area</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>New York, NY</city-group><country code="usa">United States</country><organization>Division of Medical Toxicology, Icahn School of Medicine at Mount Sinai</organization></affiliation><author><autidx>Manini A.F.</autidx><email>alex.manini@mountsinai.org</email><given-name>Alex F.</given-name><initials>A.F.</initials><seq>1</seq><surname>Manini</surname></author></author-group><author-group><affiliation><city-group>New York, NY</city-group><country code="usa">United States</country><organization>Cardiology Division, Icahn School of Medicine at Mount Sinai</organization></affiliation><author><autidx>Stimmel B.</autidx><given-name>Barry</given-name><initials>B.</initials><seq>2</seq><surname>Stimmel</surname></author></author-group><author-group><affiliation><city-group>CA</city-group><country code="usa">United States</country><organization>School of Nursing, University of California at San Francisco</organization></affiliation><author><autidx>Vlahov D.</autidx><given-name>David</given-name><initials>D.</initials><seq>3</seq><surname>Vlahov</surname></author></author-group><authorlist><author><affiliation><city-group>New York, NY</city-group><country code="usa">United States</country><organization>Division of Medical Toxicology, Icahn School of Medicine at Mount Sinai</organization></affiliation><autidx>Manini A.F.</autidx><email>alex.manini@mountsinai.org</email><given-name>Alex F.</given-name><initials>A.F.</initials><seq>1</seq><surname>Manini</surname><aggregatedAuthorId>manini a.f.__manini__alex f.</aggregatedAuthorId><uniqueAuthorId>manini__alex f.__a.f.____RiEZjS/AuBqB</uniqueAuthorId></author><author><affiliation><city-group>New York, NY</city-group><country code="usa">United States</country><organization>Cardiology Division, Icahn School of Medicine at Mount Sinai</organization></affiliation><autidx>Stimmel B.</autidx><given-name>Barry</given-name><initials>B.</initials><seq>2</seq><surname>Stimmel</surname><aggregatedAuthorId>stimmel b.__stimmel__barry</aggregatedAuthorId><uniqueAuthorId>stimmel__barry__b.____TOMPtEYWeQ==</uniqueAuthorId></author><author><affiliation><city-group>CA</city-group><country code="usa">United States</country><organization>School of Nursing, University of California at San Francisco</organization></affiliation><autidx>Vlahov D.</autidx><given-name>David</given-name><initials>D.</initials><seq>3</seq><surname>Vlahov</surname><aggregatedAuthorId>vlahov d.__vlahov__david</aggregatedAuthorId><uniqueAuthorId>vlahov__david__d.____WbTlC7TsFq4=</uniqueAuthorId></author></authorlist><correspondence><affiliation><address-part>One Gustave L. Levy Place, Box 1620</address-part><city-group>New York, NY 10029</city-group><country code="usa">United States</country><organization>Icahn School of Medicine at Mount Sinai, Department of Emergency Medicine</organization></affiliation><email>alex.manini@mountsinai.org</email><person><degrees>Dr.</degrees><initials>A.F.</initials><persidx>Manini A.F.</persidx><surname>Manini</surname></person></correspondence></head><tail><bibliography><refcount>29</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>anticonvulsive agent</ancestor><ancestor>central depressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor></ancestors><drgterm>anticonvulsive agent</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>anticonvulsive agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>benzodiazepine derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor></ancestors><drgterm>benzodiazepine derivative</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>benzodiazepine derivative</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>citalopram</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>citalopram</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>citalopram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>agents acting on the peripheral nervous and neuromuscular systems</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central nervous system agents</ancestor><ancestor>central stimulant agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>cocaine</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dopamine receptor affecting agent</ancestor><ancestor>dopamine uptake inhibitor</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>local anesthetic agent</ancestor><ancestor>noradrenalin uptake inhibitor</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin noradrenalin reuptake inhibitor</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor><ancestor>triple reuptake inhibitor</ancestor><ancestor>tropane derivative</ancestor></ancestors><drgterm>cocaine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>cocaine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antiemetic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>antitussive agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>digestive tract agent</ancestor><ancestor>diphenhydramine</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>respiratory tract agent</ancestor></ancestors><drgterm>diphenhydramine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>diphenhydramine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>escitalopram</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>escitalopram</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>escitalopram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>alkali metal</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>element</ancestor><ancestor>general and inorganic chemicals</ancestor><ancestor>lithium</ancestor><ancestor>metal</ancestor></ancestors><drgterm>lithium</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>lithium</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>analgesic agent</ancestor><ancestor>analgesic, antiinflammatory, antirheumatic and antigout agents</ancestor><ancestor>central depressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>drugs used in the treatment of addiction</ancestor><ancestor>methadone</ancestor><ancestor>narcotic agent</ancestor><ancestor>narcotic analgesic agent</ancestor><ancestor>opiate agonist</ancestor><ancestor>opiate receptor affecting agent</ancestor></ancestors><drgterm>methadone</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>methadone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>analgesic agent</ancestor><ancestor>analgesic, antiinflammatory, antirheumatic and antigout agents</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central depressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon nitrogen oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>morphine derivative</ancestor><ancestor>narcotic agent</ancestor><ancestor>narcotic analgesic agent</ancestor><ancestor>opiate agonist</ancestor><ancestor>opiate receptor affecting agent</ancestor><ancestor>organic compound</ancestor><ancestor>oxycodone</ancestor><ancestor>polycyclic hydrocarbon</ancestor></ancestors><drgterm>oxycodone</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>oxycodone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amide</ancestor><ancestor>analgesic agent</ancestor><ancestor>analgesic, antiinflammatory, antirheumatic and antigout agents</ancestor><ancestor>antimigraine agent</ancestor><ancestor>antipyretic analgesic agent</ancestor><ancestor>carboxyl group</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>functional group</ancestor><ancestor>functional groups containing oxygen</ancestor><ancestor>hydroxyl group</ancestor><ancestor>organic compound</ancestor><ancestor>paracetamol</ancestor><ancestor>phenol derivative</ancestor><ancestor>vasoactive agent</ancestor></ancestors><drgterm>paracetamol</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>paracetamol</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>atypical antipsychotic agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dopamine receptor affecting agent</ancestor><ancestor>dopamine receptor blocking agent</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>psychotropic agent</ancestor><ancestor>quetiapine</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>quetiapine</drgterm><link><linkterm>drug toxicity</linkterm></link><mainterm>quetiapine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>african american</ancestor><ancestor>ancestry group</ancestor><ancestor>black person</ancestor><ancestor>named groups of persons</ancestor><ancestor>population group</ancestor></ancestors><mainterm>African American</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>chemical parameters</ancestor><ancestor>diseases</ancestor><ancestor>dose</ancestor><ancestor>drug dose</ancestor><ancestor>drug overdose</ancestor><ancestor>intoxication</ancestor><ancestor>parameters</ancestor><ancestor>pharmacological parameters</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>toxicity and intoxication</ancestor></ancestors><disterm>drug overdose</disterm><link><linkterm>etiology</linkterm></link><mainterm>drug overdose</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>ancestry group</ancestor><ancestor>hispanic</ancestor><ancestor>named groups of persons</ancestor><ancestor>population group</ancestor></ancestors><mainterm>Hispanic</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>major clinical study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>major clinical study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diagnostic procedure</ancestor><ancestor>disease management</ancestor><ancestor>evaluation and follow up</ancestor><ancestor>health care concepts</ancestor><ancestor>health care quality</ancestor><ancestor>medical procedures</ancestor><ancestor>outcome assessment</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>treatment outcome</ancestor></ancestors><mainterm>outcome assessment</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>priority journal</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>priority journal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><link><linkterm>etiology</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>ethnic or racial aspects</ancestor><ancestor>race difference</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>race difference</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>environment</ancestor><ancestor>land use</ancestor><ancestor>society and environment</ancestor><ancestor>urban area</ancestor></ancestors><mainterm>urban area</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>adult</ag></agidx><dgidx><dt>anticonvulsive agent</dt><dt>benzodiazepine derivative</dt><dt>citalopram</dt><dt>cocaine</dt><dt>diphenhydramine</dt><dt>escitalopram</dt><dt>lithium</dt><dt>methadone</dt><dt>oxycodone</dt><dt>paracetamol</dt><dt>quetiapine</dt></dgidx><dsidx><dst>drug overdose</dst><dst>qt prolongation</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>human</stt><stt>major clinical study</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-05-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2010 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.hrthm.2010.03.033</doi><lui>L70121685</lui><pui>70121685</pui><absn>PO5-114</absn><pii>S1547527110002754</pii></itemidlist><history><date-created>2010-05-05</date-created><date-loaded>2010-05-17</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Intravenous sotalol induced QT prolongation predicts serum sotalol concentration</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Introduction: Sotalol (S) prolongs the cardiac action potential that can be observed as QT interval (QT) prolongation on the surface EKG. It is known that S causes Torsade de Pointes ventricular tachycardia (TdP) that is due to dose related QT prolongation. We were able to develop a correlation between QT prolongation and S serum concentration. Methods: 15 healthy volunteers (age: 32±8 y) received 75 mg intravenous S over 2.5 hr at a constant infusion rate. Serum S concentrations were determined and a 12-lead EKG was recorded at baseline, 0.5, 1, 2, 3, 4, and 5 hrs following dosing. The QT and RR intervals were measured by two blinded investigators. Heart rate corrected QT (QTc) was calculated by the Bazett (B), Fridericia (Fi), and Framingham (Fh) formulas. Linear regression analysis was performed between S concentration and QT measurements. Results: The analysis showed close correlation between S concentration and QT (r=0.938, p&lt;0.02), B QTc (r=0.860, p&lt;0.02), Fh QTc (r=0.960, p=0.001), and Fi QTc (r=0.967, p&lt;0.001). The equation of the regression line was: QTc= 0.0388 x (S concentration) + 402.63, which closely predicted actual QTc at any S concentration. Conversely any degree of QT prolongation can predict the measured serum S concentration. Conclusions: A simple equation was found that predicts serum S concentration from QT prolongation. Measuring QT prolongation can yield a quick method of estimating serum S concentration as well as the electrophysiologic effects of serum S. Excessive serum S levels that causes increased QT prolongation can be avoided, possibly reducing the risk of TdP. (Graph presnted).</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Heart Rhythm</sourcetitle><sourcetitle-abbrev>Heart Rhythm</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>15475271</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Denver, CO</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>31st Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm 2010</confname><enddate>2010-05-15</enddate><startdate>2010-05-12</startdate></confevent></conferenceinfo><contributor-group><affiliation><city-group>Washington, DC</city-group><country code="USA">United States</country><organization>Heart Rhythm Society</organization></affiliation><contributor><ctrbidx>Wilkoff B.L.</ctrbidx><given-name>Bruce L.</given-name><initials>B.L.</initials><degrees>Dr.</degrees><role code="edit">editor</role><seq>1</seq><surname>Wilkoff</surname></contributor></contributor-group><volisspag><volume>7</volume><issue>5</issue><firstpage>S360</firstpage><volissidx>15475271||2010||7||5</volissidx><supplement>SUPPL. 1</supplement></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>May 2010</pubdatetext></publicationdate><publisher><publishername>Elsevier</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>a</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><mainterm>serum</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>heart rhythm</mainterm><weight>a</weight></descriptor><descriptor><mainterm>action potential</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>RR interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>blood level</mainterm><weight>b</weight></descriptor><descriptor><mainterm>normal human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>infusion rate</mainterm><weight>b</weight></descriptor><descriptor><mainterm>heart rate</mainterm><weight>b</weight></descriptor><descriptor><mainterm>linear regression analysis</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle tachycardia</disterm><mainterm>heart ventricle tachycardia</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><author><autidx>Somberg J.C.</autidx><given-name>John C.</given-name><initials>J.C.</initials><seq>1</seq><surname>Somberg</surname></author><author><autidx>Ranade V.V.</autidx><given-name>Vasant V.</given-name><initials>V.V.</initials><seq>2</seq><surname>Ranade</surname></author><author><autidx>Molnar Z.</autidx><given-name>Zita</given-name><initials>Z.</initials><seq>3</seq><surname>Molnar</surname></author><author><autidx>Somberg T.</autidx><given-name>Trudie</given-name><initials>T.</initials><seq>4</seq><surname>Somberg</surname></author><author><autidx>Molnar J.</autidx><given-name>Janos</given-name><initials>J.</initials><seq>5</seq><surname>Molnar</surname></author></author-group><authorlist><author><autidx>Somberg J.C.</autidx><given-name>John C.</given-name><initials>J.C.</initials><seq>1</seq><surname>Somberg</surname><aggregatedAuthorId>somberg j.c.__somberg__john c.</aggregatedAuthorId><uniqueAuthorId>somberg__john c.__j.c.____</uniqueAuthorId></author><author><autidx>Ranade V.V.</autidx><given-name>Vasant V.</given-name><initials>V.V.</initials><seq>2</seq><surname>Ranade</surname><aggregatedAuthorId>ranade v.v.__ranade__vasant v.</aggregatedAuthorId><uniqueAuthorId>ranade__vasant v.__v.v.____</uniqueAuthorId></author><author><autidx>Molnar Z.</autidx><given-name>Zita</given-name><initials>Z.</initials><seq>3</seq><surname>Molnar</surname><aggregatedAuthorId>molnar z.__molnar__zita</aggregatedAuthorId><uniqueAuthorId>molnar__zita__z.____</uniqueAuthorId></author><author><autidx>Somberg T.</autidx><given-name>Trudie</given-name><initials>T.</initials><seq>4</seq><surname>Somberg</surname><aggregatedAuthorId>somberg t.__somberg__trudie</aggregatedAuthorId><uniqueAuthorId>somberg__trudie__t.____</uniqueAuthorId></author><author><autidx>Molnar J.</autidx><given-name>Janos</given-name><initials>J.</initials><seq>5</seq><surname>Molnar</surname><aggregatedAuthorId>molnar j.__molnar__janos</aggregatedAuthorId><uniqueAuthorId>molnar__janos__j.____</uniqueAuthorId></author></authorlist><correspondence><person><degrees>Dr.</degrees><initials>J.C.</initials><persidx>Somberg J.C.</persidx><surname>Somberg</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>beta adrenergic receptor blocking agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>sotalol</ancestor></ancestors><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>anatomical concepts</ancestor><ancestor>blood</ancestor><ancestor>blood and hemopoietic system</ancestor><ancestor>body fluid</ancestor><ancestor>body fluids and secretions</ancestor><ancestor>hemolymphatic system</ancestor><ancestor>organ systems</ancestor><ancestor>serum</ancestor></ancestors><mainterm>serum</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>heart rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rhythm</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>action potential</ancestor><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>electrical parameters</ancestor><ancestor>electrical potential parameters</ancestor><ancestor>electrophysiology</ancestor><ancestor>parameters</ancestor><ancestor>physical parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>action potential</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>rr interval</ancestor></ancestors><mainterm>RR interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>blood level</ancestor><ancestor>chemical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>blood level</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>normal human</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>normal human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>administration of drugs, food and chemicals</ancestor><ancestor>infusion</ancestor><ancestor>infusion rate</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>infusion rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>linear regression analysis</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>regression analysis</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor></ancestors><mainterm>linear regression analysis</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>heart ventricle tachycardia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>tachycardia</ancestor></ancestors><disterm>heart ventricle tachycardia</disterm><mainterm>heart ventricle tachycardia</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>sotalol</dt></dgidx><dsidx><dst>heart ventricle tachycardia</dst><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><stidx><stt>normal human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-12-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2011 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L361807226</lui><pui>361807226</pui><embase>2011285643</embase></itemidlist><history><date-created>2011-06-01</date-created><date-loaded>2011-06-02</date-loaded><date-aip-loaded>2011-05-31</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="ja">Japanese</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Avoidance and early recognition</author-keyword><author-keyword>Drug-induced QT prolongation</author-keyword><author-keyword>Secondary long QT syndrome</author-keyword><author-keyword>Software</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>The follow-up survey of medicinal drugs associated with QT prolongation, and a new software for avoidance and early recognition of drug-induced QT prolongation</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>In recent years, the mechanisms that cause congenital and secondary long QT syndrome have been elucidated in considerable detail. We have attempted to determine of treatment courses for individual patients when it is necessary to administer medicines associated with QT prolongation. Therefore we decided to conduct a follow-up survey of these medicines, and aim to develop a software for avoidance and early recognition of drug-induced QT prolongation in association with cardiovascular internal medicine at our hospital.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="jpn">Japan</sourcecountry><sourcetitle>Sapporo Medical journal</sourcetitle><sourcetitle-abbrev>Sapporo Med. J.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>0036472X</issnnr></issn><codencode>SIZSA</codencode><volisspag><volume>79</volume><issue>1-6</issue><firstpage>13</firstpage><volissidx>0036472X||2010||79||1-6</volissidx><lastpage>19</lastpage></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>December 2010</pubdatetext></publicationdate><publisher><affiliation><address-part>S.1, W.17, Chuo-ku</address-part><city>Sapporo</city><country code="jpn">Japan</country></affiliation><publishername>Sapporo Medical University</publishername></publisher></source><enhancement><classifications><clsemclass>18</clsemclass><clsemclass>36</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>software</mainterm><weight>b</weight></descriptor><descriptor><disterm>drug induced disease</disterm><mainterm>drug induced disease</mainterm><weight>a</weight></descriptor><descriptor><mainterm>follow up</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospital subdivisions and components</mainterm><weight>b</weight></descriptor><descriptor><mainterm>internal medicine</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><country code="jpn">Japan</country><organization>Division of Pharmaceutical Health Care and Sciences</organization><organization>Sapporo Medical University Graduate School of Medicine</organization></affiliation><author><autidx>Shiozaki Y.</autidx><given-name>Yoshitomo</given-name><initials>Y.</initials><seq>1</seq><surname>Shiozaki</surname></author><author><autidx>Miyamoto A.</autidx><email>atsushi@sapmed.ac.jp</email><given-name>Atsushi</given-name><initials>A.</initials><seq>5</seq><surname>Miyamoto</surname></author></author-group><author-group><affiliation><country code="jpn">Japan</country><organization>Division of Hospital Pharmacy</organization><organization>Sapporo Medical University Hospital</organization></affiliation><author><autidx>Shiozaki Y.</autidx><given-name>Yoshitomo</given-name><initials>Y.</initials><seq>1</seq><surname>Shiozaki</surname></author><author><autidx>Sasaki N.</autidx><given-name>Naomi</given-name><initials>N.</initials><seq>3</seq><surname>Sasaki</surname></author><author><autidx>Miyamoto A.</autidx><email>atsushi@sapmed.ac.jp</email><given-name>Atsushi</given-name><initials>A.</initials><seq>5</seq><surname>Miyamoto</surname></author></author-group><author-group><affiliation><country code="jpn">Japan</country><organization>Second Department of Internal Medicine</organization><organization>Sapporo Medical University School of Medicine</organization></affiliation><author><autidx>Hashimoto A.</autidx><given-name>Akiyoshi</given-name><initials>A.</initials><seq>2</seq><surname>Hashimoto</surname></author><author><autidx>Shimamoto K.</autidx><given-name>Kazuaki</given-name><initials>K.</initials><seq>4</seq><surname>Shimamoto</surname></author></author-group><authorlist><author><affiliation><country code="jpn">Japan</country><organization>Division of Pharmaceutical Health Care and Sciences</organization><organization>Sapporo Medical University Graduate School of Medicine</organization></affiliation><affiliation><country code="jpn">Japan</country><organization>Division of Hospital Pharmacy</organization><organization>Sapporo Medical University Hospital</organization></affiliation><autidx>Shiozaki Y.</autidx><given-name>Yoshitomo</given-name><initials>Y.</initials><seq>1</seq><surname>Shiozaki</surname><aggregatedAuthorId>shiozaki y.__shiozaki__yoshitomo</aggregatedAuthorId><uniqueAuthorId>shiozaki__yoshitomo__y.____SwUAROIU3g==</uniqueAuthorId></author><author><affiliation><country code="jpn">Japan</country><organization>Second Department of Internal Medicine</organization><organization>Sapporo Medical University School of Medicine</organization></affiliation><autidx>Hashimoto A.</autidx><given-name>Akiyoshi</given-name><initials>A.</initials><seq>2</seq><surname>Hashimoto</surname><aggregatedAuthorId>hashimoto a.__hashimoto__akiyoshi</aggregatedAuthorId><uniqueAuthorId>hashimoto__akiyoshi__a.____pQIAlaIRcQ==</uniqueAuthorId></author><author><affiliation><country code="jpn">Japan</country><organization>Division of Hospital Pharmacy</organization><organization>Sapporo Medical University Hospital</organization></affiliation><autidx>Sasaki N.</autidx><given-name>Naomi</given-name><initials>N.</initials><seq>3</seq><surname>Sasaki</surname><aggregatedAuthorId>sasaki n.__sasaki__naomi</aggregatedAuthorId><uniqueAuthorId>sasaki__naomi__n.____zAEA+d8N+g==</uniqueAuthorId></author><author><affiliation><country code="jpn">Japan</country><organization>Second Department of Internal Medicine</organization><organization>Sapporo Medical University School of Medicine</organization></affiliation><autidx>Shimamoto K.</autidx><given-name>Kazuaki</given-name><initials>K.</initials><seq>4</seq><surname>Shimamoto</surname><aggregatedAuthorId>shimamoto k.__shimamoto__kazuaki</aggregatedAuthorId><uniqueAuthorId>shimamoto__kazuaki__k.____pQIAlaIRcQ==</uniqueAuthorId></author><author><affiliation><country code="jpn">Japan</country><organization>Division of Pharmaceutical Health Care and Sciences</organization><organization>Sapporo Medical University Graduate School of Medicine</organization></affiliation><affiliation><country code="jpn">Japan</country><organization>Division of Hospital Pharmacy</organization><organization>Sapporo Medical University Hospital</organization></affiliation><autidx>Miyamoto A.</autidx><email>atsushi@sapmed.ac.jp</email><given-name>Atsushi</given-name><initials>A.</initials><seq>5</seq><surname>Miyamoto</surname><aggregatedAuthorId>miyamoto a.__miyamoto__atsushi</aggregatedAuthorId><uniqueAuthorId>miyamoto__atsushi__a.____SwUAROIU3g==</uniqueAuthorId></author></authorlist><correspondence><affiliation><country code="jpn">Japan</country><organization>Division of Pharmaceutical Health Care and Sciences</organization><organization>Sapporo Medical University Graduate School of Medicine</organization></affiliation><email>atsushi@sapmed.ac.jp</email><person><initials>A.</initials><persidx>Miyamoto A.</persidx><surname>Miyamoto</surname></person></correspondence></head><tail><bibliography><refcount>16</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor><ancestor>software</ancestor></ancestors><mainterm>software</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adverse drug reaction</ancestor><ancestor>adverse event</ancestor><ancestor>diseases</ancestor><ancestor>drug induced disease</ancestor><ancestor>iatrogenic disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>side effect</ancestor></ancestors><disterm>drug induced disease</disterm><mainterm>drug induced disease</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>aftercare</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>evaluation and follow up</ancestor><ancestor>follow up</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>long term care</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>follow up</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor><ancestor>hospital subdivisions and components</ancestor></ancestors><mainterm>hospital subdivisions and components</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biomedical disciplines, science and art</ancestor><ancestor>biomedicine</ancestor><ancestor>internal medicine</ancestor><ancestor>medicine</ancestor></ancestors><mainterm>internal medicine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion></explosions><idxs><dsidx><dst>drug induced disease</dst><dst>qt prolongation</dst></dsidx></idxs></bibrecord><bibrecord><item-info><date-sort>2011-10-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2012 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L70647884</lui><pui>70647884</pui><absn>4E</absn></itemidlist><history><date-created>2012-01-25</date-created><date-loaded>2012-01-28</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Evaluating the occurrence of QT prolongation resulting from drug-drug interactions</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>PURPOSE: Over 50 medications cause QT prolongation, which can deteriorate into Torsades de pointes. Information is lacking on the frequency of QT prolongation due to drug-drug interactions (DDIs) accounting for temporal sequence in intensive care units (ICUs). This evaluation is of particular interest to clinicians in cardiac ICUs, since there is at heightened risk for adverse outcomes. The primary objective was to determine the frequency of QT prolongation from potentially interacting drugs in the coronary ICU and cardiothoracic ICU. METHODS: A retrospective evaluation was performed using the institution's electronic data repository. Inclusion criteria were admission to the cardiac ICUs between January 2009 and July 2009, age ≥ 18 years, and electrocardiographic (EKG) evidence of a QTc ≥ 500 ms. Medications known to prolong the QT interval were identified using the Arizona CERT database. Patients receiving two concomitant medications known to prolong the QT interval were considered to experience a pharmacodynamic DDI. Medications known to be CYP450 enzyme inhibitors of QT prolonging medications were considered to cause pharmacokinetic DDIs. Interactions were evaluated for temporal relationship and causality related to the QT prolongation. RESULTS: 187 (54.5 % male) patients, with a mean age of 62 years, experienced QT prolongation out of a total of 501 patients (37%) admitted during the study period. 154 and 163 patients had a potential pharmacodynamic and pharmacokinetic interaction, respectively, receiving an average of 2.9 QT prolonging medications during their admission. Of these patients, 43% (66/154) had 133 pharmacodynamic interactions confirmed by temporal sequence, and 47% (77/163) of patients experienced 179 potential pharmacokinetic interactions temporally related to QT prolongation. CONCLUSION: DDIs may be a significant cause of QT prolongation in cardiac ICUs. These data can be used to educate clinicians on safe medication use. Computerized clinical decision support could be applied to aid in the detection of these events.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Pharmacotherapy</sourcetitle><sourcetitle-abbrev>Pharmacotherapy</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>02770008</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Pittsburgh, PA</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>2011 Annual Meeting of the American College of Clinical Pharmacy</confname><enddate>2011-10-19</enddate><startdate>2011-10-16</startdate></confevent></conferenceinfo><volisspag><volume>31</volume><issue>10</issue><firstpage>312e</firstpage><volissidx>02770008||2011||31||10</volissidx><lastpage>313e</lastpage></volisspag><publicationyear>2011</publicationyear><publicationdate><pubdatetext>October 2011</pubdatetext></publicationdate><website><url>http://pharmacotherapyjournal.org/doi/pdf/10.1592/phco.31.10.1044</url></website><publisher><publishername>Pharmacotherapy Publications Inc.</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>enzyme inhibitor</drgterm><mainterm>enzyme inhibitor</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>clinical pharmacy</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug interaction</mainterm><weight>a</weight></descriptor><descriptor><mainterm>college</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug therapy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>pharmacokinetics</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><mainterm>adverse outcome</mainterm><weight>b</weight></descriptor><descriptor><mainterm>United States</mainterm><weight>b</weight></descriptor><descriptor><mainterm>epidemiology</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>decision support system</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>intensive care unit</mainterm><weight>b</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>UPMC Presbyterian</organization><state>PA</state></affiliation><author><autidx>Armahizer M.J.</autidx><given-name>Michael J.</given-name><initials>M.J.</initials><seq>1</seq><surname>Armahizer</surname></author></author-group><author-group><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization><state>PA</state></affiliation><author><autidx>Kane-Gill S.</autidx><given-name>Sandra</given-name><initials>S.</initials><seq>2</seq><surname>Kane-Gill</surname></author><author><autidx>Smithburger P.L.</autidx><given-name>Pamela L.</given-name><initials>P.L.</initials><seq>3</seq><surname>Smithburger</surname></author><author><autidx>Seybert A.L.</autidx><given-name>Amy L.</given-name><initials>A.L.</initials><seq>4</seq><surname>Seybert</surname></author></author-group><authorlist><author><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>UPMC Presbyterian</organization><state>PA</state></affiliation><autidx>Armahizer M.J.</autidx><given-name>Michael J.</given-name><initials>M.J.</initials><seq>1</seq><surname>Armahizer</surname><aggregatedAuthorId>armahizer m.j.__armahizer__michael j.</aggregatedAuthorId><uniqueAuthorId>armahizer__michael j.__m.j.____zAMAPakG7g==</uniqueAuthorId></author><author><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization><state>PA</state></affiliation><autidx>Kane-Gill S.</autidx><given-name>Sandra</given-name><initials>S.</initials><seq>2</seq><surname>Kane-Gill</surname><aggregatedAuthorId>kane-gill s.__kane-gill__sandra</aggregatedAuthorId><uniqueAuthorId>kane-gill__sandra__s.____TK4EAEGZBvM=</uniqueAuthorId></author><author><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization><state>PA</state></affiliation><autidx>Smithburger P.L.</autidx><given-name>Pamela L.</given-name><initials>P.L.</initials><seq>3</seq><surname>Smithburger</surname><aggregatedAuthorId>smithburger p.l.__smithburger__pamela l.</aggregatedAuthorId><uniqueAuthorId>smithburger__pamela l.__p.l.____TK4EAEGZBvM=</uniqueAuthorId></author><author><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization><state>PA</state></affiliation><autidx>Seybert A.L.</autidx><given-name>Amy L.</given-name><initials>A.L.</initials><seq>4</seq><surname>Seybert</surname><aggregatedAuthorId>seybert a.l.__seybert__amy l.</aggregatedAuthorId><uniqueAuthorId>seybert__amy l.__a.l.____TK4EAEGZBvM=</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Pittsburgh</city><country code="USA">United States</country><organization>UPMC Presbyterian</organization><state>PA</state></affiliation><person><initials>M.J.</initials><persidx>Armahizer M.J.</persidx><surname>Armahizer</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>enzyme inhibitor</ancestor></ancestors><drgterm>enzyme inhibitor</drgterm><mainterm>enzyme inhibitor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>clinical pharmacy</ancestor><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor></ancestors><mainterm>clinical pharmacy</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug interaction</ancestor><ancestor>pharmacodynamics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>drug interaction</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>college</ancestor><ancestor>education</ancestor><ancestor>school</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>college</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>pharmacokinetics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>pharmacokinetics</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adverse outcome</ancestor><ancestor>disease course</ancestor><ancestor>disease severity</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>prediction and forecasting</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>adverse outcome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>geographic names</ancestor><ancestor>north america</ancestor><ancestor>united states</ancestor><ancestor>western hemisphere</ancestor></ancestors><mainterm>United States</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor></ancestors><mainterm>epidemiology</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>decision support system</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>information system</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>decision support system</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor><ancestor>hospital subdivisions and components</ancestor><ancestor>intensive care unit</ancestor><ancestor>ward</ancestor></ancestors><mainterm>intensive care unit</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>enzyme inhibitor</dt></dgidx><dsidx><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><gnidx><gn>male</gn></gnidx><stidx><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-02-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2010 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L358284400</lui><pui>358284400</pui><embase>2010104846</embase><medl>20455340</medl></itemidlist><history><date-created>2010-03-26</date-created><date-loaded>2010-03-29</date-loaded><date-aip-loaded>2010-02-22</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="re">Review</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Cetirizine and loratadine: Minimal risk of QT prolongation</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>• Some antihistamines, such as mizolastine and ebastine, can prolong the QT interval and provoke severe cardiac arrhythmias. This review examines the effects of two widely used antihistamines, cetirizine and loratadine, on the QT interval. • As of mid 2009 very few clinical data had been published on the risk of QT prolongation with cetirizine or loratadine. • The very rare reported cases of torsades de pointes linked to loratadine mainly appear to involve drug interactions, especially with amiodarone and enzyme inhibitors. • We found no reports of QT prolongation attributed to desloratadine, the main metabolite of loratadine. • Two cases of QT prolongation with cetirizine have been published, one of which involved overdose and renal failure. The reports are too vague to conclude that cetirizine was implicated. • We found no reports of QT prolongation attributed to levocetirizine. • Cetirizine is a metabolite of hydroxyzine, another antihistamine. In the 1960s, a study of patients with psychosis showed a risk of QT prolongation. A case of recurrent syncope with QT prolongation has since been reported, along with rare cases of cardiac arrhythmia. • In practice, cetirizine and loratadine are first-line antihistamines. However, caution is needed in certain circumstances. In particular, it is best that patients who have risk factors for torsades de pointes or who are taking certain enzyme inhibitors avoid using loratadine. It is best to avoid using cetirizine in cases of renal failure.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="fra">France</sourcecountry><sourcetitle>Prescrire International</sourcetitle><sourcetitle-abbrev>Prescrire Int.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>11677422</issnnr></issn><codencode>PRINF</codencode><volisspag><volume>19</volume><issue>105</issue><firstpage>26</firstpage><volissidx>11677422||2010||19||105</volissidx><lastpage>28</lastpage></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>February 2010</pubdatetext></publicationdate><publisher><affiliation><address-part>83, boulevard Voltaire</address-part><city>Paris</city><country code="fra">France</country></affiliation><publishername>Association Mieux Prescrire</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>1951-25-3</cas-registry-number><cas-registry-number>19774-82-4</cas-registry-number><cas-registry-number>62067-87-2</cas-registry-number><chemical-name>amiodarone</chemical-name></chemical><chemical><cas-registry-number>83881-51-0</cas-registry-number><cas-registry-number>83881-52-1</cas-registry-number><chemical-name>cetirizine</chemical-name></chemical><chemical><cas-registry-number>100643-71-8</cas-registry-number><chemical-name>desloratadine</chemical-name></chemical><chemical><cas-registry-number>2192-20-3</cas-registry-number><cas-registry-number>64095-02-9</cas-registry-number><cas-registry-number>68-88-2</cas-registry-number><chemical-name>hydroxyzine</chemical-name></chemical><chemical><cas-registry-number>65277-42-1</cas-registry-number><chemical-name>ketoconazole</chemical-name></chemical><chemical><cas-registry-number>130018-77-8</cas-registry-number><chemical-name>levocetirizine</chemical-name></chemical><chemical><cas-registry-number>79794-75-5</cas-registry-number><chemical-name>loratadine</chemical-name></chemical><chemical><cas-registry-number>82752-99-6</cas-registry-number><cas-registry-number>83366-66-9</cas-registry-number><chemical-name>nefazodone</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><classifications><clsemclass>18</clsemclass><clsemclass>28</clsemclass><clsemclass>30</clsemclass><clsemclass>37</clsemclass><clsemclass>38</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>amiodarone</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><link><linkterm>drug therapy</linkterm><sublink><sublinkterm>heart atrium fibrillation</sublinkterm></sublink></link><mainterm>amiodarone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>cetirizine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>kidney failure</sublinkterm></sublink><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>ketoconazole</sublinkterm></sublink></link><link><linkterm>pharmacology</linkterm></link><mainterm>cetirizine</mainterm><weight>a</weight></descriptor><descriptor><drgterm>desloratadine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><mainterm>desloratadine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>enzyme inhibitor</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><mainterm>enzyme inhibitor</mainterm><weight>b</weight></descriptor><descriptor><drgterm>hydroxyzine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>levocetirizine</sublinkterm></sublink></link><mainterm>hydroxyzine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>ketoconazole</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>cetirizine</sublinkterm></sublink></link><mainterm>ketoconazole</mainterm><weight>b</weight></descriptor><descriptor><drgterm>levocetirizine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>hydroxyzine</sublinkterm></sublink></link><mainterm>levocetirizine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>loratadine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>amiodarone</sublinkterm></sublink><sublink><sublinkterm>enzyme inhibitor</sublinkterm></sublink><sublink><sublinkterm>nefazodone</sublinkterm></sublink></link><link><linkterm>pharmacology</linkterm></link><mainterm>loratadine</mainterm><weight>a</weight></descriptor><descriptor><drgterm>nefazodone</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><mainterm>nefazodone</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><mainterm>aged</mainterm><weight>b</weight></descriptor><descriptor><mainterm>case report</mainterm><weight>b</weight></descriptor><descriptor><devterm>defibrillator</devterm><mainterm>defibrillator</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug effect</mainterm><weight>b</weight></descriptor><descriptor><disterm>drug overdose</disterm><mainterm>drug overdose</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><disterm>atrial fibrillation</disterm><link><linkterm>drug therapy</linkterm><sublink><sublinkterm>amiodarone</sublinkterm></sublink></link><mainterm>atrial fibrillation</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>kidney failure</disterm><link><linkterm>side effect</linkterm><sublink><sublinkterm>cetirizine</sublinkterm></sublink></link><mainterm>kidney failure</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><link><linkterm>side effect</linkterm><sublink><sublinkterm>cetirizine</sublinkterm></sublink><sublink><sublinkterm>desloratadine</sublinkterm></sublink><sublink><sublinkterm>hydroxyzine</sublinkterm></sublink><sublink><sublinkterm>levocetirizine</sublinkterm></sublink><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><link><linkterm>side effect</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><disterm>recurrent disease</disterm><mainterm>recurrent disease</mainterm><weight>b</weight></descriptor><descriptor><mainterm>review</mainterm><weight>b</weight></descriptor><descriptor><disterm>faintness</disterm><mainterm>faintness</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn></head><tail><bibliography><refcount>25</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>amiodarone</ancestor><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor></ancestors><drgterm>amiodarone</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><link><linkterm>drug therapy</linkterm><sublink><sublinkterm>heart atrium fibrillation</sublinkterm></sublink></link><mainterm>amiodarone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>cetirizine</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>cetirizine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>kidney failure</sublinkterm></sublink><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>ketoconazole</sublinkterm></sublink></link><link><linkterm>pharmacology</linkterm></link><mainterm>cetirizine</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemical compound</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>desloratadine</ancestor><ancestor>drug</ancestor><ancestor>drug metabolite</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>general and inorganic chemicals</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>piperidine derivative</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>pyridine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>desloratadine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><mainterm>desloratadine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>enzyme inhibitor</ancestor></ancestors><drgterm>enzyme inhibitor</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><mainterm>enzyme inhibitor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>anxiolytic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>hydroxyzine</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>hydroxyzine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>levocetirizine</sublinkterm></sublink></link><mainterm>hydroxyzine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>1,3 dioxolane derivative</ancestor><ancestor>agents affecting metabolism</ancestor><ancestor>antifungal agent</ancestor><ancestor>antiinfective agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>carbon oxygen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>imidazole derivative</ancestor><ancestor>ketoconazole</ancestor><ancestor>organic compound</ancestor><ancestor>oxidoreductase inhibitor</ancestor><ancestor>oxygenase inhibitor</ancestor><ancestor>piperazine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>ketoconazole</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>cetirizine</sublinkterm></sublink></link><mainterm>ketoconazole</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>levocetirizine</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>levocetirizine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>hydroxyzine</sublinkterm></sublink></link><mainterm>levocetirizine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>loratadine</ancestor><ancestor>organic compound</ancestor><ancestor>piperidine derivative</ancestor><ancestor>pyridine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>loratadine</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>amiodarone</sublinkterm></sublink><sublink><sublinkterm>enzyme inhibitor</sublinkterm></sublink><sublink><sublinkterm>nefazodone</sublinkterm></sublink></link><link><linkterm>pharmacology</linkterm></link><mainterm>loratadine</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha 1 adrenergic receptor blocking agent</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>antidepressant agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>nefazodone</ancestor><ancestor>organic compound</ancestor><ancestor>piperazine derivative</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>triazole derivative</ancestor></ancestors><drgterm>nefazodone</drgterm><link><linkterm>drug interaction</linkterm><sublink><sublinkterm>loratadine</sublinkterm></sublink></link><mainterm>nefazodone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>aged</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>aged</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>case report</ancestor><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>case report</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac equipment</ancestor><ancestor>cardiac rhythm management device</ancestor><ancestor>cardiovascular equipment</ancestor><ancestor>cardiovascular therapeutic device</ancestor><ancestor>defibrillator</ancestor><ancestor>devices</ancestor><ancestor>life support equipment</ancestor><ancestor>medical device</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><devterm>defibrillator</devterm><mainterm>defibrillator</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug activity</ancestor><ancestor>drug effect</ancestor><ancestor>pharmacodynamics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>drug effect</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>chemical parameters</ancestor><ancestor>diseases</ancestor><ancestor>dose</ancestor><ancestor>drug dose</ancestor><ancestor>drug overdose</ancestor><ancestor>intoxication</ancestor><ancestor>parameters</ancestor><ancestor>pharmacological parameters</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>toxicity and intoxication</ancestor></ancestors><disterm>drug overdose</disterm><mainterm>drug overdose</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>atrial fibrillation</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart atrium arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart fibrillation</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>atrial fibrillation</disterm><link><linkterm>drug therapy</linkterm><sublink><sublinkterm>amiodarone</sublinkterm></sublink></link><mainterm>atrial fibrillation</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>kidney disease</ancestor><ancestor>kidney failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>urinary tract disease</ancestor><ancestor>urogenital tract disease</ancestor></ancestors><disterm>kidney failure</disterm><link><linkterm>side effect</linkterm><sublink><sublinkterm>cetirizine</sublinkterm></sublink></link><mainterm>kidney failure</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><link><linkterm>side effect</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>disease course</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>recurrent disease</ancestor></ancestors><disterm>recurrent disease</disterm><mainterm>recurrent disease</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>review</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>review</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>faintness</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by body function</ancestor></ancestors><disterm>faintness</disterm><mainterm>faintness</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>adult</ag><ag>aged</ag></agidx><dgidx><dt>amiodarone</dt><dt>cetirizine</dt><dt>desloratadine</dt><dt>enzyme inhibitor</dt><dt>hydroxyzine</dt><dt>ketoconazole</dt><dt>levocetirizine</dt><dt>loratadine</dt><dt>nefazodone</dt></dgidx><dsidx><dst>atrial fibrillation</dst><dst>drug overdose</dst><dst>faintness</dst><dst>kidney failure</dst><dst>qt prolongation</dst><dst>recurrent disease</dst><dst>torsade des pointes</dst></dsidx><dvidx><dv>defibrillator</dv></dvidx><gnidx><gn>female</gn></gnidx><stidx><stt>case report</stt><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2012-02-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2013 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1097/CCM.0b013e318232db4a</doi><lui>L51667865</lui><pui>51667865</pui><embase>2012051013</embase><medl>22001585</medl><pii>0000324620120200000004</pii></itemidlist><history><date-created>2012-02-02</date-created><date-loaded>2012-02-03</date-loaded><date-aip-loaded>2011-10-19</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>acquired</author-keyword><author-keyword>critical care</author-keyword><author-keyword>electrocardiography</author-keyword><author-keyword>long QT</author-keyword><author-keyword>mortality</author-keyword><author-keyword>predictor</author-keyword><author-keyword>prevalence</author-keyword><author-keyword>QT prolongation</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) study</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Objective: To test the potential value of more frequent QT interval measurement in hospitalized patients. Design: We performed a prospective, observational study. Setting: All adult intensive care unit and progressive care unit beds of a university medical center. Patients: All patients admitted to one of six critical care units over a 2-month period were included in analyses. Interventions: All critical care beds (n = 154) were upgraded to a continuous QT monitoring system (Philips Healthcare). Measurements and Main Results; QT data were extracted from the bedside monitors for offline analysis. A corrected QT interval &gt;500 msecs was considered prolonged. Episodes of QT prolongation were manually over-read. Electrocardiogram data (67,648 hrs, mean 65 hrs/patient) were obtained. QT prolongation was present in 24%. There were 16 cardiac arrests, with one resulting from Torsade de Pointes (6%). Predictors of QT prolongation were female sex, QT-prolonging drugs, hypokalemia, hypocalcemia, hyperglycemia, high creatinine, history of stroke, and hypothyroidism. Patients with QT prolongation had longer hospitalization (276 hrs vs. 132 hrs, p &lt; .0005) and had three times the odds for all-cause in-hospital mortality compared to patients without QT prolongation (odds ratio 2.99 95% confidence interval 1.1-8.1). Conclusions: We find QT prolongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardiac arrests. Predictors of QT prolongation in the acutely ill population are similar to those previously identified in ambulatory populations. Acutely ill patients with QT prolongation have longer lengths of hospitalization and nearly three times the odds for mortality then those without QT prolongation. Copyright © 2012 by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>Critical Care Medicine</sourcetitle><sourcetitle-abbrev>Crit. Care Med.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00903493</issnnr></issn><issn><issntype>electronic</issntype><issnnr>15300293</issnnr></issn><codencode>CCMDC</codencode><volisspag><volume>40</volume><issue>2</issue><firstpage>394</firstpage><volissidx>00903493||2012||40||2</volissidx><volissidx>15300293||2012||40||2</volissidx><lastpage>399</lastpage></volisspag><publicationyear>2012</publicationyear><publicationdate><pubdatetext>February 2012</pubdatetext></publicationdate><publisher><affiliation><address-part>530 Walnut Street,P O Box 327</address-part><city>Philadelphia</city><country code="usa">United States</country></affiliation><publishername>Lippincott Williams and Wilkins</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>19230-81-0</cas-registry-number><cas-registry-number>60-27-5</cas-registry-number><chemical-name>creatinine</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><classifications><clsemclass>6</clsemclass><clsemclass>18</clsemclass><clsemclass>37</clsemclass><clsemclass>38</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>cardiac agent</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><mainterm>cardiac agent</mainterm><weight>b</weight></descriptor><descriptor><drgterm>creatinine</drgterm><link><linkterm>endogenous compound</linkterm></link><mainterm>creatinine</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>controlled study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>creatinine blood level</mainterm><weight>b</weight></descriptor><descriptor><mainterm>disease association</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart arrest</disterm><mainterm>heart arrest</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospital patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hospitalization</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>hyperglycemia</disterm><mainterm>hyperglycemia</mainterm><weight>b</weight></descriptor><descriptor><disterm>hypocalcemia</disterm><mainterm>hypocalcemia</mainterm><weight>b</weight></descriptor><descriptor><disterm>hypokalemia</disterm><mainterm>hypokalemia</mainterm><weight>b</weight></descriptor><descriptor><disterm>hypothyroidism</disterm><mainterm>hypothyroidism</mainterm><weight>b</weight></descriptor><descriptor><mainterm>intensive care</mainterm><weight>b</weight></descriptor><descriptor><mainterm>length of stay</mainterm><weight>a</weight></descriptor><descriptor><mainterm>major clinical study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>mortality</mainterm><weight>a</weight></descriptor><descriptor><mainterm>observational study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prediction</mainterm><weight>b</weight></descriptor><descriptor><mainterm>priority journal</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prospective study</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><link><linkterm>side effect</linkterm><sublink><sublinkterm>cardiac agent</sublinkterm></sublink></link><link><linkterm>side effect</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>sex difference</mainterm><weight>b</weight></descriptor><descriptor><disterm>cerebrovascular accident</disterm><mainterm>cerebrovascular accident</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><author><autidx>Pickham D.</autidx><email>david.pickham@ucsf.edu</email><given-name>David</given-name><initials>D.</initials><seq>1</seq><surname>Pickham</surname></author><author><autidx>Chan G.</autidx><given-name>Garrett</given-name><initials>G.</initials><seq>4</seq><surname>Chan</surname></author><author><autidx>Liu J.-N.</autidx><given-name>Jia-Ni</given-name><initials>J.-N.</initials><seq>7</seq><surname>Liu</surname></author><author><autidx>Drew B.J.</autidx><given-name>Barbara J.</given-name><initials>B.J.</initials><seq>8</seq><surname>Drew</surname></author></author-group><author-group><affiliation><city-group>San Jose, CA</city-group><country code="usa">United States</country><organization>Advanced Algorithm Research Center</organization><organization>Philips Healthcare</organization></affiliation><author><autidx>Helfenbein E.</autidx><given-name>Eric</given-name><initials>E.</initials><seq>2</seq><surname>Helfenbein</surname></author></author-group><author-group><affiliation><city-group>Stanford, CA</city-group><country code="usa">United States</country><organization>Stanford University Medical Center</organization></affiliation><author><autidx>Shinn J.A.</autidx><given-name>Julie A.</given-name><initials>J.A.</initials><seq>3</seq><surname>Shinn</surname></author><author><autidx>Weinacker A.</autidx><given-name>Ann</given-name><initials>A.</initials><seq>6</seq><surname>Weinacker</surname></author></author-group><author-group><affiliation><city-group>New Haven, CT</city-group><country code="usa">United States</country><organization>School of Nursing</organization><organization>Yale University</organization></affiliation><author><autidx>Funk M.</autidx><given-name>Marjorie</given-name><initials>M.</initials><seq>5</seq><surname>Funk</surname></author></author-group><authorlist><author><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><autidx>Pickham D.</autidx><email>david.pickham@ucsf.edu</email><given-name>David</given-name><initials>D.</initials><seq>1</seq><surname>Pickham</surname><aggregatedAuthorId>pickham d.__pickham__david</aggregatedAuthorId><uniqueAuthorId>pickham__david__d.____zgcAI9kOyg==</uniqueAuthorId></author><author><affiliation><city-group>San Jose, CA</city-group><country code="usa">United States</country><organization>Advanced Algorithm Research Center</organization><organization>Philips Healthcare</organization></affiliation><autidx>Helfenbein E.</autidx><given-name>Eric</given-name><initials>E.</initials><seq>2</seq><surname>Helfenbein</surname><aggregatedAuthorId>helfenbein e.__helfenbein__eric</aggregatedAuthorId><uniqueAuthorId>helfenbein__eric__e.____LEoFAERBBys=</uniqueAuthorId></author><author><affiliation><city-group>Stanford, CA</city-group><country code="usa">United States</country><organization>Stanford University Medical Center</organization></affiliation><autidx>Shinn J.A.</autidx><given-name>Julie A.</given-name><initials>J.A.</initials><seq>3</seq><surname>Shinn</surname><aggregatedAuthorId>shinn j.a.__shinn__julie a.</aggregatedAuthorId><uniqueAuthorId>shinn__julie a.__j.a.____K0ktAgDulQ10</uniqueAuthorId></author><author><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><autidx>Chan G.</autidx><given-name>Garrett</given-name><initials>G.</initials><seq>4</seq><surname>Chan</surname><aggregatedAuthorId>chan g.__chan__garrett</aggregatedAuthorId><uniqueAuthorId>chan__garrett__g.____zgcAI9kOyg==</uniqueAuthorId></author><author><affiliation><city-group>New Haven, CT</city-group><country code="usa">United States</country><organization>School of Nursing</organization><organization>Yale University</organization></affiliation><autidx>Funk M.</autidx><given-name>Marjorie</given-name><initials>M.</initials><seq>5</seq><surname>Funk</surname><aggregatedAuthorId>funk m.__funk__marjorie</aggregatedAuthorId><uniqueAuthorId>funk__marjorie__m.____LKkEAC/+Bi4=</uniqueAuthorId></author><author><affiliation><city-group>Stanford, CA</city-group><country code="usa">United States</country><organization>Stanford University Medical Center</organization></affiliation><autidx>Weinacker A.</autidx><given-name>Ann</given-name><initials>A.</initials><seq>6</seq><surname>Weinacker</surname><aggregatedAuthorId>weinacker a.__weinacker__ann</aggregatedAuthorId><uniqueAuthorId>weinacker__ann__a.____K0ktAgDulQ10</uniqueAuthorId></author><author><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><autidx>Liu J.-N.</autidx><given-name>Jia-Ni</given-name><initials>J.-N.</initials><seq>7</seq><surname>Liu</surname><aggregatedAuthorId>liu j.-n.__liu__jia-ni</aggregatedAuthorId><uniqueAuthorId>liu__jia-ni__j.-n.____zgcAI9kOyg==</uniqueAuthorId></author><author><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><autidx>Drew B.J.</autidx><given-name>Barbara J.</given-name><initials>B.J.</initials><seq>8</seq><surname>Drew</surname><aggregatedAuthorId>drew b.j.__drew__barbara j.</aggregatedAuthorId><uniqueAuthorId>drew__barbara j.__b.j.____zgcAI9kOyg==</uniqueAuthorId></author></authorlist><correspondence><affiliation><city-group>San Francisco, CA</city-group><country code="usa">United States</country><organization>Department of Physiological Nursing</organization><organization>University of California San Francisco</organization></affiliation><email>david.pickham@ucsf.edu</email><person><degrees>Dr.</degrees><initials>D.</initials><persidx>Pickham D.</persidx><surname>Pickham</surname></person></correspondence></head><tail><bibliography><refcount>28</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>cardiac agent</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor></ancestors><drgterm>cardiac agent</drgterm><link><linkterm>adverse drug reaction</linkterm><sublink><sublinkterm>QT prolongation</sublinkterm></sublink></link><mainterm>cardiac agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amino acid</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>creatinine</ancestor><ancestor>functional group</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>imidazole derivative</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>polyfunctional group</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>creatinine</drgterm><link><linkterm>endogenous compound</linkterm></link><mainterm>creatinine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>controlled study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>controlled study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>blood level</ancestor><ancestor>chemical parameters</ancestor><ancestor>creatinine blood level</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>creatinine blood level</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>disease association</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor></ancestors><mainterm>disease association</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrest</ancestor><ancestor>heart disease</ancestor><ancestor>heart failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart arrest</disterm><mainterm>heart arrest</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>hospital patient</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>hospital patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care management</ancestor><ancestor>hospital management</ancestor><ancestor>hospitalization</ancestor><ancestor>management</ancestor><ancestor>organization and management</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>hospitalization</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>abnormal substrate concentration in blood</ancestor><ancestor>abnormally high substrate concentration in blood</ancestor><ancestor>diseases</ancestor><ancestor>disorders of carbohydrate metabolism</ancestor><ancestor>endocrine disease</ancestor><ancestor>hyperglycemia</ancestor><ancestor>metabolic disorder</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by body function</ancestor><ancestor>physical disease by composition of body fluids, excreta and secretions</ancestor></ancestors><disterm>hyperglycemia</disterm><mainterm>hyperglycemia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>abnormal substrate concentration in blood</ancestor><ancestor>abnormally low substrate concentration in blood</ancestor><ancestor>calcium deficiency</ancestor><ancestor>diseases</ancestor><ancestor>hypocalcemia</ancestor><ancestor>mineral deficiency</ancestor><ancestor>nutritional deficiency</ancestor><ancestor>nutritional disorder</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by body function</ancestor><ancestor>physical disease by composition of body fluids, excreta and secretions</ancestor></ancestors><disterm>hypocalcemia</disterm><mainterm>hypocalcemia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>abnormal substrate concentration in blood</ancestor><ancestor>abnormally low substrate concentration in blood</ancestor><ancestor>diseases</ancestor><ancestor>disorders of mineral, electrolyte and metal metabolism</ancestor><ancestor>electrolyte disturbance</ancestor><ancestor>hypokalemia</ancestor><ancestor>metabolic disorder</ancestor><ancestor>mineral deficiency</ancestor><ancestor>nutritional deficiency</ancestor><ancestor>nutritional disorder</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by body function</ancestor><ancestor>physical disease by composition of body fluids, excreta and secretions</ancestor><ancestor>potassium deficiency</ancestor></ancestors><disterm>hypokalemia</disterm><mainterm>hypokalemia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>disorders of hormone metabolism</ancestor><ancestor>endocrine disease</ancestor><ancestor>hypothyroidism</ancestor><ancestor>metabolic disorder</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by body function</ancestor><ancestor>thyroid disease</ancestor></ancestors><disterm>hypothyroidism</disterm><mainterm>hypothyroidism</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>hospital care</ancestor><ancestor>intensive care</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>intensive care</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>hospital care</ancestor><ancestor>length of stay</ancestor></ancestors><mainterm>length of stay</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>major clinical study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>major clinical study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mortality</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>mortality</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>observational study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>observational study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>prediction</ancestor><ancestor>prediction and forecasting</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>prediction</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>priority journal</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>priority journal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>prospective study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>prospective study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><link><linkterm>side effect</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender and sex</ancestor><ancestor>sex difference</ancestor></ancestors><mainterm>sex difference</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>brain disease</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>central nervous system disease</ancestor><ancestor>cerebrovascular accident</ancestor><ancestor>cerebrovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>neurologic disease</ancestor><ancestor>peripheral vascular disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>vascular disease</ancestor></ancestors><disterm>cerebrovascular accident</disterm><mainterm>cerebrovascular accident</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>a</weight></explosion></explosions><idxs><agidx><ag>adult</ag></agidx><dgidx><dt>cardiac agent</dt><dt>creatinine</dt></dgidx><dsidx><dst>cerebrovascular accident</dst><dst>heart arrest</dst><dst>hyperglycemia</dst><dst>hypocalcemia</dst><dst>hypokalemia</dst><dst>hypothyroidism</dst><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>controlled study</stt><stt>human</stt><stt>major clinical study</stt><stt>observational study</stt><stt>prospective study</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2015-10-22</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2016 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1007/s00246-015-1164-y</doi><lui>L603644708</lui><pui>603644708</pui><car-id>634807355</car-id><embase>2015904745</embase><medl>25845942</medl></itemidlist><history><date-created>2015-09-23</date-created><date-loaded>2015-09-29</date-loaded><date-aip-loaded>2015-04-16</date-aip-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language><author-keywords><author-keyword>Long QT syndrome</author-keyword><author-keyword>Monitoring</author-keyword><author-keyword>Mortality</author-keyword><author-keyword>QT prolongation</author-keyword><author-keyword>Risk factor</author-keyword></author-keywords></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Phenotype of Children with QT Prolongation Identified Using an Institution-Wide QT Alert System</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>QT prolongation is an independent risk factor for cardiovascular mortality in adults. However, there is little information available on pediatric patients with QT prolongation and their outcomes. Herein, we evaluated the prevalence of QT prolongation in pediatric patients identified by an institution-wide QT alert system, and the spectrum of their phenotype. Patients with documented QT prolongation on an ECG obtained between November 2010 and June 2011 were included. There were 1303 pediatric ECGs, and 68 children had electrographically isolated QT prolongation. Comprehensive review of medical records was performed with particular attention to QT-prolonging clinical, laboratory, and medication data, which were summarized into a pro-QTc score. Overall, 68 (5 %) pediatric patients had isolated QT prolongation. The mean age of this pediatric cohort was 9 ± 6 years, and the average QTc was 494 ± 42 ms. All children had 1 or more QT-prolonging risk factor(s), most commonly QT-prolonging medications. One patient was identified with congenital long QT syndrome (LQTS), which was not previously diagnosed. In one-year follow-up, only one pediatric death (non-cardiac) occurred (1.5 %). Potentially QT-offending/pro-arrhythmic medications were changed in 80 % of pediatric patients after the physician received the QT alert. Children with QT prolongation had very low mortality and minimal polypharmacy. Still, medications and other modifiable conditions were the most common causes of QT prolongation. Children with a prolonged QTc should be evaluated for modifiable QT-prolonging factors. However, if no risk factors are present or the QTc does not attenuate after risk factor modification/removal, the child should be evaluated for congenital LQTS.</para><publishercopyright>© 2015, Springer Science+Business Media New York.</publishercopyright></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>Pediatric Cardiology</sourcetitle><sourcetitle-abbrev>Pediatr. Cardiol.</sourcetitle-abbrev><issn><issntype>electronic</issntype><issnnr>14321971</issnnr></issn><issn><issntype>print</issntype><issnnr>01720643</issnnr></issn><codencode>PECAD</codencode><volisspag><volume>36</volume><issue>7</issue><firstpage>1350</firstpage><volissidx>14321971||2015||36||7</volissidx><volissidx>01720643||2015||36||7</volissidx><lastpage>1356</lastpage></volisspag><publicationyear>2015</publicationyear><publicationdate><pubdate day="22" month="10" year="2015">2015-10-22</pubdate></publicationdate><website><email>link.springer.de/link/service/journals/00246/index.htm</email></website><publisher><email>barbara.b.bertram@gsk.com</email><publishername>Springer New York LLC</publishername></publisher></source><enhancement><classifications><clsemclass>18</clsemclass><clsemclass>27</clsemclass><clsemclass>7</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>child</mainterm><weight>b</weight></descriptor><descriptor><mainterm>child death</mainterm><weight>b</weight></descriptor><descriptor><devterm>computer system</devterm><mainterm>computer system</mainterm><weight>a</weight></descriptor><descriptor><mainterm>controlled study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrocardiogram</mainterm><weight>b</weight></descriptor><descriptor><mainterm>electrography</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><mainterm>follow up</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm candidate="true">institution wide QT alert system</mainterm><weight>a</weight></descriptor><descriptor><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></descriptor><descriptor><mainterm>major clinical study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>medical record review</mainterm><weight>b</weight></descriptor><descriptor><mainterm>mortality</mainterm><weight>b</weight></descriptor><descriptor><mainterm>phenotype</mainterm><weight>a</weight></descriptor><descriptor><mainterm>polypharmacy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>prevalence</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup><enhancement-status>002</enhancement-status><enhancement-type>8</enhancement-type></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Anderson H.N.</autidx><given-name>Heather N.</given-name><initials>H.N.</initials><seq>1</seq><surname>Anderson</surname></author><author><autidx>Bos J.M.</autidx><given-name>J. Martijn</given-name><initials>J.M.</initials><seq>2</seq><surname>Bos</surname></author><author><autidx>Ackerman M.J.</autidx><email>ackerman.michael@mayo.edu</email><given-name>Michael J.</given-name><initials>M.J.</initials><seq>7</seq><surname>Ackerman</surname></author></author-group><author-group><affiliation><address-part>Guggenheim 501, 200 First Street SW</address-part><city>Rochester</city><country code="usa">United States</country><organization>Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Bos J.M.</autidx><given-name>J. Martijn</given-name><initials>J.M.</initials><seq>2</seq><surname>Bos</surname></author><author><autidx>Haugaa K.H.</autidx><given-name>Kristina H.</given-name><initials>K.H.</initials><seq>3</seq><surname>Haugaa</surname></author><author><autidx>Ackerman M.J.</autidx><email>ackerman.michael@mayo.edu</email><given-name>Michael J.</given-name><initials>M.J.</initials><seq>7</seq><surname>Ackerman</surname></author></author-group><author-group><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Internal Medicine/Division of Cardiovascular Diseases, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Bos J.M.</autidx><given-name>J. Martijn</given-name><initials>J.M.</initials><seq>2</seq><surname>Bos</surname></author><author><autidx>Ackerman M.J.</autidx><email>ackerman.michael@mayo.edu</email><given-name>Michael J.</given-name><initials>M.J.</initials><seq>7</seq><surname>Ackerman</surname></author></author-group><author-group><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Health Care Policy and Research, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Morlan B.W.</autidx><given-name>Bruce W.</given-name><initials>B.W.</initials><seq>4</seq><surname>Morlan</surname></author></author-group><author-group><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Statistics, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Tarrell R.F.</autidx><given-name>Robert F.</given-name><initials>R.F.</initials><seq>5</seq><surname>Tarrell</surname></author></author-group><author-group><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Internal Medicine, Division of General Internal Medicine, Mayo Clinic</organization><state>MN</state></affiliation><author><autidx>Caraballo P.J.</autidx><given-name>Pedro J.</given-name><initials>P.J.</initials><seq>6</seq><surname>Caraballo</surname></author></author-group><authorlist><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Anderson H.N.</autidx><given-name>Heather N.</given-name><initials>H.N.</initials><seq>1</seq><surname>Anderson</surname><aggregatedAuthorId>anderson h.n.__anderson__heather n.</aggregatedAuthorId><uniqueAuthorId>anderson__heather n.__h.n.____R0IefaEjMQ==</uniqueAuthorId></author><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic</organization><state>MN</state></affiliation><affiliation><address-part>Guggenheim 501, 200 First Street SW</address-part><city>Rochester</city><country code="usa">United States</country><organization>Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic</organization><state>MN</state></affiliation><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Internal Medicine/Division of Cardiovascular Diseases, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Bos J.M.</autidx><given-name>J. Martijn</given-name><initials>J.M.</initials><seq>2</seq><surname>Bos</surname><aggregatedAuthorId>bos j.m.__bos__j. martijn</aggregatedAuthorId><uniqueAuthorId>bos__j. martijn__j.m.____R0IefaEjMQ==</uniqueAuthorId></author><author><affiliation><address-part>Guggenheim 501, 200 First Street SW</address-part><city>Rochester</city><country code="usa">United States</country><organization>Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Haugaa K.H.</autidx><given-name>Kristina H.</given-name><initials>K.H.</initials><seq>3</seq><surname>Haugaa</surname><aggregatedAuthorId>haugaa k.h.__haugaa__kristina h.</aggregatedAuthorId><uniqueAuthorId>haugaa__kristina h.__k.h.____TEPpD0MuMp8=</uniqueAuthorId></author><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Health Care Policy and Research, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Morlan B.W.</autidx><given-name>Bruce W.</given-name><initials>B.W.</initials><seq>4</seq><surname>Morlan</surname><aggregatedAuthorId>morlan b.w.__morlan__bruce w.</aggregatedAuthorId><uniqueAuthorId>morlan__bruce w.__b.w.____QcPT9QeArBV/</uniqueAuthorId></author><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Statistics, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Tarrell R.F.</autidx><given-name>Robert F.</given-name><initials>R.F.</initials><seq>5</seq><surname>Tarrell</surname><aggregatedAuthorId>tarrell r.f.__tarrell__robert f.</aggregatedAuthorId><uniqueAuthorId>tarrell__robert f.__r.f.____zMtMBgAQ+A4p</uniqueAuthorId></author><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Internal Medicine, Division of General Internal Medicine, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Caraballo P.J.</autidx><given-name>Pedro J.</given-name><initials>P.J.</initials><seq>6</seq><surname>Caraballo</surname><aggregatedAuthorId>caraballo p.j.__caraballo__pedro j.</aggregatedAuthorId><uniqueAuthorId>caraballo__pedro j.__p.j.____KfoDJegfGA==</uniqueAuthorId></author><author><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic</organization><state>MN</state></affiliation><affiliation><address-part>Guggenheim 501, 200 First Street SW</address-part><city>Rochester</city><country code="usa">United States</country><organization>Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic</organization><state>MN</state></affiliation><affiliation><city>Rochester</city><country code="usa">United States</country><organization>Department of Internal Medicine/Division of Cardiovascular Diseases, Mayo Clinic</organization><state>MN</state></affiliation><autidx>Ackerman M.J.</autidx><email>ackerman.michael@mayo.edu</email><given-name>Michael J.</given-name><initials>M.J.</initials><seq>7</seq><surname>Ackerman</surname><aggregatedAuthorId>ackerman m.j.__ackerman__michael j.</aggregatedAuthorId><uniqueAuthorId>ackerman__michael j.__m.j.____R0IefaEjMQ==</uniqueAuthorId></author></authorlist><correspondence><affiliation><address-part>Guggenheim 501, 200 First Street SW</address-part><city>Rochester</city><country code="usa">United States</country><organization>Department of Molecular Pharmacology and Experimental Therapeutics/Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic</organization><state>MN</state></affiliation><email>ackerman.michael@mayo.edu</email><person><given-name>Michael J.</given-name><initials>M.J.</initials><persidx>Ackerman M.J.</persidx><surname>Ackerman</surname></person></correspondence></head><tail><bibliography><refcount>16</refcount></bibliography></tail><explosions><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>child</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor><ancestor>juvenile</ancestor></ancestors><mainterm>child</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>child death</ancestor><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor></ancestors><mainterm>child death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>computer</ancestor><ancestor>computer system</ancestor><ancestor>devices</ancestor><ancestor>electronic device</ancestor><ancestor>general device</ancestor><ancestor>information technology device</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><devterm>computer system</devterm><mainterm>computer system</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>controlled study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>controlled study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiogram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diagnostic procedure</ancestor><ancestor>electrography</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrography</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>aftercare</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>evaluation and follow up</ancestor><ancestor>follow up</ancestor><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>long term care</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>follow up</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>institution wide qt alert system</ancestor></ancestors><mainterm candidate="true">institution wide QT alert system</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiac channelopathy</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>channelopathy</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>long qt syndrome</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>major clinical study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>major clinical study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data collection method</ancestor><ancestor>medical record review</ancestor><ancestor>methodology</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>medical record review</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mortality</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>mortality</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>heredity</ancestor><ancestor>phenotype</ancestor></ancestors><mainterm>phenotype</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>polypharmacy</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>polypharmacy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diseases</ancestor><ancestor>epidemiological data</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>mathematical parameters</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>parameters</ancestor><ancestor>prevalence</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>statistical concepts</ancestor><ancestor>statistical parameters</ancestor></ancestors><mainterm>prevalence</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><link><linkterm>diagnosis</linkterm></link><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>child</ag></agidx><dsidx><dst>long qt syndrome</dst><dst>qt prolongation</dst></dsidx><dvidx><dv>computer system</dv></dvidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>controlled study</stt><stt>human</stt><stt>major clinical study</stt><stt>medical record review</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-12-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2010 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1097/01.ccm.0000390903.16849.8c</doi><lui>L70317306</lui><pui>70317306</pui><absn>89</absn><pii>0000324620101200100001</pii></itemidlist><history><date-created>2010-12-31</date-created><date-loaded>2011-01-04</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Evaluating the occurrence of QT prolongation resulting from drug-drug interactions</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Introduction: Over 50 medications cause QT prolongation, which can deteriorate into torsade de pointes. Information is lacking on the frequency of QT prolongation due to drug-drug interactions (DDIs) accounting for temporal sequence in intensive care units (ICUs). This evaluation is of particular interest to clinicians in cardiac ICUs, since there is at heightened risk for adverse outcomes. Hypothesis: The primary objective was to determine the frequency of QT prolongation from potentially interacting drugs in the coronary ICU and cardiothoracic ICU. Methods: After obtaining IRB approval, a retrospective evaluation was performed using the institution's electronic data repository. Inclusion criteria were admission to the cardiac ICUs between January 2009 and July 2009, age ≥18 years, and electrocardiographic (EKG) evidence of a QTc ≥ 500 ms. Medications known to prolong the QT interval were identified using the Arizona CERT database. Patients receiving 2 concomitant medications known to prolong the QT interval were considered to experience a pharmacodynamic DDI. Medications known to be CYP450 enzyme inhibitors of QT prolonging medications were considered to cause pharmacokinetic DDIs. Interactions were evaluated for temporal relationship to the QT prolongation. Results: 187 (54.5 % male) patients, with a mean age of 62 years, experienced QT prolongation out of a total of 501 patients (37%) admitted during the study period. 154 and 163 patients had a potential pharmacodynamic and pharmacokinetic interaction, respectively, receiving an average of 2.9 QT prolonging medications during their admission. Of these patients, 43% (66/154) had 133 pharmacodynamic interactions confirmed by temporal sequence, and 47% (77/163) of patients experienced 179 potential pharmacokinetic interactions temporally related to QT prolongation. Most common medications related to these DDIs were amiodarone, ondansetron, tacrolimus, diphenhydramine, voriconazole, risperidone and haloperidol. Conclusions: DDIs may be a significant cause of QT prolongation in cardiac ICUs. These data can be used to educate clinicians on safe medication use. Computerized clinical decision support could be applied to aid in the detection of these events.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Critical Care Medicine</sourcetitle><sourcetitle-abbrev>Crit. Care Med.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00903493</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>San Diego, CA</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>40th Critical Care Congress of the Society of Critical Care Medicine</confname><enddate>2011-01-19</enddate><startdate>2011-01-15</startdate></confevent></conferenceinfo><volisspag><volume>38</volume><firstpage>A21</firstpage><volissidx>00903493||2010||38||</volissidx><supplement>SUPPL. 12</supplement></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>December 2010</pubdatetext></publicationdate><publisher><publishername>Lippincott Williams and Wilkins</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>haloperidol</drgterm><mainterm>haloperidol</mainterm><weight>b</weight></descriptor><descriptor><drgterm>enzyme inhibitor</drgterm><mainterm>enzyme inhibitor</mainterm><weight>b</weight></descriptor><descriptor><drgterm>amiodarone</drgterm><mainterm>amiodarone</mainterm><weight>b</weight></descriptor><descriptor><drgterm>ondansetron</drgterm><mainterm>ondansetron</mainterm><weight>b</weight></descriptor><descriptor><drgterm>tacrolimus</drgterm><mainterm>tacrolimus</mainterm><weight>b</weight></descriptor><descriptor><drgterm>diphenhydramine</drgterm><mainterm>diphenhydramine</mainterm><weight>b</weight></descriptor><descriptor><drgterm>voriconazole</drgterm><mainterm>voriconazole</mainterm><weight>b</weight></descriptor><descriptor><drgterm>risperidone</drgterm><mainterm>risperidone</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>intensive care</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug interaction</mainterm><weight>a</weight></descriptor><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug therapy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>pharmacokinetics</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>decision support system</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>intensive care unit</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor><mainterm>adverse outcome</mainterm><weight>b</weight></descriptor><descriptor><mainterm>hypothesis</mainterm><weight>b</weight></descriptor><descriptor><mainterm>United States</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><country code="USA">United States</country><organization>UPMC Presbyterian-Shadyside</organization></affiliation><author><autidx>Armahizer M.</autidx><given-name>Michael</given-name><initials>M.</initials><seq>1</seq><surname>Armahizer</surname></author></author-group><author-group><affiliation><country code="USA">United States</country><organization>University of Pittsburgh Medical Center</organization></affiliation><author><autidx>Seybert A.</autidx><given-name>Amy</given-name><initials>A.</initials><seq>2</seq><surname>Seybert</surname></author></author-group><author-group><affiliation><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization></affiliation><author><autidx>Smithburger P.</autidx><given-name>Pamela</given-name><initials>P.</initials><seq>3</seq><surname>Smithburger</surname></author><author><autidx>Kane-Gill S.</autidx><given-name>Sandra</given-name><initials>S.</initials><seq>4</seq><surname>Kane-Gill</surname></author></author-group><authorlist><author><affiliation><country code="USA">United States</country><organization>UPMC Presbyterian-Shadyside</organization></affiliation><autidx>Armahizer M.</autidx><given-name>Michael</given-name><initials>M.</initials><seq>1</seq><surname>Armahizer</surname><aggregatedAuthorId>armahizer m.__armahizer__michael</aggregatedAuthorId><uniqueAuthorId>armahizer__michael__m.____TEkFAJeSCtk=</uniqueAuthorId></author><author><affiliation><country code="USA">United States</country><organization>University of Pittsburgh Medical Center</organization></affiliation><autidx>Seybert A.</autidx><given-name>Amy</given-name><initials>A.</initials><seq>2</seq><surname>Seybert</surname><aggregatedAuthorId>seybert a.__seybert__amy</aggregatedAuthorId><uniqueAuthorId>seybert__amy__a.____SS0CADehD1Q=</uniqueAuthorId></author><author><affiliation><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization></affiliation><autidx>Smithburger P.</autidx><given-name>Pamela</given-name><initials>P.</initials><seq>3</seq><surname>Smithburger</surname><aggregatedAuthorId>smithburger p.__smithburger__pamela</aggregatedAuthorId><uniqueAuthorId>smithburger__pamela__p.____TK4EAEGZBvM=</uniqueAuthorId></author><author><affiliation><country code="USA">United States</country><organization>University of Pittsburgh</organization><organization>School of Pharmacy</organization></affiliation><autidx>Kane-Gill S.</autidx><given-name>Sandra</given-name><initials>S.</initials><seq>4</seq><surname>Kane-Gill</surname><aggregatedAuthorId>kane-gill s.__kane-gill__sandra</aggregatedAuthorId><uniqueAuthorId>kane-gill__sandra__s.____TK4EAEGZBvM=</uniqueAuthorId></author></authorlist><correspondence><affiliation><country code="USA">United States</country><organization>UPMC Presbyterian-Shadyside</organization></affiliation><person><initials>M.</initials><persidx>Armahizer M.</persidx><surname>Armahizer</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>alkyl aryl ketone</ancestor><ancestor>alkyl phenyl ketone</ancestor><ancestor>butyrophenone derivative</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>functional group</ancestor><ancestor>functional groups containing oxygen</ancestor><ancestor>haloperidol</ancestor><ancestor>ketone</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>organic compound</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>haloperidol</drgterm><mainterm>haloperidol</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>enzyme inhibitor</ancestor></ancestors><drgterm>enzyme inhibitor</drgterm><mainterm>enzyme inhibitor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amiodarone</ancestor><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor></ancestors><drgterm>amiodarone</drgterm><mainterm>amiodarone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiemetic agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>digestive tract agent</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>imidazole derivative</ancestor><ancestor>ondansetron</ancestor><ancestor>organic compound</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>ondansetron</drgterm><mainterm>ondansetron</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>antibiotic agent</ancestor><ancestor>antieczema agent</ancestor><ancestor>antiinfective agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>calcineurin inhibitor</ancestor><ancestor>carboxyl group</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dermatological agent</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>ester</ancestor><ancestor>esterase inhibitor</ancestor><ancestor>functional group</ancestor><ancestor>functional groups containing oxygen</ancestor><ancestor>hydrolase inhibitor</ancestor><ancestor>immunomodulating agent</ancestor><ancestor>immunosuppressive agent</ancestor><ancestor>lactone</ancestor><ancestor>macrocyclic compound</ancestor><ancestor>macrolide</ancestor><ancestor>organic compound</ancestor><ancestor>tacrolimus</ancestor></ancestors><drgterm>tacrolimus</drgterm><mainterm>tacrolimus</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antiallergic agent</ancestor><ancestor>antiemetic agent</ancestor><ancestor>antihistaminic agent</ancestor><ancestor>antitussive agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>digestive tract agent</ancestor><ancestor>diphenhydramine</ancestor><ancestor>histamine h1 receptor antagonist</ancestor><ancestor>histaminergic receptor affecting agent</ancestor><ancestor>respiratory tract agent</ancestor></ancestors><drgterm>diphenhydramine</drgterm><mainterm>diphenhydramine</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>antifungal agent</ancestor><ancestor>antiinfective agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>nucleic acids, nucleic acid components and their derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>oxidoreductase inhibitor</ancestor><ancestor>oxygenase inhibitor</ancestor><ancestor>pyrimidine derivative</ancestor><ancestor>pyrimidines and pyrimidine derivatives</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>triazole derivative</ancestor><ancestor>voriconazole</ancestor></ancestors><drgterm>voriconazole</drgterm><mainterm>voriconazole</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>alpha adrenergic receptor blocking agent</ancestor><ancestor>atypical antipsychotic agent</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>dopamine receptor affecting agent</ancestor><ancestor>dopamine receptor blocking agent</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>nucleic acids, nucleic acid components and their derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>piperidine derivative</ancestor><ancestor>psychotropic agent</ancestor><ancestor>pyrimidine derivative</ancestor><ancestor>pyrimidines and pyrimidine derivatives</ancestor><ancestor>risperidone</ancestor><ancestor>serotonin antagonist</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>risperidone</drgterm><mainterm>risperidone</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>health care</ancestor><ancestor>health care concepts</ancestor><ancestor>health care delivery</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health service</ancestor><ancestor>hospital care</ancestor><ancestor>intensive care</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>intensive care</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug interaction</ancestor><ancestor>pharmacodynamics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>drug interaction</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>pharmacokinetics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>pharmacokinetics</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data processing</ancestor><ancestor>decision support system</ancestor><ancestor>information</ancestor><ancestor>information processing</ancestor><ancestor>information system</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>decision support system</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care facilities and services</ancestor><ancestor>health care facility</ancestor><ancestor>hospital</ancestor><ancestor>hospital subdivisions and components</ancestor><ancestor>intensive care unit</ancestor><ancestor>ward</ancestor></ancestors><mainterm>intensive care unit</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adverse outcome</ancestor><ancestor>disease course</ancestor><ancestor>disease severity</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>prediction and forecasting</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>adverse outcome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biomedical disciplines, science and art</ancestor><ancestor>hypothesis</ancestor><ancestor>science in general</ancestor><ancestor>theory</ancestor></ancestors><mainterm>hypothesis</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>geographic names</ancestor><ancestor>north america</ancestor><ancestor>united states</ancestor><ancestor>western hemisphere</ancestor></ancestors><mainterm>United States</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>amiodarone</dt><dt>diphenhydramine</dt><dt>enzyme inhibitor</dt><dt>haloperidol</dt><dt>ondansetron</dt><dt>risperidone</dt><dt>tacrolimus</dt><dt>voriconazole</dt></dgidx><dsidx><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><gnidx><gn>male</gn></gnidx></idxs></bibrecord><bibrecord><item-info><date-sort>2002-06-01</date-sort><kind>regular</kind><copyright><cprtype>Medline</cprtype><cprtext>Copyright 2016 Medline is the source for the citation and abstract of this record.</cprtext></copyright><itemidlist><lui>L611776600</lui><pui>611776600</pui><car-id>654219029</car-id><medl>12473967</medl></itemidlist><history><date-created>2016-08-26</date-created><date-loaded>2002-06-01</date-loaded></history><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Antipsychotic medications and sudden cardiac death</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>The objectives of this paper are to: 1) discuss practical aspects of antipsychotic induced QT prolongation, torsades de pointes (TdP) and sudden cardiac death, 2) discuss its possible mechanisms, 3) review data for each antipsychotic medication or class of medications and, 4) present recommendations from the literature. We performed computerized searches of the biomedical literature utilizing MEDLINE and PsycINFO computer databases (1966-2001), and by reviewing bibliographies to identify all pertinent case reports, case series, and formal studies using the following search terms: antipsychotics, sudden cardiac death, and QT prolongation. QT prolongation is a dynamic phenomena affected by various factors (mood, disease states, gender, medication, etc.). Sudden cardiac death attributable to antipsychotic medications seems to occurs in a step-wise fashion beginning with QT prolongation, leading to TdP, which can progress to cardiac arrest. Blocking the rapidly-acting potassium rectifier current appears be the primary mechanism of QT prolongation in drugs known to cause TdP and sudden cardiac death. All antipsychotic medications have been shown to cause QT prolongation, however, the degree to which this occurs and the risk of TdP varies. The risk of sudden cardiac death increases with higher doses of medications, use of phenothiazines or intravenous butyrophenones, and in patients with certain medical illnesses, especially cardiac disease. In order to prevent sudden death from antipsychotic medications, we recommend obtaining screening electrocardiograms in all at-risk patients, follow-up electrocardiograms after the initiation of medication, and using the lowest effective dose of medication. If QT prolongation occurs, the risks and benefits of therapy should be considered and medication adjustments made if warranted.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>Psychopharmacology bulletin</sourcetitle><sourcetitle-abbrev>Psychopharmacol Bull</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00485764</issnnr></issn><volisspag><volume>36</volume><issue>3</issue><firstpage>91</firstpage><volissidx>00485764||2002||36||3</volissidx><lastpage>99</lastpage></volisspag><publicationyear>2002</publicationyear><publicationdate><pubdate day="01" month="06" year="2002">2002-06-01</pubdate></publicationdate></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>neuroleptic agent</drgterm><mainterm>neuroleptic agent</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>electrocardiography</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup><enhancement-status>002</enhancement-status><enhancement-type>8</enhancement-type></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><afftext>Duke University Medical Center, Durham, North Carolina, USA</afftext></affiliation><author><autidx>Harrison M.O.</autidx><given-name>M Ojinga</given-name><initials>M.O.</initials><seq>1</seq><surname>Harrison</surname></author><author><autidx>Krishnan K.R.</autidx><given-name>K Ranga</given-name><initials>K.R.</initials><seq>2</seq><surname>Krishnan</surname></author></author-group><authorlist><author><affiliation><afftext>Duke University Medical Center, Durham, North Carolina, USA</afftext></affiliation><autidx>Harrison M.O.</autidx><given-name>M Ojinga</given-name><initials>M.O.</initials><seq>1</seq><surname>Harrison</surname><aggregatedAuthorId>harrison m.o.__harrison__m ojinga</aggregatedAuthorId><uniqueAuthorId>harrison__m ojinga__m.o.____vvwAoOQV/g==</uniqueAuthorId></author><author><affiliation><afftext>Duke University Medical Center, Durham, North Carolina, USA</afftext></affiliation><autidx>Krishnan K.R.</autidx><given-name>K Ranga</given-name><initials>K.R.</initials><seq>2</seq><surname>Krishnan</surname><aggregatedAuthorId>krishnan k.r.__krishnan__k ranga</aggregatedAuthorId><uniqueAuthorId>krishnan__k ranga__k.r.____vvwAoOQV/g==</uniqueAuthorId></author></authorlist></head><explosions><explosion><ancestors><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>neuroleptic agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>tranquilizer</ancestor></ancestors><drgterm>neuroleptic agent</drgterm><mainterm>neuroleptic agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiography</ancestor><ancestor>cardiovascular system examination</ancestor><ancestor>diagnosis</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>electrocardiography</ancestor><ancestor>electrodiagnosis</ancestor><ancestor>electrography</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>electrocardiography</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac channelopathy</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>channelopathy</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>long qt syndrome</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>heart arrest</ancestor><ancestor>heart disease</ancestor><ancestor>heart failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>sudden cardiac death</ancestor><ancestor>sudden death</ancestor></ancestors><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>a</weight></explosion></explosions><idxs><dgidx><dt>neuroleptic agent</dt></dgidx><dsidx><dst>long qt syndrome</dst><dst>sudden cardiac death</dst><dst>torsade des pointes</dst></dsidx><stidx><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2013-10-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2013 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1002/pds.3512</doi><lui>L71244473</lui><pui>71244473</pui><absn>492</absn></itemidlist><history><date-created>2013-12-04</date-created><date-loaded>2013-12-06</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Estimating the association between qt prolongation and SSRI utilization from the FDA's adverse event reports</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: Citalopram (Celexa®) is in the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. It is taken orally. Citalopram has been linked to both QT prolongation and Torsade de pointes (TdP), and these risks may be dose related. Objectives: The purpose of this study was to analyze the association between QT prolongation and TdP adverse events and the utilization of citalopram and other SSRIs. Methods: This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting System (FAERS) database. The database included 7,840,225 adverse events associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The number of reported QT-prolongation and TdP cases associated with each study drug was calculated over time. Furthermore, for each case, dosage of the drug, when available in the report, was noted. Results: A total of 1,192 reported cases of QT prolongation and TdP were associated with SSRI drugs over the 14-year study period. Only 18% (219) of the adverse event reports were related specifically to citalopram, while the rest were related to other SSRI drugs. There were 911 reports for women, 252 for men, and 29 reports without gender information. The rate of QT prolongation and TdP associated with dosages of 20, 40, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. However, the percentage of reports without dosage information was 37%, so we were unable to draw any conclusions regarding dosage-related events. Conclusions: The results confirmed an association between the use of citalopram with QT prolongation and TdP. Furthermore, the association was not limited to citalopram alone but was widespread across the SSRIs. There were more adverse events observed for women than for men. Dose dependency was not established in this study. Future studies are warranted.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Pharmacoepidemiology and Drug Safety</sourcetitle><sourcetitle-abbrev>Pharmacoepidemiol. Drug Saf.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10538569</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Montreal, QC</city-group><clcountry code="CAN">Canada</clcountry></conflocation><confname>29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management</confname><enddate>2013-08-28</enddate><startdate>2013-08-25</startdate></confevent></conferenceinfo><volisspag><volume>22</volume><firstpage>241</firstpage><volissidx>10538569||2013||22||</volissidx><lastpage>242</lastpage><supplement>SUPPL. 1</supplement></volisspag><publicationyear>2013</publicationyear><publicationdate><pubdatetext>October 2013</pubdatetext></publicationdate><publisher><publishername>John Wiley and Sons Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>a</weight></descriptor><descriptor><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></descriptor><descriptor><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>pharmacoepidemiology</mainterm><weight>a</weight></descriptor><descriptor><mainterm>risk management</mainterm><weight>a</weight></descriptor><descriptor><mainterm>Food and Drug Administration</mainterm><weight>a</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gender</mainterm><weight>b</weight></descriptor><descriptor><mainterm>United States</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Pharmacy</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><author><autidx>Guo J.</autidx><given-name>Jing</given-name><initials>J.</initials><seq>1</seq><surname>Guo</surname></author><author><autidx>Guo J.J.</autidx><given-name>Jeff J.</given-name><initials>J.J.</initials><seq>2</seq><surname>Guo</surname></author><author><autidx>Wigle P.</autidx><given-name>Patricia</given-name><initials>P.</initials><seq>4</seq><surname>Wigle</surname></author></author-group><author-group><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Business</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><author><autidx>Kelton C.M.L.</autidx><given-name>Christina M.L.</given-name><initials>C.M.L.</initials><seq>3</seq><surname>Kelton</surname></author></author-group><authorlist><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Pharmacy</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><autidx>Guo J.</autidx><given-name>Jing</given-name><initials>J.</initials><seq>1</seq><surname>Guo</surname><aggregatedAuthorId>guo j.__guo__jing</aggregatedAuthorId><uniqueAuthorId>guo__jing__j.____vMSSTAB5bQmY</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Pharmacy</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><autidx>Guo J.J.</autidx><given-name>Jeff J.</given-name><initials>J.J.</initials><seq>2</seq><surname>Guo</surname><aggregatedAuthorId>guo j.j.__guo__jeff j.</aggregatedAuthorId><uniqueAuthorId>guo__jeff j.__j.j.____vMSSTAB5bQmY</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Business</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><autidx>Kelton C.M.L.</autidx><given-name>Christina M.L.</given-name><initials>C.M.L.</initials><seq>3</seq><surname>Kelton</surname><aggregatedAuthorId>kelton c.m.l.__kelton__christina m.l.</aggregatedAuthorId><uniqueAuthorId>kelton__christina m.l.__c.m.l.____vMSSTAB5bQmY</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Pharmacy</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><autidx>Wigle P.</autidx><given-name>Patricia</given-name><initials>P.</initials><seq>4</seq><surname>Wigle</surname><aggregatedAuthorId>wigle p.__wigle__patricia</aggregatedAuthorId><uniqueAuthorId>wigle__patricia__p.____vMSSTAB5bQmY</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>College of Pharmacy</organization><organization>University of Cincinnati</organization><state>OH</state></affiliation><person><initials>J.</initials><persidx>Guo J.</persidx><surname>Guo</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>citalopram</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor></ancestors><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>diseases</ancestor><ancestor>epidemiology</ancestor><ancestor>general aspects of disease</ancestor><ancestor>pharmacoepidemiology</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>pharmacoepidemiology</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk management</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk management</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>food and drug administration</ancestor><ancestor>health care concepts</ancestor><ancestor>health care organization</ancestor></ancestors><mainterm>Food and Drug Administration</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender</ancestor><ancestor>gender and sex</ancestor></ancestors><mainterm>gender</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>geographic names</ancestor><ancestor>north america</ancestor><ancestor>united states</ancestor><ancestor>western hemisphere</ancestor></ancestors><mainterm>United States</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>antidepressant agent</dt><dt>citalopram</dt><dt>serotonin uptake inhibitor</dt></dgidx><dsidx><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2019-10-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2019 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.jtho.2019.08.2398</doi><lui>L2003406185</lui><pui>2003406185</pui><car-id>921097186</car-id><osin>78898199</osin><pii>S1556086419330813</pii></itemidlist><history><date-created>2019-10-23</date-created><date-loaded>2019-10-24</date-loaded></history><dbcollection code="EMBCNF">EMBCNF</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>EP1.16-33 QT Prolongation in an EGFR 19 Deletion Lung Adenocarcinoma Patient from Icotinib Treatment</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib). Screening for QT prolongation in (high risk) patients is advised for these TKIs. When a QT prolongation develops, the physician is challenged with the question whether to (permanently) discontinue the TKI. Method: In this perspective, we report on a patient who developed a QT prolongation during icotinib (a first-generation epidermal growth factor receptor [EGFR]-TKI) treatment. Result: On discontinuation of icotinib, he developed a symptomatic disease flare, not responding to subsequent systemic treatment. The main aim of this perspective is to describe the management of QT prolongation in stage IV EGFR 19 deletion mutation NSCLC patients. We also discuss the ethical question of how to weigh the risk of a disease flare due to therapy cessation against the risk of sudden cardiac death. A family history of sudden death and a prolonged QT interval might indicate a familiar long QT syndrome. Conclusion: We have summarised the current monitoring advice for TKIs used in the treatment of lung cancer and the most common druge TKI interactions to consider and to optimise TKI treatment in EGFR mutation patients. Keywords: lung adenocarcinoma, icotinib, QT prolongation</para><publishercopyright>© 2019</publishercopyright></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="nld">Netherlands</sourcecountry><sourcetitle>Journal of Thoracic Oncology</sourcetitle><sourcetitle-abbrev>J. Thorac. Oncol.</sourcetitle-abbrev><issn><issntype>electronic</issntype><issnnr>15561380</issnnr></issn><issn><issntype>print</issntype><issnnr>15560864</issnnr></issn><conferenceinfo><confevent><conflocation><clcountry code="ESP">Spain</clcountry><city>Barcelona</city></conflocation><confname>IASLC 2019 World Conference on Lung Cancer (WCLC)</confname><enddate>2019-09-10</enddate><startdate>2019-09-07</startdate></confevent></conferenceinfo><volisspag><volume>14</volume><issue>10</issue><firstpage>S1077</firstpage><volissidx>15561380||2019||14||10</volissidx><volissidx>15560864||2019||14||10</volissidx><supplement>Supplement</supplement></volisspag><publicationyear>2019</publicationyear><publicationdate><pubdate day="01" month="10" year="2019">2019-10-01</pubdate></publicationdate><publisher><publishername>Elsevier Inc.</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>877399-52-5</cas-registry-number><chemical-name>crizotinib</chemical-name></chemical><chemical><cas-registry-number>79079-06-4</cas-registry-number><chemical-name>epidermal growth factor receptor</chemical-name></chemical><chemical><cas-registry-number>610798-31-7</cas-registry-number><chemical-name>icotinib</chemical-name></chemical><chemical><cas-registry-number>1421373-65-0</cas-registry-number><cas-registry-number>1421373-66-1</cas-registry-number><chemical-name>osimertinib</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>crizotinib</drgterm><mainterm>crizotinib</mainterm><weight>b</weight></descriptor><descriptor><drgterm>endogenous compound</drgterm><mainterm>endogenous compound</mainterm><weight>b</weight></descriptor><descriptor><drgterm>epidermal growth factor receptor</drgterm><mainterm>epidermal growth factor receptor</mainterm><weight>a</weight></descriptor><descriptor><drgterm>icotinib</drgterm><mainterm>icotinib</mainterm><weight>a</weight></descriptor><descriptor><drgterm>osimertinib</drgterm><mainterm>osimertinib</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><disterm>adverse drug reaction</disterm><mainterm>adverse drug reaction</mainterm><weight>b</weight></descriptor><descriptor><mainterm>cancer patient</mainterm><weight>a</weight></descriptor><descriptor><mainterm>cancer staging</mainterm><weight>b</weight></descriptor><descriptor><mainterm>case report</mainterm><weight>b</weight></descriptor><descriptor><mainterm>clinical article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>conference abstract</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug therapy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug withdrawal</mainterm><weight>b</weight></descriptor><descriptor><mainterm>family history</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gene deletion</mainterm><weight>a</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></descriptor><descriptor><disterm>lung adenocarcinoma</disterm><mainterm>lung adenocarcinoma</mainterm><weight>a</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>physician</mainterm><weight>b</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><disterm>side effect</disterm><mainterm>side effect</mainterm><weight>b</weight></descriptor><descriptor><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></descriptor><descriptor><mainterm>systemic therapy</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><author><autidx>Wu L.</autidx><author-instance-id>S1556086419330813-82bb285decb6a70eed3e063c9ff56d02</author-instance-id><initials>L.</initials><seq>1</seq><surname>Wu</surname></author><author><autidx>Chen H.</autidx><author-instance-id>S1556086419330813-bca28cb75e473ce658b95aed5d0dbe0e</author-instance-id><initials>H.</initials><seq>2</seq><surname>Chen</surname></author><author><autidx>Li X.</autidx><author-instance-id>S1556086419330813-a0605ac4e72e44712381b82def9271d2</author-instance-id><initials>X.</initials><seq>3</seq><surname>Li</surname></author><author><autidx>Zhu Y.</autidx><author-instance-id>S1556086419330813-1fb0ab925cfcdaacb160193d82c1a978</author-instance-id><initials>Y.</initials><seq>4</seq><surname>Zhu</surname></author><author><autidx>Du K.</autidx><author-instance-id>S1556086419330813-1e9c1807ddeb45c4930b30a6056e1ab0</author-instance-id><initials>K.</initials><seq>5</seq><surname>Du</surname></author></author-group><author-group><affiliation><affiliation-instance-id>S1556086419330813-ed76b44bc5d46556453944965454f827</affiliation-instance-id><city>Hangzhou</city><country code="chn">China</country><organization>Chemotherapy, Zhejiang Cancer Hospital</organization></affiliation><author><autidx>Wang W.</autidx><author-instance-id>S1556086419330813-baf7b898698081f4eeb25cd3f563f536</author-instance-id><initials>W.</initials><seq>6</seq><surname>Wang</surname></author></author-group><author-group><affiliation><affiliation-instance-id>S1556086419330813-92a7499066fde6b39d298db19855eb1b</affiliation-instance-id><city>Fuzhou</city><country code="chn">China</country><organization>Fujian Cancer Hospital</organization></affiliation><author><autidx>Xu C.</autidx><author-instance-id>S1556086419330813-872cd8260b1782f9ec57f4eb9d101c54</author-instance-id><initials>C.</initials><seq>7</seq><surname>Xu</surname></author></author-group><authorlist><author><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><autidx>Wu L.</autidx><author-instance-id>S1556086419330813-82bb285decb6a70eed3e063c9ff56d02</author-instance-id><initials>L.</initials><seq>1</seq><surname>Wu</surname><aggregatedAuthorId>wu l.__wu__</aggregatedAuthorId><uniqueAuthorId>wu____l.____/frI8wPl0BMw</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><autidx>Chen H.</autidx><author-instance-id>S1556086419330813-bca28cb75e473ce658b95aed5d0dbe0e</author-instance-id><initials>H.</initials><seq>2</seq><surname>Chen</surname><aggregatedAuthorId>chen h.__chen__</aggregatedAuthorId><uniqueAuthorId>chen____h.____/frI8wPl0BMw</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><autidx>Li X.</autidx><author-instance-id>S1556086419330813-a0605ac4e72e44712381b82def9271d2</author-instance-id><initials>X.</initials><seq>3</seq><surname>Li</surname><aggregatedAuthorId>li x.__li__</aggregatedAuthorId><uniqueAuthorId>li____x.____/frI8wPl0BMw</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><autidx>Zhu Y.</autidx><author-instance-id>S1556086419330813-1fb0ab925cfcdaacb160193d82c1a978</author-instance-id><initials>Y.</initials><seq>4</seq><surname>Zhu</surname><aggregatedAuthorId>zhu y.__zhu__</aggregatedAuthorId><uniqueAuthorId>zhu____y.____/frI8wPl0BMw</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-350f377f4e3b8b8729b73d096427322d</affiliation-instance-id><city>Jiaxing</city><country code="chn">China</country><organization>Thoracic Disease Center, Zhejiang Rongjun Hospital</organization></affiliation><autidx>Du K.</autidx><author-instance-id>S1556086419330813-1e9c1807ddeb45c4930b30a6056e1ab0</author-instance-id><initials>K.</initials><seq>5</seq><surname>Du</surname><aggregatedAuthorId>du k.__du__</aggregatedAuthorId><uniqueAuthorId>du____k.____/frI8wPl0BMw</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-ed76b44bc5d46556453944965454f827</affiliation-instance-id><city>Hangzhou</city><country code="chn">China</country><organization>Chemotherapy, Zhejiang Cancer Hospital</organization></affiliation><autidx>Wang W.</autidx><author-instance-id>S1556086419330813-baf7b898698081f4eeb25cd3f563f536</author-instance-id><initials>W.</initials><seq>6</seq><surname>Wang</surname><aggregatedAuthorId>wang w.__wang__</aggregatedAuthorId><uniqueAuthorId>wang____w.____zAEAH6YOtg==</uniqueAuthorId></author><author><affiliation><affiliation-instance-id>S1556086419330813-92a7499066fde6b39d298db19855eb1b</affiliation-instance-id><city>Fuzhou</city><country code="chn">China</country><organization>Fujian Cancer Hospital</organization></affiliation><autidx>Xu C.</autidx><author-instance-id>S1556086419330813-872cd8260b1782f9ec57f4eb9d101c54</author-instance-id><initials>C.</initials><seq>7</seq><surname>Xu</surname><aggregatedAuthorId>xu c.__xu__</aggregatedAuthorId><uniqueAuthorId>xu____c.____LEnMAQBhPwiO</uniqueAuthorId></author></authorlist></head><explosions><explosion><ancestors><ancestor>agents affecting cell division</ancestor><ancestor>agents affecting metabolism</ancestor><ancestor>anaplastic lymphoma kinase inhibitor</ancestor><ancestor>angiogenesis inhibitor</ancestor><ancestor>angiogenesis modulator</ancestor><ancestor>antineoplastic agent</ancestor><ancestor>biologic factors and agents acting on the immune system</ancestor><ancestor>biological factor</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>crizotinib</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>growth factor</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>mitogenic agent</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>peptides and proteins</ancestor><ancestor>phosphotransferase inhibitor</ancestor><ancestor>piperidine derivative</ancestor><ancestor>protein kinase inhibitor</ancestor><ancestor>protein tyrosine kinase inhibitor</ancestor><ancestor>pyrazole derivative</ancestor><ancestor>pyridine derivative</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>transferase inhibitor</ancestor></ancestors><drgterm>crizotinib</drgterm><mainterm>crizotinib</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>chemicals and drugs</ancestor><ancestor>endogenous compound</ancestor><ancestor>natural products and their synthetic derivatives</ancestor></ancestors><drgterm>endogenous compound</drgterm><mainterm>endogenous compound</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>carrier proteins and binding proteins</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>enzyme</ancestor><ancestor>epidermal growth factor receptor</ancestor><ancestor>growth factor receptor</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>peptides and proteins</ancestor><ancestor>phosphotransferase</ancestor><ancestor>protein kinase</ancestor><ancestor>protein tyrosine kinase</ancestor><ancestor>receptor</ancestor><ancestor>transferase</ancestor></ancestors><drgterm>epidermal growth factor receptor</drgterm><mainterm>epidermal growth factor receptor</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>antineoplastic agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>epidermal growth factor receptor kinase inhibitor</ancestor><ancestor>icotinib</ancestor><ancestor>phosphotransferase inhibitor</ancestor><ancestor>protein kinase inhibitor</ancestor><ancestor>protein tyrosine kinase inhibitor</ancestor><ancestor>transferase inhibitor</ancestor></ancestors><drgterm>icotinib</drgterm><mainterm>icotinib</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents affecting metabolism</ancestor><ancestor>antineoplastic agent</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>enzyme inhibitor</ancestor><ancestor>epidermal growth factor receptor kinase inhibitor</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>indole derivative</ancestor><ancestor>natural products and their synthetic derivatives</ancestor><ancestor>nucleic acids, nucleic acid components and their derivatives</ancestor><ancestor>organic compound</ancestor><ancestor>osimertinib</ancestor><ancestor>phosphotransferase inhibitor</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>protein kinase inhibitor</ancestor><ancestor>protein tyrosine kinase inhibitor</ancestor><ancestor>pyrimidine derivative</ancestor><ancestor>pyrimidines and pyrimidine derivatives</ancestor><ancestor>single heterocyclic rings</ancestor><ancestor>transferase inhibitor</ancestor></ancestors><drgterm>osimertinib</drgterm><mainterm>osimertinib</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adverse drug reaction</ancestor><ancestor>adverse event</ancestor><ancestor>diseases</ancestor><ancestor>iatrogenic disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>adverse drug reaction</disterm><mainterm>adverse drug reaction</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cancer patient</ancestor><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>cancer patient</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cancer classification</ancestor><ancestor>cancer diagnosis</ancestor><ancestor>cancer staging</ancestor><ancestor>classification</ancestor><ancestor>coding and classification</ancestor><ancestor>controlled vocabulary</ancestor><ancestor>diagnosis</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>disease classification</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>medical procedures</ancestor><ancestor>medical terminology</ancestor><ancestor>oncological procedure</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>tumor classification</ancestor><ancestor>tumor diagnosis</ancestor></ancestors><mainterm>cancer staging</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>case report</ancestor><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>case report</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical article</ancestor><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>clinical article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>conference abstract</ancestor><ancestor>conference paper</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>conference abstract</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>drug therapy</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>drug therapy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>detoxification</ancestor><ancestor>drug withdrawal</ancestor><ancestor>medical procedures</ancestor><ancestor>metabolism</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>therapy</ancestor><ancestor>treatment withdrawal</ancestor></ancestors><mainterm>drug withdrawal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>anamnesis</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>family history</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>family history</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cellular, subcellular and molecular biological phenomena and functions</ancestor><ancestor>gene deletion</ancestor><ancestor>gene mutation</ancestor><ancestor>heredity</ancestor><ancestor>molecular genetic phenomena and functions</ancestor><ancestor>mutation</ancestor></ancestors><mainterm>gene deletion</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiac channelopathy</ancestor><ancestor>cardiovascular disease</ancestor><ancestor>channelopathy</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>long qt syndrome</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor></ancestors><disterm>long QT syndrome</disterm><mainterm>long QT syndrome</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adenocarcinoma</ancestor><ancestor>carcinoma</ancestor><ancestor>diseases</ancestor><ancestor>lung adenocarcinoma</ancestor><ancestor>lung cancer</ancestor><ancestor>lung carcinoma</ancestor><ancestor>lung disease</ancestor><ancestor>lung tumor</ancestor><ancestor>malignant neoplasm</ancestor><ancestor>malignant neoplasms subdivided by anatomical site</ancestor><ancestor>neoplasm</ancestor><ancestor>neoplasms subdivided by anatomical site</ancestor><ancestor>non small cell lung cancer</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>respiratory tract cancer</ancestor><ancestor>respiratory tract carcinoma</ancestor><ancestor>respiratory tract disease</ancestor><ancestor>respiratory tract tumor</ancestor><ancestor>solid malignant neoplasm</ancestor></ancestors><disterm>lung adenocarcinoma</disterm><mainterm>lung adenocarcinoma</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care personnel</ancestor><ancestor>medical personnel</ancestor><ancestor>named groups by occupation</ancestor><ancestor>named groups of persons</ancestor><ancestor>physician</ancestor></ancestors><mainterm>physician</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>diseases</ancestor><ancestor>iatrogenic disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by etiology and pathogenesis</ancestor><ancestor>side effect</ancestor></ancestors><disterm>side effect</disterm><mainterm>side effect</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>death</ancestor><ancestor>diseases</ancestor><ancestor>general aspects of disease</ancestor><ancestor>heart arrest</ancestor><ancestor>heart disease</ancestor><ancestor>heart failure</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>sudden cardiac death</ancestor><ancestor>sudden death</ancestor></ancestors><disterm>sudden cardiac death</disterm><mainterm>sudden cardiac death</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>systemic therapy</ancestor><ancestor>therapy</ancestor></ancestors><mainterm>systemic therapy</mainterm><weight>b</weight></explosion></explosions><idxs><agidx><ag>adult</ag></agidx><dgidx><dt>crizotinib</dt><dt>endogenous compound</dt><dt>epidermal growth factor receptor</dt><dt>icotinib</dt><dt>osimertinib</dt></dgidx><dsidx><dst>adverse drug reaction</dst><dst>long qt syndrome</dst><dst>lung adenocarcinoma</dst><dst>qt prolongation</dst><dst>side effect</dst><dst>sudden cardiac death</dst></dsidx><gnidx><gn>male</gn></gnidx><stidx><stt>case report</stt><stt>clinical article</stt><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2010-04-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2013 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.231/JIM.0b013e3181d85541</doi><lui>L70982851</lui><pui>70982851</pui><absn>111</absn></itemidlist><history><date-created>2013-02-07</date-created><date-loaded>2013-02-08</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Intravenous sotalol induced QT prolongation predicts serum sotalol concentration</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Introduction: Sotalol is an antiarrhythmic agent that prolongs the cardiac action potential that can be observed as QT interval (QT) prolongation on the surface EKG. It is known that sotalol causes Torsade de Pointes ventricular tachycardia (TdP) that is due to dose related QT prolongation. We were able to develop a correlation betweenQTprolongation and sotalol serum concentration. Methods: 15 healthy volunteers (age: 32 ± 8 y) received 75 mg intravenous sotalol over 2.5 hr at a constant infusion rate. Serum sotalol concentrations were determined and a 12-lead EKG was recorded at baseline, 0.5, 1, 2, 3, 4, and 5 hrs following dosing. The QT and RR intervals were measured by two blinded investigators. Heart rate corrected QT (QTc) was calculated by the Bazett, Fridericia, and Framingham formulas. Linear regression analysis was performed between S concentration and QT measurements. Results: The analysis showed close correlation between sotalol serum concentration and QT (r=0.938, p&lt;0.02), Bazett QTc (r=0.860, p&lt;0.02), Framingham QTc (r=0.960, p=0.001), and Fridericia QTc (r=0.967, p&lt;0.001). The equation of the regression line was: QTc= 0.0388 x (sotalol concentration) + 402.63, which closely predicted actual QTc at any sotalol concentration. Conversely any degree of QT prolongation can predict the measured serum sotalol concentration. Conclusion: A simple equation was found that predicts serum sotalol concentration from QT prolongation. Measuring QT prolongation can yield a quick method of estimating serum sotalol concentration, as well as the electrophysiologic effects of serum sotalol. Excessive serum sotalol levels that causes excessive QT prolongation can be avoided, possibly reducing the risk of TdP.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Journal of Investigative Medicine</sourcetitle><sourcetitle-abbrev>J. Invest. Med.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10815589</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Chicago, IL</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>2010 Combined Annual Meeting of the Central Society for Clinical Research and the Midwestern Section American Federation for Medical Research</confname><enddate>2010-04-23</enddate><startdate>2010-04-22</startdate></confevent></conferenceinfo><volisspag><volume>58</volume><issue>4</issue><firstpage>677</firstpage><volissidx>10815589||2010||58||4</volissidx></volisspag><publicationyear>2010</publicationyear><publicationdate><pubdatetext>April 2010</pubdatetext></publicationdate><publisher><publishername>Lippincott Williams and Wilkins</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>a</weight></descriptor><descriptor><drgterm>antiarrhythmic agent</drgterm><mainterm>antiarrhythmic agent</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>serum</mainterm><weight>a</weight></descriptor><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><mainterm>clinical research</mainterm><weight>a</weight></descriptor><descriptor><mainterm>medical research</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>blood level</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>linear regression analysis</mainterm><weight>b</weight></descriptor><descriptor><mainterm>heart rate</mainterm><weight>b</weight></descriptor><descriptor><mainterm>normal human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>action potential</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle tachycardia</disterm><mainterm>heart ventricle tachycardia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>RR interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>infusion rate</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><author><autidx>Somberg J.C.</autidx><initials>J.C.</initials><seq>1</seq><surname>Somberg</surname></author><author><autidx>Ranade V.V.</autidx><initials>V.V.</initials><seq>2</seq><surname>Ranade</surname></author><author><autidx>Molnar Z.</autidx><initials>Z.</initials><seq>3</seq><surname>Molnar</surname></author><author><autidx>Somberg T.</autidx><initials>T.</initials><seq>4</seq><surname>Somberg</surname></author><author><autidx>Molnar J.</autidx><initials>J.</initials><seq>5</seq><surname>Molnar</surname></author></author-group><authorlist><author><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><autidx>Somberg J.C.</autidx><initials>J.C.</initials><seq>1</seq><surname>Somberg</surname><aggregatedAuthorId>somberg j.c.__somberg__</aggregatedAuthorId><uniqueAuthorId>somberg____j.c.____rD8//N8bFA==</uniqueAuthorId></author><author><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><autidx>Ranade V.V.</autidx><initials>V.V.</initials><seq>2</seq><surname>Ranade</surname><aggregatedAuthorId>ranade v.v.__ranade__</aggregatedAuthorId><uniqueAuthorId>ranade____v.v.____rD8//N8bFA==</uniqueAuthorId></author><author><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><autidx>Molnar Z.</autidx><initials>Z.</initials><seq>3</seq><surname>Molnar</surname><aggregatedAuthorId>molnar z.__molnar__</aggregatedAuthorId><uniqueAuthorId>molnar____z.____rD8//N8bFA==</uniqueAuthorId></author><author><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><autidx>Somberg T.</autidx><initials>T.</initials><seq>4</seq><surname>Somberg</surname><aggregatedAuthorId>somberg t.__somberg__</aggregatedAuthorId><uniqueAuthorId>somberg____t.____rD8//N8bFA==</uniqueAuthorId></author><author><affiliation><afftext>Chicago, IL,USA Lake Bluff, IL USA and New York, NY USA. Rush University USA</afftext></affiliation><autidx>Molnar J.</autidx><initials>J.</initials><seq>5</seq><surname>Molnar</surname><aggregatedAuthorId>molnar j.__molnar__</aggregatedAuthorId><uniqueAuthorId>molnar____j.____rD8//N8bFA==</uniqueAuthorId></author></authorlist><correspondence><person><initials>J.C.</initials><persidx>Somberg J.C.</persidx><surname>Somberg</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>adrenergic receptor affecting agent</ancestor><ancestor>adrenergic receptor blocking agent</ancestor><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>beta adrenergic receptor blocking agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>sotalol</ancestor></ancestors><drgterm>sotalol</drgterm><mainterm>sotalol</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor></ancestors><drgterm>antiarrhythmic agent</drgterm><mainterm>antiarrhythmic agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>anatomical concepts</ancestor><ancestor>blood</ancestor><ancestor>blood and hemopoietic system</ancestor><ancestor>body fluid</ancestor><ancestor>body fluids and secretions</ancestor><ancestor>hemolymphatic system</ancestor><ancestor>organ systems</ancestor><ancestor>serum</ancestor></ancestors><mainterm>serum</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biomedical disciplines, science and art</ancestor><ancestor>clinical research</ancestor><ancestor>medical research</ancestor><ancestor>research</ancestor><ancestor>science in general</ancestor></ancestors><mainterm>clinical research</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biomedical disciplines, science and art</ancestor><ancestor>medical research</ancestor><ancestor>research</ancestor><ancestor>science in general</ancestor></ancestors><mainterm>medical research</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>blood level</ancestor><ancestor>chemical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>blood level</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>analysis</ancestor><ancestor>chemical, physical and mathematical phenomena</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>linear regression analysis</ancestor><ancestor>mathematical analysis</ancestor><ancestor>mathematical and statistical procedures</ancestor><ancestor>mathematical phenomena</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>regression analysis</ancestor><ancestor>statistical analysis</ancestor><ancestor>statistical concepts</ancestor></ancestors><mainterm>linear regression analysis</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>heart function</ancestor><ancestor>heart rate</ancestor><ancestor>heart rate and rhythm</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>heart rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>normal human</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>normal human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>action potential</ancestor><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>electrical parameters</ancestor><ancestor>electrical potential parameters</ancestor><ancestor>electrophysiology</ancestor><ancestor>parameters</ancestor><ancestor>physical parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>action potential</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>heart ventricle tachycardia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>tachycardia</ancestor></ancestors><disterm>heart ventricle tachycardia</disterm><mainterm>heart ventricle tachycardia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>rr interval</ancestor></ancestors><mainterm>RR interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>administration of drugs, food and chemicals</ancestor><ancestor>infusion</ancestor><ancestor>infusion rate</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>infusion rate</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>antiarrhythmic agent</dt><dt>sotalol</dt></dgidx><dsidx><dst>heart ventricle tachycardia</dst><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><stidx><stt>human</stt><stt>normal human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2013-05-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2013 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1016/j.jval.2013.03.1593</doi><lui>L71061424</lui><pui>71061424</pui><absn>PMH47</absn><pii>S1098301513016641</pii></itemidlist><history><date-created>2013-05-21</date-created><date-loaded>2013-05-23</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Estimating the association between QT prolongation and SSRI utilization from the FDA's adverse event reports</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Citalopram (Celexa®) is in the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. It is taken orally. Citalopram has been linked to both QT prolongation and Torsade de pointes (TdP), and these risks may be dose related. OBJECTIVES: To analyze the association between QT prolongation and TdP adverse events and the utilization of citalopram and other SSRIs. METHODS: This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting System (FAERS) database. The database included 7,840,225 adverse events associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The number of reported QT-prolongation and TdP cases associated with each study drug was calculated over time. Furthermore, for each case, dosage of the drug, when available in the report, was noted. RESULTS: A total of 1192 reported cases of QT prolongation and TdP were associated with SSRI drugs over the 14-year study period. Only 18% (219) of the adverse event reports were related specifically to citalopram, while the rest were related to other SSRI drugs. There were 911 reports for women, 252 for men, and 29 reports without gender information. The rate of QT prolongation and TdP associated with dosages of 20 mg, 40 mg, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. However, the percentage of reports without dosage information was 37%, so we were unable to draw any conclusions regarding dosage-related events. CONCLUSIONS: The results confirmed an association between the use of citalopram with QT prolongation and TdP. Furthermore, the association was not limited to citalopram alone but was widespread across the SSRIs. There were more adverse events observed for women than for men. Dose dependency was not established in this study. Future studies are warranted.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Value in Health</sourcetitle><sourcetitle-abbrev>Value Health</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>10983015</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>New Orleans, LA</city-group><clcountry code="USA">United States</clcountry></conflocation><confname>ISPOR 18th Annual International Meeting</confname><enddate>2013-05-22</enddate><startdate>2013-05-18</startdate></confevent></conferenceinfo><volisspag><volume>16</volume><issue>3</issue><firstpage>A63</firstpage><volissidx>10983015||2013||16||3</volissidx></volisspag><publicationyear>2013</publicationyear><publicationdate><pubdatetext>May 2013</pubdatetext></publicationdate><publisher><publishername>Elsevier Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>a</weight></descriptor><descriptor><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></descriptor><descriptor><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>Food and Drug Administration</mainterm><weight>a</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><mainterm>data base</mainterm><weight>b</weight></descriptor><descriptor><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></descriptor><descriptor><mainterm>gender</mainterm><weight>b</weight></descriptor><descriptor><mainterm>United States</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Pharmacy</organization><state>OH</state></affiliation><author><autidx>Guo J.</autidx><initials>J.</initials><seq>1</seq><surname>Guo</surname></author><author><autidx>Guo J.J.</autidx><initials>J.J.</initials><seq>2</seq><surname>Guo</surname></author><author><autidx>Wigle P.R.</autidx><initials>P.R.</initials><seq>4</seq><surname>Wigle</surname></author></author-group><author-group><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Business</organization><state>OH</state></affiliation><author><autidx>Kelton C.M.</autidx><initials>C.M.</initials><seq>3</seq><surname>Kelton</surname></author></author-group><authorlist><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Pharmacy</organization><state>OH</state></affiliation><autidx>Guo J.</autidx><initials>J.</initials><seq>1</seq><surname>Guo</surname><aggregatedAuthorId>guo j.__guo__</aggregatedAuthorId><uniqueAuthorId>guo____j.____TUyuBABIIwdG</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Pharmacy</organization><state>OH</state></affiliation><autidx>Guo J.J.</autidx><initials>J.J.</initials><seq>2</seq><surname>Guo</surname><aggregatedAuthorId>guo j.j.__guo__</aggregatedAuthorId><uniqueAuthorId>guo____j.j.____TUyuBABIIwdG</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Business</organization><state>OH</state></affiliation><autidx>Kelton C.M.</autidx><initials>C.M.</initials><seq>3</seq><surname>Kelton</surname><aggregatedAuthorId>kelton c.m.__kelton__</aggregatedAuthorId><uniqueAuthorId>kelton____c.m.____Sy0uBgBIdwdd</uniqueAuthorId></author><author><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Pharmacy</organization><state>OH</state></affiliation><autidx>Wigle P.R.</autidx><initials>P.R.</initials><seq>4</seq><surname>Wigle</surname><aggregatedAuthorId>wigle p.r.__wigle__</aggregatedAuthorId><uniqueAuthorId>wigle____p.r.____TUyuBABIIwdG</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Cincinnati</city><country code="USA">United States</country><organization>University of Cincinnati</organization><organization>College of Pharmacy</organization><state>OH</state></affiliation><person><initials>J.</initials><persidx>Guo J.</persidx><surname>Guo</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>serotonin uptake inhibitor</drgterm><mainterm>serotonin uptake inhibitor</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents interacting with transmitter, hormone or drug receptors</ancestor><ancestor>antidepressant agent</ancestor><ancestor>benzofuran derivative</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>citalopram</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon oxygen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor><ancestor>serotonin receptor affecting agent</ancestor><ancestor>serotonin uptake inhibitor</ancestor></ancestors><drgterm>citalopram</drgterm><mainterm>citalopram</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>antidepressant agent</ancestor><ancestor>central nervous system agents</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>psychostimulant agent</ancestor><ancestor>psychotropic agent</ancestor></ancestors><drgterm>antidepressant agent</drgterm><mainterm>antidepressant agent</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>food and drug administration</ancestor><ancestor>health care concepts</ancestor><ancestor>health care organization</ancestor></ancestors><mainterm>Food and Drug Administration</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>data base</ancestor><ancestor>data processing</ancestor><ancestor>information</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>data base</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>torsade des pointes</ancestor></ancestors><disterm>torsade des pointes</disterm><mainterm>torsade des pointes</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>gender</ancestor><ancestor>gender and sex</ancestor></ancestors><mainterm>gender</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>geographic names</ancestor><ancestor>north america</ancestor><ancestor>united states</ancestor><ancestor>western hemisphere</ancestor></ancestors><mainterm>United States</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>antidepressant agent</dt><dt>citalopram</dt><dt>serotonin uptake inhibitor</dt></dgidx><dsidx><dst>qt prolongation</dst><dst>torsade des pointes</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>2013-09-01</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2014 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><doi>10.1007/s40264-013-0087-x</doi><lui>L71277632</lui><pui>71277632</pui><absn>ISP3510-37</absn></itemidlist><history><date-created>2014-01-06</date-created><date-loaded>2014-01-08</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection></item-info><head><citation-info><citation-type code="cb">Conference Abstract</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Quality of label information on qt-interval prolongation of medicinal products registered in the EU</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>Background: The summary of product characteristics (SPC) is the most important (indirect) source of information for healthcare providers (HCP) to gain information on QT prolonging properties of drugs. However, we have noticed that information regarding QT prolongation varies between different products, which may hamper the uptake of the information. Objective: To systematically assess the number of products reporting an impact on QT interval in the SPC, and the variation in nature of the observed QT prolonging effect described and recommendations given to the HCP. Methods: The SPCs of products centrally approved in Europe between 1.1.2006 and 1.5.2012 were screened. Of those mentioning 'QT', we examined in which sections of the SPC 'QT prolongation' was mentioned. The nature of the message on QT prolongation and the advice on cautionary measures related to QT prolongation was examined as well as the relation between both. Results: Of the 172 screened products, 44 products contained information on QT in the SPC. QT related issues were most commonly reported in section 4.4 (special warnings and precautions, 66 %) and section 4.8 (undesirable effects, 57 %). In almost half of the products, the main message was that either the drug prolongs the QT interval (18 %), or potentially prolongs the QT interval (20 %). The SPC contained a negative message (the drug does not prolong the QT interval) in 23 % and no clear positive or negative message on QT prolongation in 39 % of the SPCs. Sixty-two percent of the SPCs gave the advice to act with caution in patients with QT related risk factors (n = 25), and 16 % explained the association of QT prolongation with ventricular arrhythmias (n = 27). The advice on monitoring of patients was given in 34 % of the SPCs (n = 15). Products that were more likely to have QT-prolonging properties according to the SPC provided more information on QT prolongation in the SPC. Conclusion: We observed that products, that were more likely to have QT prolonging properties according to the SPC, provided more information on QT prolongation in the SPC. We advise the development of a more extensive guideline concerning reporting on QT prolonging in SPCs, in order to guide prescribers more clearly.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcetitle>Drug Safety</sourcetitle><sourcetitle-abbrev>Drug Saf.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>01145916</issnnr></issn><conferenceinfo><confevent><conflocation><city-group>Pisa</city-group><clcountry code="ITA">Italy</clcountry></conflocation><confname>13th International Society of Pharmacovigilance, ISoP Annual Meeting: "The Renaissance of Pharmacovigilance"</confname><enddate>2013-10-04</enddate><startdate>2013-10-01</startdate></confevent></conferenceinfo><volisspag><volume>36</volume><issue>9</issue><firstpage>827</firstpage><volissidx>01145916||2013||36||9</volissidx></volisspag><publicationyear>2013</publicationyear><publicationdate><pubdatetext>September 2013</pubdatetext></publicationdate><publisher><publishername>Adis International Ltd</publishername></publisher></source><enhancement><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>nitrogen 15</drgterm><mainterm>nitrogen 15</mainterm><weight>b</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>drug surveillance program</mainterm><weight>a</weight></descriptor><descriptor><mainterm>society</mainterm><weight>a</weight></descriptor><descriptor><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>patient</mainterm><weight>b</weight></descriptor><descriptor><mainterm>monitoring</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></descriptor><descriptor><mainterm>health care personnel</mainterm><weight>b</weight></descriptor><descriptor><mainterm>risk factor</mainterm><weight>b</weight></descriptor><descriptor><mainterm>Europe</mainterm><weight>b</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>false</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><author><autidx>Warnier M.</autidx><initials>M.</initials><seq>1</seq><surname>Warnier</surname></author><author><autidx>De Boer A.</autidx><initials>A.</initials><seq>5</seq><surname>De Boer</surname></author><author><autidx>De Bruin M.</autidx><initials>M.</initials><seq>7</seq><surname>De Bruin</surname></author></author-group><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><author><autidx>Holtkamp F.</autidx><initials>F.</initials><seq>2</seq><surname>Holtkamp</surname></author><author><autidx>Mol P.</autidx><initials>P.</initials><seq>6</seq><surname>Mol</surname></author></author-group><author-group><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><author><autidx>Rutten F.</autidx><initials>F.</initials><seq>3</seq><surname>Rutten</surname></author><author><autidx>Hoes A.</autidx><initials>A.</initials><seq>4</seq><surname>Hoes</surname></author></author-group><authorlist><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>Warnier M.</autidx><initials>M.</initials><seq>1</seq><surname>Warnier</surname><aggregatedAuthorId>warnier m.__warnier__</aggregatedAuthorId><uniqueAuthorId>warnier____m.____LKkEAEZ/B4I=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><autidx>Holtkamp F.</autidx><initials>F.</initials><seq>2</seq><surname>Holtkamp</surname><aggregatedAuthorId>holtkamp f.__holtkamp__</aggregatedAuthorId><uniqueAuthorId>holtkamp____f.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><autidx>Rutten F.</autidx><initials>F.</initials><seq>3</seq><surname>Rutten</surname><aggregatedAuthorId>rutten f.__rutten__</aggregatedAuthorId><uniqueAuthorId>rutten____f.____zigBAODTDRI=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Julius Center for Health Sciences and Primary Care</organization><organization>University Medical Center Utrecht</organization></affiliation><autidx>Hoes A.</autidx><initials>A.</initials><seq>4</seq><surname>Hoes</surname><aggregatedAuthorId>hoes a.__hoes__</aggregatedAuthorId><uniqueAuthorId>hoes____a.____zigBAODTDRI=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>De Boer A.</autidx><initials>A.</initials><seq>5</seq><surname>De Boer</surname><aggregatedAuthorId>de boer a.__de boer__</aggregatedAuthorId><uniqueAuthorId>de boer____a.____LKkEAEZ/B4I=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Medicines Evaluation Board (CBG-MEB)</organization></affiliation><autidx>Mol P.</autidx><initials>P.</initials><seq>6</seq><surname>Mol</surname><aggregatedAuthorId>mol p.__mol__</aggregatedAuthorId><uniqueAuthorId>mol____p.____TdIEAP/wDTA=</uniqueAuthorId></author><author><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><autidx>De Bruin M.</autidx><initials>M.</initials><seq>7</seq><surname>De Bruin</surname><aggregatedAuthorId>de bruin m.__de bruin__</aggregatedAuthorId><uniqueAuthorId>de bruin____m.____LKkEAEZ/B4I=</uniqueAuthorId></author></authorlist><correspondence><affiliation><city>Utrecht</city><country code="NLD">Netherlands</country><organization>Division of Pharmacoepidemiology and Clinical Pharmacology</organization><organization>Utrecht University</organization></affiliation><person><initials>M.</initials><persidx>Warnier M.</persidx><surname>Warnier</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>chemicals and drugs</ancestor><ancestor>general and inorganic chemicals</ancestor><ancestor>isotope</ancestor><ancestor>nitrogen 15</ancestor></ancestors><drgterm>nitrogen 15</drgterm><mainterm>nitrogen 15</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>drug surveillance program</ancestor><ancestor>in vivo study</ancestor><ancestor>postmarketing surveillance</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>drug surveillance program</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>society</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>society</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart muscle conduction disturbance</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>qt prolongation</ancestor></ancestors><disterm>QT prolongation</disterm><mainterm>QT prolongation</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>miscellaneous named groups</ancestor><ancestor>named groups of persons</ancestor><ancestor>patient</ancestor></ancestors><mainterm>patient</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>diagnostic procedure</ancestor><ancestor>medical procedures</ancestor><ancestor>monitoring</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>quality control procedures</ancestor></ancestors><mainterm>monitoring</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>heart ventricle arrhythmia</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart ventricle arrhythmia</disterm><mainterm>heart ventricle arrhythmia</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>health care concepts</ancestor><ancestor>health care personnel</ancestor><ancestor>named groups by occupation</ancestor><ancestor>named groups of persons</ancestor></ancestors><mainterm>health care personnel</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>danger, risk, safety and related phenomena</ancestor><ancestor>environment</ancestor><ancestor>risk</ancestor><ancestor>risk factor</ancestor><ancestor>society and environment</ancestor></ancestors><mainterm>risk factor</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>eastern hemisphere</ancestor><ancestor>europe</ancestor><ancestor>geographic names</ancestor></ancestors><mainterm>Europe</mainterm><weight>b</weight></explosion></explosions><idxs><dgidx><dt>nitrogen 15</dt></dgidx><dsidx><dst>heart ventricle arrhythmia</dst><dst>qt prolongation</dst></dsidx><stidx><stt>drug surveillance program</stt><stt>human</stt></stidx></idxs></bibrecord><bibrecord><item-info><date-sort>1993-07-28</date-sort><kind>regular</kind><copyright><cprtype>Elsevier</cprtype><cprtext>Copyright 2009 Elsevier B.V., All rights reserved.</cprtext></copyright><itemidlist><lui>L23201581</lui><pui>23201581</pui><embase>1993201595</embase><medl>8391748</medl></itemidlist><history><date-created>1993-07-28</date-created><date-loaded>1993-07-27</date-loaded></history><dbcollection code="EMBASE">EMBASE</dbcollection><dbcollection code="MEDL">MEDLINE</dbcollection></item-info><head><citation-info><citation-type code="ar">Article</citation-type><citation-language code="en">English</citation-language><abstract-language code="en">English</abstract-language></citation-info><citation-title><titletext><language code="en">English</language><original>y</original><__translated>false</__translated><ttltext>Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy</ttltext></titletext></citation-title><abstracts><abstract><original>y</original><__translated>false</__translated><abstract-language code="en">English</abstract-language><para>We measured the QRS duration during a treadmill exercise test and the QT interval using a 24-hour Holter electrocardiogram at various heart rates to identify use-dependent QRS prolongation and reverse use-dependent QT prolongation of class I and III antiarrhythmic drugs. Use-dependent QRS prolongation was detected in 61%, 53%, and 64% of patients receiving disopyramide, mexiletine, and pilsicainide, respectively. Reverse use-dependent QT prolongation was found in 40% and 70% of patients receiving disopyramide and E4031. Drugs suppressed ≥ 75% of the total premature ventricular contractions in all patients who had both use-dependent QRS prolongation and reverse use-dependent QT prolongation, in 79% of patients with use-dependent QRS prolongation alone, in 70% with reverse use-dependent QT prolongation alone, and in 11% with neither use-dependent QRS prolongation nor reverse use-dependent QT prolongation. Use-dependent QRS prolongation and reverse use-dependent QT prolongation were identified noninvasively and were useful in evaluating antiarrhythmic efficacy.</para></abstract></abstracts><source><sourcetype code="j">Journal</sourcetype><sourcecountry code="usa">United States</sourcecountry><sourcetitle>American Heart Journal</sourcetitle><sourcetitle-abbrev>AM. HEART J.</sourcetitle-abbrev><issn><issntype>print</issntype><issnnr>00028703</issnnr></issn><codencode>AHJOA</codencode><volisspag><volume>126</volume><issue>1</issue><firstpage>114</firstpage><volissidx>00028703||1993||126||1</volissidx><lastpage>121</lastpage></volisspag><publicationyear>1993</publicationyear><publicationdate><pubdate year="1993">1993-01-01</pubdate></publicationdate><publisher><affiliation><address-part>11830 Westline Industrial Drive</address-part><city>St. Louis</city><country code="usa">United States</country></affiliation><publishername>Mosby Inc.</publishername></publisher></source><enhancement><chemicalgroup><chemicals><chemical><cas-registry-number>113558-89-7</cas-registry-number><chemical-name>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</chemical-name></chemical><chemical><cas-registry-number>3737-09-5</cas-registry-number><chemical-name>disopyramide</chemical-name></chemical><chemical><cas-registry-number>31828-71-4</cas-registry-number><cas-registry-number>5370-01-4</cas-registry-number><chemical-name>mexiletine</chemical-name></chemical><chemical><cas-registry-number>88069-49-2</cas-registry-number><chemical-name>pilsicainide</chemical-name></chemical><chemical-source>esbd</chemical-source></chemicals></chemicalgroup><classifications><clsemclass>6</clsemclass><clsemclass>18</clsemclass><clsemclass>20</clsemclass><clsemclass>30</clsemclass><clsemclass>37</clsemclass></classifications><descriptorgroup><descriptors><controlled>y</controlled><descriptor><drgterm>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</mainterm><weight>a</weight></descriptor><descriptor><drgterm>disopyramide</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>disopyramide</mainterm><weight>a</weight></descriptor><descriptor><drgterm>mexiletine</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>mexiletine</mainterm><weight>a</weight></descriptor><descriptor><drgterm>pilsicainide</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>pilsicainide</mainterm><weight>a</weight></descriptor><descriptor-type>DRG</descriptor-type></descriptors><descriptors><controlled>y</controlled><descriptor><mainterm>adult</mainterm><weight>b</weight></descriptor><descriptor><mainterm>aged</mainterm><weight>b</weight></descriptor><descriptor><mainterm>article</mainterm><weight>b</weight></descriptor><descriptor><mainterm>controlled study</mainterm><weight>b</weight></descriptor><descriptor><disterm>coronary artery disease</disterm><mainterm>coronary artery disease</mainterm><weight>a</weight></descriptor><descriptor><mainterm>drug blood level</mainterm><weight>b</weight></descriptor><descriptor><mainterm>drug efficacy</mainterm><weight>b</weight></descriptor><descriptor><mainterm>exercise</mainterm><weight>b</weight></descriptor><descriptor><mainterm>female</mainterm><weight>b</weight></descriptor><descriptor><disterm>heart arrhythmia</disterm><link><linkterm>complication</linkterm></link><link><linkterm>drug therapy</linkterm></link><mainterm>heart arrhythmia</mainterm><weight>a</weight></descriptor><descriptor><mainterm>Holter monitoring</mainterm><weight>b</weight></descriptor><descriptor><mainterm>human</mainterm><weight>b</weight></descriptor><descriptor><mainterm>major clinical study</mainterm><weight>b</weight></descriptor><descriptor><mainterm>male</mainterm><weight>b</weight></descriptor><descriptor><mainterm>priority journal</mainterm><weight>b</weight></descriptor><descriptor><mainterm>QRS complex</mainterm><weight>a</weight></descriptor><descriptor><mainterm>QT interval</mainterm><weight>a</weight></descriptor><descriptor-type>MED</descriptor-type></descriptors></descriptorgroup></enhancement><hasabstract>true</hasabstract><hascasnr>true</hascasnr><hasdevicemanufacturer>false</hasdevicemanufacturer><hasdrugmanufacturer>false</hasdrugmanufacturer><hasdevicetradename>false</hasdevicetradename><hasdrugtradename>false</hasdrugtradename><hasmsn>false</hasmsn><author-group><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><author><autidx>Sadanaga T.</autidx><initials>T.</initials><seq>1</seq><surname>Sadanaga</surname></author><author><autidx>Ogawa S.</autidx><initials>S.</initials><seq>2</seq><surname>Ogawa</surname></author><author><autidx>Okada Y.</autidx><initials>Y.</initials><seq>3</seq><surname>Okada</surname></author><author><autidx>Tsutsumi N.</autidx><initials>N.</initials><seq>4</seq><surname>Tsutsumi</surname></author><author><autidx>Iwanaga S.</autidx><initials>S.</initials><seq>5</seq><surname>Iwanaga</surname></author><author><autidx>Yoshikawa T.</autidx><initials>T.</initials><seq>6</seq><surname>Yoshikawa</surname></author><author><autidx>Akaishi M.</autidx><initials>M.</initials><seq>7</seq><surname>Akaishi</surname></author><author><autidx>Handa S.</autidx><initials>S.</initials><seq>8</seq><surname>Handa</surname></author></author-group><authorlist><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Sadanaga T.</autidx><initials>T.</initials><seq>1</seq><surname>Sadanaga</surname><aggregatedAuthorId>sadanaga t.__sadanaga__</aggregatedAuthorId><uniqueAuthorId>sadanaga____t.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Ogawa S.</autidx><initials>S.</initials><seq>2</seq><surname>Ogawa</surname><aggregatedAuthorId>ogawa s.__ogawa__</aggregatedAuthorId><uniqueAuthorId>ogawa____s.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Okada Y.</autidx><initials>Y.</initials><seq>3</seq><surname>Okada</surname><aggregatedAuthorId>okada y.__okada__</aggregatedAuthorId><uniqueAuthorId>okada____y.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Tsutsumi N.</autidx><initials>N.</initials><seq>4</seq><surname>Tsutsumi</surname><aggregatedAuthorId>tsutsumi n.__tsutsumi__</aggregatedAuthorId><uniqueAuthorId>tsutsumi____n.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Iwanaga S.</autidx><initials>S.</initials><seq>5</seq><surname>Iwanaga</surname><aggregatedAuthorId>iwanaga s.__iwanaga__</aggregatedAuthorId><uniqueAuthorId>iwanaga____s.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Yoshikawa T.</autidx><initials>T.</initials><seq>6</seq><surname>Yoshikawa</surname><aggregatedAuthorId>yoshikawa t.__yoshikawa__</aggregatedAuthorId><uniqueAuthorId>yoshikawa____t.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Akaishi M.</autidx><initials>M.</initials><seq>7</seq><surname>Akaishi</surname><aggregatedAuthorId>akaishi m.__akaishi__</aggregatedAuthorId><uniqueAuthorId>akaishi____m.____zsxLBQDodw0m</uniqueAuthorId></author><author><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><autidx>Handa S.</autidx><initials>S.</initials><seq>8</seq><surname>Handa</surname><aggregatedAuthorId>handa s.__handa__</aggregatedAuthorId><uniqueAuthorId>handa____s.____zsxLBQDodw0m</uniqueAuthorId></author></authorlist><correspondence><affiliation><address-part>35 Shinano-machi</address-part><city-group>Shinjuku-ku, Tokyo 160</city-group><country code="jpn">Japan</country><organization>Cardiopulmonary Division</organization><organization>Department of Medicine</organization><organization>Keio University School of Medicine</organization></affiliation><person><degrees>Dr.</degrees><initials>T.</initials><persidx>Sadanaga T.</persidx><surname>Sadanaga</surname></person></correspondence></head><explosions><explosion><ancestors><ancestor>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</ancestor><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>carbon nitrogen monocycle</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>organic compound</ancestor><ancestor>piperidine derivative</ancestor><ancestor>pyridine derivative</ancestor><ancestor>single heterocyclic rings</ancestor></ancestors><drgterm>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>disopyramide</ancestor></ancestors><drgterm>disopyramide</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>disopyramide</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>agents affecting water, molecule or ion transport</ancestor><ancestor>amine</ancestor><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>aromatic amine</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>functional group</ancestor><ancestor>groups with a carbon-nitrogen bond only</ancestor><ancestor>ion transport affecting agent</ancestor><ancestor>mexiletine</ancestor><ancestor>organic compound</ancestor><ancestor>organonitrogen derivative</ancestor><ancestor>sodium channel affecting agent</ancestor><ancestor>sodium channel blocking agent</ancestor><ancestor>voltage gated sodium channel blocking agent</ancestor></ancestors><drgterm>mexiletine</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>mexiletine</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>antiarrhythmic agent</ancestor><ancestor>antiarrhythmic and arrhythmia-inducing agents</ancestor><ancestor>bridged bicyclo compounds</ancestor><ancestor>bridged compound</ancestor><ancestor>cardiovascular agent</ancestor><ancestor>chemicals and drugs</ancestor><ancestor>compounds according to chemical structure</ancestor><ancestor>fused carbon nitrogen heterocycle</ancestor><ancestor>fused heterocyclic rings</ancestor><ancestor>heterocyclic compound</ancestor><ancestor>hydrocarbon</ancestor><ancestor>organic compound</ancestor><ancestor>pilsicainide</ancestor><ancestor>polycyclic hydrocarbon</ancestor><ancestor>pyrrolizine derivative</ancestor></ancestors><drgterm>pilsicainide</drgterm><link><linkterm>drug comparison</linkterm></link><link><linkterm>drug concentration</linkterm></link><link><linkterm>drug therapy</linkterm></link><link><linkterm>pharmacology</linkterm></link><mainterm>pilsicainide</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>adult</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>adult</ancestor><ancestor>aged</ancestor><ancestor>groups by age</ancestor><ancestor>groups by age and sex</ancestor></ancestors><mainterm>aged</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>article</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>article</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>controlled study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>controlled study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>coronary artery disease</ancestor><ancestor>diseases</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor><ancestor>vascular disease</ancestor></ancestors><disterm>coronary artery disease</disterm><mainterm>coronary artery disease</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>analytical parameters</ancestor><ancestor>blood level</ancestor><ancestor>chemical parameters</ancestor><ancestor>concentration (parameter)</ancestor><ancestor>drug blood level</ancestor><ancestor>drug concentration</ancestor><ancestor>parameters</ancestor><ancestor>pharmacological parameters</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>drug blood level</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>drug activity</ancestor><ancestor>drug efficacy</ancestor><ancestor>pharmacodynamics</ancestor><ancestor>pharmacology</ancestor></ancestors><mainterm>drug efficacy</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>exercise</ancestor><ancestor>physical activity, capacity and performance</ancestor></ancestors><mainterm>exercise</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>female</ancestor><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor></ancestors><mainterm>female</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>cardiovascular disease</ancestor><ancestor>diseases</ancestor><ancestor>heart arrhythmia</ancestor><ancestor>heart disease</ancestor><ancestor>physical disease</ancestor><ancestor>physical disease by anatomical structure</ancestor></ancestors><disterm>heart arrhythmia</disterm><link><linkterm>complication</linkterm></link><link><linkterm>drug therapy</linkterm></link><mainterm>heart arrhythmia</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>cardiography</ancestor><ancestor>cardiovascular system examination</ancestor><ancestor>diagnosis</ancestor><ancestor>diagnostic procedure</ancestor><ancestor>electrocardiography</ancestor><ancestor>electrodiagnosis</ancestor><ancestor>electrography</ancestor><ancestor>holter monitoring</ancestor><ancestor>medical procedures</ancestor><ancestor>procedures</ancestor><ancestor>procedures, parameters and devices</ancestor></ancestors><mainterm>Holter monitoring</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>amniote</ancestor><ancestor>animal</ancestor><ancestor>ape</ancestor><ancestor>bilateria</ancestor><ancestor>catarrhini</ancestor><ancestor>chordata</ancestor><ancestor>deuterostomia</ancestor><ancestor>euarchontoglires</ancestor><ancestor>eukaryote</ancestor><ancestor>haplorhini</ancestor><ancestor>hominid</ancestor><ancestor>human</ancestor><ancestor>human versus nonhuman data</ancestor><ancestor>mammal</ancestor><ancestor>opisthokonta</ancestor><ancestor>organisms</ancestor><ancestor>placental mammal</ancestor><ancestor>primate</ancestor><ancestor>simian</ancestor><ancestor>tetrapod</ancestor><ancestor>therian</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor><ancestor>vertebrate</ancestor></ancestors><mainterm>human</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>clinical study</ancestor><ancestor>in vivo study</ancestor><ancestor>major clinical study</ancestor><ancestor>types of article or study</ancestor><ancestor>types of study</ancestor></ancestors><mainterm>major clinical study</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>groups by age and sex</ancestor><ancestor>groups by sex</ancestor><ancestor>male</ancestor></ancestors><mainterm>male</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>priority journal</ancestor><ancestor>types of article</ancestor><ancestor>types of article or study</ancestor></ancestors><mainterm>priority journal</mainterm><weight>b</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qrs complex</ancestor></ancestors><mainterm>QRS complex</mainterm><weight>a</weight></explosion><explosion><ancestors><ancestor>biological functions</ancestor><ancestor>biological phenomena and functions concerning organ systems</ancestor><ancestor>biological phenomena and functions concerning the entire organism</ancestor><ancestor>cardiovascular function</ancestor><ancestor>cardiovascular parameters</ancestor><ancestor>electrocardiogram</ancestor><ancestor>electrophysiology</ancestor><ancestor>heart electrophysiology</ancestor><ancestor>heart function</ancestor><ancestor>medical parameters</ancestor><ancestor>parameters</ancestor><ancestor>procedures, parameters and devices</ancestor><ancestor>qt interval</ancestor></ancestors><mainterm>QT interval</mainterm><weight>a</weight></explosion></explosions><idxs><agidx><ag>adult</ag><ag>aged</ag></agidx><dgidx><dt>1 [2 (6 methyl 2 pyridyl)ethyl] 4 (4 methylsulfonylaminobenzoyl)piperidine</dt><dt>disopyramide</dt><dt>mexiletine</dt><dt>pilsicainide</dt></dgidx><dsidx><dst>coronary artery disease</dst><dst>heart arrhythmia</dst></dsidx><gnidx><gn>female</gn><gn>male</gn></gnidx><stidx><stt>controlled study</stt><stt>human</stt><stt>major clinical study</stt></stidx></idxs></bibrecord></bibdataset></results></xml>